{ "instance": { "ipii_20f.htm": { "axisCustom": 0, "axisStandard": 22, "contextCount": 284, "dts": { "calculationLink": { "local": [ "ipci-20201130_cal.xml" ] }, "definitionLink": { "local": [ "ipci-20201130_def.xml" ] }, "inline": { "local": [ "ipii_20f.htm" ] }, "labelLink": { "local": [ "ipci-20201130_lab.xml" ] }, "presentationLink": { "local": [ "ipci-20201130_pre.xml" ] }, "schema": { "local": [ "ipci-20201130.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd", "https://xbrl.sec.gov/country/2021/country-2021.xsd", "https://xbrl.sec.gov/currency/2021/currency-2021.xsd", "https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd", "https://xbrl.sec.gov/exch/2021/exch-2021.xsd", "https://xbrl.sec.gov/naics/2021/naics-2021.xsd", "https://xbrl.sec.gov/sic/2021/sic-2021.xsd", "https://xbrl.sec.gov/stpr/2021/stpr-2021.xsd" ] } }, "elementCount": 547, "entityCount": 1, "hidden": { "http://fasb.org/us-gaap/2021-01-31": 103, "http://intellipharmaceutics.com/20201130": 71, "http://xbrl.sec.gov/dei/2021q4": 5, "total": 179 }, "keyCustom": 145, "keyStandard": 241, "memberCustom": 56, "memberStandard": 19, "nsprefix": "ipci", "nsuri": "http://intellipharmaceutics.com/20201130", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "strong", "p", "td", "tr", "tbody", "table", "body", "html" ], "baseRef": "ipii_20f.htm", "contextRef": "From2019-12-01to2020-11-30", "decimals": null, "first": true, "lang": "en-US", "name": "dei:EntityRegistrantName", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "000001 - Document - Cover", "role": "http://intellipharmaceutics.com/role/Cover", "shortName": "Cover", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "strong", "p", "td", "tr", "tbody", "table", "body", "html" ], "baseRef": "ipii_20f.htm", "contextRef": "From2019-12-01to2020-11-30", "decimals": null, "first": true, "lang": "en-US", "name": "dei:EntityRegistrantName", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R10": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "ipii_20f.htm", "contextRef": "From2020-12-01to2021-11-30", "decimals": null, "first": true, "lang": "en-US", "name": "ipci:TradeAndOtherReceivablesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000010 - Disclosure - Trade and other receivables", "role": "http://intellipharmaceutics.com/role/TradeAndOtherReceivables", "shortName": "Trade and other receivables", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "ipii_20f.htm", "contextRef": "From2020-12-01to2021-11-30", "decimals": null, "first": true, "lang": "en-US", "name": "ipci:TradeAndOtherReceivablesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R11": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "ipii_20f.htm", "contextRef": "From2020-12-01to2021-11-30", "decimals": null, "first": true, "lang": "en-US", "name": "ipci:Accountspayableandaccruedliabilitiesdisclosuretextblock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000011 - Disclosure - Accrued Liabilities", "role": "http://intellipharmaceutics.com/role/AccruedLiabilities", "shortName": "Accrued Liabilities", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "ipii_20f.htm", "contextRef": "From2020-12-01to2021-11-30", "decimals": null, "first": true, "lang": "en-US", "name": "ipci:Accountspayableandaccruedliabilitiesdisclosuretextblock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R12": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "ipii_20f.htm", "contextRef": "From2020-12-01to2021-11-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000012 - Disclosure - Property and Equipment", "role": "http://intellipharmaceutics.com/role/PropertyAndEquipment", "shortName": "Property and Equipment", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "ipii_20f.htm", "contextRef": "From2020-12-01to2021-11-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R13": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "ipii_20f.htm", "contextRef": "From2020-12-01to2021-11-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000013 - Disclosure - Convertible Debentures", "role": "http://intellipharmaceutics.com/role/ConvertibleDebentures", "shortName": "Convertible Debentures", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "ipii_20f.htm", "contextRef": "From2020-12-01to2021-11-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R14": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "ipii_20f.htm", "contextRef": "From2020-12-01to2021-11-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CompensationRelatedCostsGeneralTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000014 - Disclosure - Employee costs payable", "role": "http://intellipharmaceutics.com/role/EmployeeCostsPayable", "shortName": "Employee costs payable", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "ipii_20f.htm", "contextRef": "From2020-12-01to2021-11-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CompensationRelatedCostsGeneralTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R15": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "ipii_20f.htm", "contextRef": "From2020-12-01to2021-11-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LeasesOfLesseeDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000015 - Disclosure - Lease", "role": "http://intellipharmaceutics.com/role/Lease", "shortName": "Lease", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "ipii_20f.htm", "contextRef": "From2020-12-01to2021-11-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LeasesOfLesseeDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R16": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "ipii_20f.htm", "contextRef": "From2020-12-01to2021-11-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000016 - Disclosure - Capital Stock", "role": "http://intellipharmaceutics.com/role/CapitalStock", "shortName": "Capital Stock", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "ipii_20f.htm", "contextRef": "From2020-12-01to2021-11-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R17": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "ipii_20f.htm", "contextRef": "From2020-12-01to2021-11-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000017 - Disclosure - Options", "role": "http://intellipharmaceutics.com/role/Options", "shortName": "Options", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "ipii_20f.htm", "contextRef": "From2020-12-01to2021-11-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R18": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "ipii_20f.htm", "contextRef": "From2020-12-01to2021-11-30", "decimals": null, "first": true, "lang": "en-US", "name": "ipci:DeferredCompensationArrangementsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000018 - Disclosure - Deferred Share Units", "role": "http://intellipharmaceutics.com/role/DeferredShareUnits", "shortName": "Deferred Share Units", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "ipii_20f.htm", "contextRef": "From2020-12-01to2021-11-30", "decimals": null, "first": true, "lang": "en-US", "name": "ipci:DeferredCompensationArrangementsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R19": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "ipii_20f.htm", "contextRef": "From2020-12-01to2021-11-30", "decimals": null, "first": true, "lang": "en-US", "name": "ipci:RestrictedShareUnitsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000019 - Disclosure - Restricted share units", "role": "http://intellipharmaceutics.com/role/RestrictedShareUnits", "shortName": "Restricted share units", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "ipii_20f.htm", "contextRef": "From2020-12-01to2021-11-30", "decimals": null, "first": true, "lang": "en-US", "name": "ipci:RestrictedShareUnitsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R2": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "body", "html" ], "baseRef": "ipii_20f.htm", "contextRef": "AsOf2021-11-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "000002 - Statement - Consolidated Balance Sheets", "role": "http://intellipharmaceutics.com/role/ConsolidatedBalanceSheets", "shortName": "Consolidated Balance Sheets", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "body", "html" ], "baseRef": "ipii_20f.htm", "contextRef": "AsOf2021-11-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R20": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "ipii_20f.htm", "contextRef": "From2020-12-01to2021-11-30", "decimals": null, "first": true, "lang": "en-US", "name": "ipci:WarrantsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000020 - Disclosure - Warrants", "role": "http://intellipharmaceutics.com/role/Warrants", "shortName": "Warrants", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "ipii_20f.htm", "contextRef": "From2020-12-01to2021-11-30", "decimals": null, "first": true, "lang": "en-US", "name": "ipci:WarrantsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R21": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "ipii_20f.htm", "contextRef": "From2020-12-01to2021-11-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000021 - Disclosure - Income Taxes", "role": "http://intellipharmaceutics.com/role/IncomeTaxes", "shortName": "Income Taxes", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "ipii_20f.htm", "contextRef": "From2020-12-01to2021-11-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R22": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "ipii_20f.htm", "contextRef": "From2020-12-01to2021-11-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000022 - Disclosure - Contingencies", "role": "http://intellipharmaceutics.com/role/Contingencies", "shortName": "Contingencies", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "ipii_20f.htm", "contextRef": "From2020-12-01to2021-11-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R23": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "ipii_20f.htm", "contextRef": "From2020-12-01to2021-11-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FinancialInstrumentsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000023 - Disclosure - Financial Instruments", "role": "http://intellipharmaceutics.com/role/FinancialInstruments", "shortName": "Financial Instruments", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "ipii_20f.htm", "contextRef": "From2020-12-01to2021-11-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FinancialInstrumentsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R24": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "ipii_20f.htm", "contextRef": "From2020-12-01to2021-11-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SegmentReportingDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000024 - Disclosure - Segmented Information", "role": "http://intellipharmaceutics.com/role/SegmentedInformation", "shortName": "Segmented Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "ipii_20f.htm", "contextRef": "From2020-12-01to2021-11-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SegmentReportingDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R25": { "firstAnchor": { "ancestors": [ "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "ipii_20f.htm", "contextRef": "From2020-12-01to2021-11-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CashAndCashEquivalentsPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000026 - Disclosure - Significant Accounting Policies (Policies)", "role": "http://intellipharmaceutics.com/role/SignificantAccountingPoliciesPolicies", "shortName": "Significant Accounting Policies (Policies)", "subGroupType": "policies", "uniqueAnchor": { "ancestors": [ "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "ipii_20f.htm", "contextRef": "From2020-12-01to2021-11-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CashAndCashEquivalentsPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R26": { "firstAnchor": { "ancestors": [ "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock", "ix:continuation", "body", "html" ], "baseRef": "ipii_20f.htm", "contextRef": "From2020-12-01to2021-11-30", "decimals": null, "first": true, "lang": "en-US", "name": "ipci:Scheduleofdepreciationratestabletextblock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000027 - Disclosure - Significant Accounting Policies (Tables)", "role": "http://intellipharmaceutics.com/role/SignificantAccountingPoliciesTables", "shortName": "Significant Accounting Policies (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock", "ix:continuation", "body", "html" ], "baseRef": "ipii_20f.htm", "contextRef": "From2020-12-01to2021-11-30", "decimals": null, "first": true, "lang": "en-US", "name": "ipci:Scheduleofdepreciationratestabletextblock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R27": { "firstAnchor": { "ancestors": [ "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "body", "html" ], "baseRef": "ipii_20f.htm", "contextRef": "From2020-12-01to2021-11-30", "decimals": null, "first": true, "lang": "en-US", "name": "ipci:Propertyplantandequipmenttextblock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000028 - Disclosure - Property and Equipment (Tables)", "role": "http://intellipharmaceutics.com/role/PropertyAndEquipmentTables", "shortName": "Property and Equipment (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "body", "html" ], "baseRef": "ipii_20f.htm", "contextRef": "From2020-12-01to2021-11-30", "decimals": null, "first": true, "lang": "en-US", "name": "ipci:Propertyplantandequipmenttextblock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R28": { "firstAnchor": { "ancestors": [ "ipci:Accountspayableandaccruedliabilitiesdisclosuretextblock", "body", "html" ], "baseRef": "ipii_20f.htm", "contextRef": "From2020-12-01to2021-11-30", "decimals": null, "first": true, "lang": "en-US", "name": "ipci:Scheduleofaccruedliabilitiestabletextblock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000029 - Disclosure - Accrued Liabilities (Tables)", "role": "http://intellipharmaceutics.com/role/AccruedLiabilitiesTables", "shortName": "Accrued Liabilities (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ipci:Accountspayableandaccruedliabilitiesdisclosuretextblock", "body", "html" ], "baseRef": "ipii_20f.htm", "contextRef": "From2020-12-01to2021-11-30", "decimals": null, "first": true, "lang": "en-US", "name": "ipci:Scheduleofaccruedliabilitiestabletextblock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R29": { "firstAnchor": { "ancestors": [ "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "body", "html" ], "baseRef": "ipii_20f.htm", "contextRef": "From2020-12-01to2021-11-30", "decimals": null, "first": true, "lang": "en-US", "name": "ipci:Scheduleofrelatedpartytransactionstabletextblock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000030 - Disclosure - Convertible Debentures and Promissory Notes Payable (Tables)", "role": "http://intellipharmaceutics.com/role/ConvertibleDebenturesAndPromissoryNotesPayableTables", "shortName": "Convertible Debentures and Promissory Notes Payable (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "body", "html" ], "baseRef": "ipii_20f.htm", "contextRef": "From2020-12-01to2021-11-30", "decimals": null, "first": true, "lang": "en-US", "name": "ipci:Scheduleofrelatedpartytransactionstabletextblock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R3": { "firstAnchor": { "ancestors": [ "p", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "baseRef": "ipii_20f.htm", "contextRef": "AsOf2021-11-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:CommonStockSharesIssued", "reportCount": 1, "unitRef": "Shares", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "000003 - Statement - Consolidated Balance Sheets (Parenthetical)", "role": "http://intellipharmaceutics.com/role/ConsolidatedBalanceSheetsParenthetical", "shortName": "Consolidated Balance Sheets (Parenthetical)", "subGroupType": "parenthetical", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "tbody", "table", "body", "html" ], "baseRef": "ipii_20f.htm", "contextRef": "AsOf2021-11-30", "decimals": "0", "lang": null, "name": "us-gaap:CommonStockSharesOutstanding", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" } }, "R30": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "ipii_20f.htm", "contextRef": "From2020-12-01to2021-11-30", "decimals": null, "first": true, "lang": "en-US", "name": "ipci:Operatingleasesoflesseedisclosuretextblock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000031 - Disclosure - Lease (Tables)", "role": "http://intellipharmaceutics.com/role/LeaseTables", "shortName": "Lease (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "ipii_20f.htm", "contextRef": "From2020-12-01to2021-11-30", "decimals": null, "first": true, "lang": "en-US", "name": "ipci:Operatingleasesoflesseedisclosuretextblock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R31": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "ipii_20f.htm", "contextRef": "From2020-12-01to2021-11-30", "decimals": null, "first": true, "lang": "en-US", "name": "ipci:Scheduleofsharebasedpaymentawardstockoptionsvaluationassumptionstabletextblock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000032 - Disclosure - Options (Tables)", "role": "http://intellipharmaceutics.com/role/OptionsTables", "shortName": "Options (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "ipii_20f.htm", "contextRef": "From2020-12-01to2021-11-30", "decimals": null, "first": true, "lang": "en-US", "name": "ipci:Scheduleofsharebasedpaymentawardstockoptionsvaluationassumptionstabletextblock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R32": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "ipii_20f.htm", "contextRef": "From2020-12-01to2021-11-30", "decimals": null, "first": true, "lang": "en-US", "name": "ipci:Scheduleofstockholdersequitynotewarrantsorrightstextblock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000033 - Disclosure - Warrants (Tables)", "role": "http://intellipharmaceutics.com/role/WarrantsTables", "shortName": "Warrants (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "ipii_20f.htm", "contextRef": "From2020-12-01to2021-11-30", "decimals": null, "first": true, "lang": "en-US", "name": "ipci:Scheduleofstockholdersequitynotewarrantsorrightstextblock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R33": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "ipii_20f.htm", "contextRef": "From2020-12-01to2021-11-30", "decimals": null, "first": true, "lang": "en-US", "name": "ipci:Scheduleofeffectiveincometaxratereconciliationtabletextblock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000034 - Disclosure - Income Taxes (Tables)", "role": "http://intellipharmaceutics.com/role/IncomeTaxesTables", "shortName": "Income Taxes (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "ipii_20f.htm", "contextRef": "From2020-12-01to2021-11-30", "decimals": null, "first": true, "lang": "en-US", "name": "ipci:Scheduleofeffectiveincometaxratereconciliationtabletextblock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R34": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "ipii_20f.htm", "contextRef": "From2020-12-01to2021-11-30", "decimals": null, "first": true, "lang": "en-US", "name": "ipci:Fairvalueassetsmeasuredonnonrecurringbasistextblock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000035 - Disclosure - Financial Instruments (Tables)", "role": "http://intellipharmaceutics.com/role/FinancialInstrumentsTables", "shortName": "Financial Instruments (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "ipii_20f.htm", "contextRef": "From2020-12-01to2021-11-30", "decimals": null, "first": true, "lang": "en-US", "name": "ipci:Fairvalueassetsmeasuredonnonrecurringbasistextblock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R35": { "firstAnchor": { "ancestors": [ "us-gaap:SegmentReportingDisclosureTextBlock", "body", "html" ], "baseRef": "ipii_20f.htm", "contextRef": "From2020-12-01to2021-11-30", "decimals": null, "first": true, "lang": "en-US", "name": "ipci:Scheduleofrevenuesfromexternalcustomersandlonglivedassetsbygeographicalareastabletextblock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000036 - Disclosure - Segmented Information (Tables)", "role": "http://intellipharmaceutics.com/role/SegmentedInformationTables", "shortName": "Segmented Information (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:SegmentReportingDisclosureTextBlock", "body", "html" ], "baseRef": "ipii_20f.htm", "contextRef": "From2020-12-01to2021-11-30", "decimals": null, "first": true, "lang": "en-US", "name": "ipci:Scheduleofrevenuesfromexternalcustomersandlonglivedassetsbygeographicalareastabletextblock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R36": { "firstAnchor": { "ancestors": [ "p", "us-gaap:NatureOfOperations", "body", "html" ], "baseRef": "ipii_20f.htm", "contextRef": "From2020-12-01to2021-11-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000037 - Disclosure - Nature of Operations (Details Narrative)", "role": "http://intellipharmaceutics.com/role/NatureOfOperationsDetailsNarrative", "shortName": "Nature of Operations (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:NatureOfOperations", "body", "html" ], "baseRef": "ipii_20f.htm", "contextRef": "AsOf2021-11-30", "decimals": "0", "lang": null, "name": "ipci:WorkingCapitalDeficit", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R37": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "ipci:Scheduleofdepreciationratestabletextblock", "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock", "ix:continuation", "body", "html" ], "baseRef": "ipii_20f.htm", "contextRef": "From2020-12-01to2021-11-30_us-gaap_ComputerSoftwareIntangibleAssetMember_ipci_DecliningBalanceMember", "decimals": "INF", "first": true, "lang": null, "name": "ipci:DecliningBalanceDepreciationRate", "reportCount": 1, "unique": true, "unitRef": "Pure", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000038 - Disclosure - Significant Accounting Policies (Detail)", "role": "http://intellipharmaceutics.com/role/SignificantAccountingPoliciesDetail", "shortName": "Significant Accounting Policies (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "ipci:Scheduleofdepreciationratestabletextblock", "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock", "ix:continuation", "body", "html" ], "baseRef": "ipii_20f.htm", "contextRef": "From2020-12-01to2021-11-30_us-gaap_ComputerSoftwareIntangibleAssetMember_ipci_DecliningBalanceMember", "decimals": "INF", "first": true, "lang": null, "name": "ipci:DecliningBalanceDepreciationRate", "reportCount": 1, "unique": true, "unitRef": "Pure", "xsiNil": "false" } }, "R38": { "firstAnchor": { "ancestors": [ "p", "us-gaap:InventoryPolicyTextBlock", "ix:continuation", "body", "html" ], "baseRef": "ipii_20f.htm", "contextRef": "AsOf2020-11-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:InventoryRawMaterials", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000039 - Disclosure - Significant Accounting Policies (Details Narratives)", "role": "http://intellipharmaceutics.com/role/SignificantAccountingPoliciesDetailsNarratives", "shortName": "Significant Accounting Policies (Details Narratives)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:InventoryPolicyTextBlock", "ix:continuation", "body", "html" ], "baseRef": "ipii_20f.htm", "contextRef": "AsOf2020-11-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:InventoryRawMaterials", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R39": { "firstAnchor": { "ancestors": [ "p", "ipci:TradeAndOtherReceivablesDisclosureTextBlock", "body", "html" ], "baseRef": "ipii_20f.htm", "contextRef": "AsOf2020-11-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:AccountsReceivableNet", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000040 - Disclosure - Trade and Other Receivables (Details Narrative)", "role": "http://intellipharmaceutics.com/role/TradeAndOtherReceivablesDetailsNarrative", "shortName": "Trade and Other Receivables (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "ipci:TradeAndOtherReceivablesDisclosureTextBlock", "body", "html" ], "baseRef": "ipii_20f.htm", "contextRef": "AsOf2020-11-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:AccountsReceivableNet", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R4": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "body", "html" ], "baseRef": "ipii_20f.htm", "contextRef": "From2020-12-01to2021-11-30", "decimals": "0", "first": true, "lang": null, "name": "ipci:LicensingRevenue", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "000004 - Statement - Consolidated Statements of Operations and Comprehensive Loss", "role": "http://intellipharmaceutics.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss", "shortName": "Consolidated Statements of Operations and Comprehensive Loss", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "body", "html" ], "baseRef": "ipii_20f.htm", "contextRef": "From2020-12-01to2021-11-30", "decimals": "0", "first": true, "lang": null, "name": "ipci:LicensingRevenue", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R40": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "ipci:Propertyplantandequipmenttextblock", "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "body", "html" ], "baseRef": "ipii_20f.htm", "contextRef": "AsOf2020-11-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:PropertyPlantAndEquipmentGross", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000041 - Disclosure - Property and Equipment (Details)", "role": "http://intellipharmaceutics.com/role/PropertyAndEquipmentDetails", "shortName": "Property and Equipment (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "ipci:Propertyplantandequipmenttextblock", "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "body", "html" ], "baseRef": "ipii_20f.htm", "contextRef": "AsOf2019-11-30", "decimals": "0", "lang": null, "name": "us-gaap:PropertyPlantAndEquipmentGross", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R41": { "firstAnchor": { "ancestors": [ "p", "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "body", "html" ], "baseRef": "ipii_20f.htm", "contextRef": "AsOf2020-11-30", "decimals": "0", "first": true, "lang": null, "name": "ipci:EquipmentNotInUse", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000042 - Disclosure - Property and Equipment (Details Narrative)", "role": "http://intellipharmaceutics.com/role/PropertyAndEquipmentDetailsNarrative", "shortName": "Property and Equipment (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "body", "html" ], "baseRef": "ipii_20f.htm", "contextRef": "AsOf2020-11-30", "decimals": "0", "first": true, "lang": null, "name": "ipci:EquipmentNotInUse", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R42": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "ipci:Scheduleofaccruedliabilitiestabletextblock", "ipci:Accountspayableandaccruedliabilitiesdisclosuretextblock", "body", "html" ], "baseRef": "ipii_20f.htm", "contextRef": "AsOf2021-11-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:AccruedProfessionalFeesCurrent", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000043 - Disclosure - Accrued Liabilities (Details)", "role": "http://intellipharmaceutics.com/role/AccruedLiabilitiesDetails", "shortName": "Accrued Liabilities (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "ipci:Scheduleofaccruedliabilitiestabletextblock", "ipci:Accountspayableandaccruedliabilitiesdisclosuretextblock", "body", "html" ], "baseRef": "ipii_20f.htm", "contextRef": "AsOf2021-11-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:AccruedProfessionalFeesCurrent", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R43": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "ipci:Scheduleofrelatedpartytransactionstabletextblock", "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "body", "html" ], "baseRef": "ipii_20f.htm", "contextRef": "AsOf2021-11-30", "decimals": "0", "first": true, "lang": null, "name": "ipci:ConvertibleNotesPayable1", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000044 - Disclosure - Convertible Debentures and Promissory Notes Payable (Details)", "role": "http://intellipharmaceutics.com/role/ConvertibleDebenturesAndPromissoryNotesPayableDetails", "shortName": "Convertible Debentures and Promissory Notes Payable (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "ipci:Scheduleofrelatedpartytransactionstabletextblock", "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "body", "html" ], "baseRef": "ipii_20f.htm", "contextRef": "AsOf2021-11-30", "decimals": "0", "first": true, "lang": null, "name": "ipci:ConvertibleNotesPayable1", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R44": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "ix:continuation", "body", "html" ], "baseRef": "ipii_20f.htm", "contextRef": "AsOf2021-11-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:NotesPayable", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000045 - Disclosure - Convertible Debentures and Promissory Notes Payable (Details 1)", "role": "http://intellipharmaceutics.com/role/ConvertibleDebenturesAndPromissoryNotesPayableDetails1", "shortName": "Convertible Debentures and Promissory Notes Payable (Details 1)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "ix:continuation", "body", "html" ], "baseRef": "ipii_20f.htm", "contextRef": "AsOf2021-11-30_ipci_PromissoryNotesPayableMember", "decimals": "0", "lang": null, "name": "us-gaap:NotesPayable", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R45": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "body", "html" ], "baseRef": "ipii_20f.htm", "contextRef": "From2020-12-01to2021-11-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:AccretionExpense", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000046 - Disclosure - Convertible Debentures and Promissory Notes Payable (Details Narrative)", "role": "http://intellipharmaceutics.com/role/ConvertibleDebenturesAndPromissoryNotesPayableDetailsNarrative", "shortName": "Convertible Debentures and Promissory Notes Payable (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "ix:continuation", "body", "html" ], "baseRef": "ipii_20f.htm", "contextRef": "AsOf2016-12-01", "decimals": "0", "lang": null, "name": "ipci:DebtInstrumentCarryingValue", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R46": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "body", "html" ], "baseRef": "ipii_20f.htm", "contextRef": "AsOf2021-11-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:EmployeeRelatedLiabilitiesCurrent", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000047 - Disclosure - Employee Costs Payable (Details Narrative)", "role": "http://intellipharmaceutics.com/role/EmployeeCostsPayableDetailsNarrative", "shortName": "Employee Costs Payable (Details Narrative)", "subGroupType": "details", "uniqueAnchor": null }, "R47": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "body", "html" ], "baseRef": "ipii_20f.htm", "contextRef": "AsOf2021-11-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:OperatingLeaseRightOfUseAsset", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000048 - Disclosure - Lease (Details)", "role": "http://intellipharmaceutics.com/role/LeaseDetails", "shortName": "Lease (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "ipci:Scheduleofregulatoryassetsandliabilitiestextblock", "us-gaap:LeasesOfLesseeDisclosureTextBlock", "body", "html" ], "baseRef": "ipii_20f.htm", "contextRef": "AsOf2021-11-30", "decimals": "0", "lang": null, "name": "us-gaap:OperatingLeaseLiabilityCurrent", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R48": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "ipci:Operatingleasesoflesseedisclosuretextblock", "ix:continuation", "body", "html" ], "baseRef": "ipii_20f.htm", "contextRef": "AsOf2021-11-30", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:LesseeOperatingLeaseDiscountRate", "reportCount": 1, "unique": true, "unitRef": "Pure", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000049 - Disclosure - Lease (Details 1)", "role": "http://intellipharmaceutics.com/role/LeaseDetails1", "shortName": "Lease (Details 1)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "ipci:Operatingleasesoflesseedisclosuretextblock", "ix:continuation", "body", "html" ], "baseRef": "ipii_20f.htm", "contextRef": "AsOf2021-11-30", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:LesseeOperatingLeaseDiscountRate", "reportCount": 1, "unique": true, "unitRef": "Pure", "xsiNil": "false" } }, "R49": { "firstAnchor": { "ancestors": [ "p", "ix:continuation", "body", "html" ], "baseRef": "ipii_20f.htm", "contextRef": "From2020-12-01to2021-11-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:LeaseCost", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000050 - Disclosure - Lease (Details Narrative)", "role": "http://intellipharmaceutics.com/role/LeaseDetailsNarrative", "shortName": "Lease (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "ix:continuation", "body", "html" ], "baseRef": "ipii_20f.htm", "contextRef": "From2020-12-01to2021-11-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:LeaseCost", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R5": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "body", "html" ], "baseRef": "ipii_20f.htm", "contextRef": "AsOf2018-11-30_us-gaap_CommonStockMember", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:SharesIssued", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "000005 - Statement - Consolidated Statements of Shareholders' Equity (Deficiency)", "role": "http://intellipharmaceutics.com/role/ConsolidatedStatementsOfShareholdersEquityDeficiency", "shortName": "Consolidated Statements of Shareholders' Equity (Deficiency)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "body", "html" ], "baseRef": "ipii_20f.htm", "contextRef": "AsOf2018-11-30_us-gaap_CommonStockMember", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:SharesIssued", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" } }, "R50": { "firstAnchor": { "ancestors": [ "p", "ix:continuation", "body", "html" ], "baseRef": "ipii_20f.htm", "contextRef": "AsOf2019-07-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:CommonStockSharesIssued", "reportCount": 1, "unitRef": "Shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000051 - Disclosure - Capital Stock (Details Narrative)", "role": "http://intellipharmaceutics.com/role/CapitalStockDetailsNarrative", "shortName": "Capital Stock (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "ix:continuation", "body", "html" ], "baseRef": "ipii_20f.htm", "contextRef": "From2021-04-01to2021-04-30", "decimals": "0", "lang": null, "name": "ipci:PrivatePlacementOfferingOfAnAggregateOfCommonShares", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" } }, "R51": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "tbody", "table", "ipci:Scheduleofsharebasedpaymentawardstockoptionsvaluationassumptionstabletextblock", "ix:continuation", "body", "html" ], "baseRef": "ipii_20f.htm", "contextRef": "From2018-12-01to2019-11-30_srt_MinimumMember", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:AvailableforsaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureOtherFairValueVolatilityRate", "reportCount": 1, "unique": true, "unitRef": "Pure", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000052 - Disclosure - Options (Details)", "role": "http://intellipharmaceutics.com/role/OptionsDetails", "shortName": "Options (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "tbody", "table", "ipci:Scheduleofsharebasedpaymentawardstockoptionsvaluationassumptionstabletextblock", "ix:continuation", "body", "html" ], "baseRef": "ipii_20f.htm", "contextRef": "From2018-12-01to2019-11-30_srt_MinimumMember", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:AvailableforsaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureOtherFairValueVolatilityRate", "reportCount": 1, "unique": true, "unitRef": "Pure", "xsiNil": "false" } }, "R52": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "ipci:Scheduleofsharebasedcompensationstockoptionsactivitytabletextblock", "ix:continuation", "body", "html" ], "baseRef": "ipii_20f.htm", "contextRef": "AsOf2021-11-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000053 - Disclosure - Options (Details 1)", "role": "http://intellipharmaceutics.com/role/OptionsDetails1", "shortName": "Options (Details 1)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "ipci:Scheduleofsharebasedcompensationstockoptionsactivitytabletextblock", "ix:continuation", "body", "html" ], "baseRef": "ipii_20f.htm", "contextRef": "AsOf2021-11-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" } }, "R53": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "ipci:Scheduleofsharebasedcompensationstockoptionsactivitytabletextblock", "ix:continuation", "body", "html" ], "baseRef": "ipii_20f.htm", "contextRef": "From2020-12-01to2021-11-30", "decimals": "0", "first": true, "lang": null, "name": "ipci:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationInPeriod", "reportCount": 1, "unitRef": "Shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000054 - Disclosure - Options (Details 2)", "role": "http://intellipharmaceutics.com/role/OptionsDetails2", "shortName": "Options (Details 2)", "subGroupType": "details", "uniqueAnchor": null }, "R54": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "ipci:Scheduleofemployeeservicesharebasedcompensationallocationofrecognizedperiodcoststextblock", "ix:continuation", "body", "html" ], "baseRef": "ipii_20f.htm", "contextRef": "From2020-12-01to2021-11-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:AllocatedShareBasedCompensationExpense", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000055 - Disclosure - Options (Details 3)", "role": "http://intellipharmaceutics.com/role/OptionsDetails3", "shortName": "Options (Details 3)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "ipci:Scheduleofemployeeservicesharebasedcompensationallocationofrecognizedperiodcoststextblock", "ix:continuation", "body", "html" ], "baseRef": "ipii_20f.htm", "contextRef": "From2020-12-01to2021-11-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:AllocatedShareBasedCompensationExpense", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R55": { "firstAnchor": { "ancestors": [ "p", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "baseRef": "ipii_20f.htm", "contextRef": "AsOf2021-11-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:SharesHeldInEmployeeStockOptionPlanAllocated", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000056 - Disclosure - Options (Details Narrative)", "role": "http://intellipharmaceutics.com/role/OptionsDetailsNarrative", "shortName": "Options (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "baseRef": "ipii_20f.htm", "contextRef": "AsOf2021-11-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:SharesHeldInEmployeeStockOptionPlanAllocated", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" } }, "R56": { "firstAnchor": { "ancestors": [ "p", "ix:continuation", "body", "html" ], "baseRef": "ipii_20f.htm", "contextRef": "From2019-12-01to2020-11-30", "decimals": "0", "first": true, "lang": null, "name": "ipci:ChargesFromAdditionalPaidInCapitalToCommonSharesUnderCapitalStock", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000057 - Disclosure - Deferred Share Units (Details Narrative)", "role": "http://intellipharmaceutics.com/role/DeferredShareUnitsDetailsNarrative", "shortName": "Deferred Share Units (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "ipci:DeferredCompensationArrangementsDisclosureTextBlock", "body", "html" ], "baseRef": "ipii_20f.htm", "contextRef": "AsOf2010-05-28_ipci_DeferredShareUnitsMember", "decimals": "0", "lang": null, "name": "us-gaap:CommonStockCapitalSharesReservedForFutureIssuance", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" } }, "R57": { "firstAnchor": { "ancestors": [ "p", "ipci:RestrictedShareUnitsDisclosureTextBlock", "body", "html" ], "baseRef": "ipii_20f.htm", "contextRef": "AsOf2010-05-28", "decimals": "0", "first": true, "lang": null, "name": "ipci:RestrictedShareUnitReservedMaximumForIssuanceUnderThePlan", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000058 - Disclosure - Restricted share units (Details Narrative)", "role": "http://intellipharmaceutics.com/role/RestrictedShareUnitsDetailsNarrative", "shortName": "Restricted share units (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "ipci:RestrictedShareUnitsDisclosureTextBlock", "body", "html" ], "baseRef": "ipii_20f.htm", "contextRef": "AsOf2010-05-28", "decimals": "0", "first": true, "lang": null, "name": "ipci:RestrictedShareUnitReservedMaximumForIssuanceUnderThePlan", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" } }, "R58": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "ipci:Scheduleofstockholdersequitynotewarrantsorrightstextblock", "ix:continuation", "body", "html" ], "baseRef": "ipii_20f.htm", "contextRef": "AsOf2021-11-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:ClassOfWarrantOrRightOutstanding", "reportCount": 1, "unitRef": "Shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000059 - Disclosure - Warrants (Details)", "role": "http://intellipharmaceutics.com/role/WarrantsDetails", "shortName": "Warrants (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "ipci:Scheduleofstockholdersequitynotewarrantsorrightstextblock", "ix:continuation", "body", "html" ], "baseRef": "ipii_20f.htm", "contextRef": "AsOf2021-11-30_ipci_FirmWarrants2018Member", "decimals": "0", "lang": null, "name": "us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" } }, "R59": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "ipci:Scheduleofwarranttransactionstabletextblock", "ix:continuation", "body", "html" ], "baseRef": "ipii_20f.htm", "contextRef": "AsOf2020-11-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:ClassOfWarrantOrRightOutstanding", "reportCount": 1, "unitRef": "Shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000060 - Disclosure - Warrants (Details 1)", "role": "http://intellipharmaceutics.com/role/WarrantsDetails1", "shortName": "Warrants (Details 1)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "ipci:Scheduleofwarranttransactionstabletextblock", "ix:continuation", "body", "html" ], "baseRef": "ipii_20f.htm", "contextRef": "From2020-12-01to2021-11-30", "decimals": "0", "lang": null, "name": "ipci:WarrantsExpiredInPeriod", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" } }, "R6": { "firstAnchor": { "ancestors": [ "p", "us-gaap:NatureOfOperations", "body", "html" ], "baseRef": "ipii_20f.htm", "contextRef": "From2020-12-01to2021-11-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "000006 - Statement - Consolidated Statements of Cash Flows", "role": "http://intellipharmaceutics.com/role/ConsolidatedStatementsOfCashFlows", "shortName": "Consolidated Statements of Cash Flows", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "body", "html" ], "baseRef": "ipii_20f.htm", "contextRef": "From2020-12-01to2021-11-30", "decimals": "0", "lang": null, "name": "us-gaap:Depreciation", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R60": { "firstAnchor": { "ancestors": [ "p", "ix:continuation", "body", "html" ], "baseRef": "ipii_20f.htm", "contextRef": "From2019-12-01to2020-11-30", "decimals": "0", "first": true, "lang": null, "name": "ipci:ChargesFromAdditionalPaidInCapitalToCommonSharesUnderCapitalStock", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000061 - Disclosure - Warrants (Details Narrative)", "role": "http://intellipharmaceutics.com/role/WarrantsDetailsNarrative", "shortName": "Warrants (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "ix:continuation", "body", "html" ], "baseRef": "ipii_20f.htm", "contextRef": "From2019-12-01to2020-11-30", "decimals": "0", "lang": null, "name": "ipci:PreFundedWarrantsExercised", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" } }, "R61": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "ipci:Scheduleofdeferredtaxassetsandliabilitiestabletextblock", "ix:continuation", "body", "html" ], "baseRef": "ipii_20f.htm", "contextRef": "AsOf2021-11-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000062 - Disclosure - Income taxes (Details)", "role": "http://intellipharmaceutics.com/role/IncomeTaxesDetails", "shortName": "Income taxes (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "ipci:Scheduleofdeferredtaxassetsandliabilitiestabletextblock", "ix:continuation", "body", "html" ], "baseRef": "ipii_20f.htm", "contextRef": "AsOf2021-11-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R62": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "ipii_20f.htm", "contextRef": "AsOf2020-11-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:DeferredTaxAssetsLiabilitiesNet", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000063 - Disclosure - Income taxes (Details 1)", "role": "http://intellipharmaceutics.com/role/IncomeTaxesDetails1", "shortName": "Income taxes (Details 1)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "ipii_20f.htm", "contextRef": "From2020-12-01to2021-11-30", "decimals": "0", "lang": null, "name": "ipci:IncreaseDecreaseInDeferredTaxAssetsLiabilitiesNetDueToRecognizationInProfitOrLoss", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R63": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "ipci:Scheduleofeffectiveincometaxratereconciliationtabletextblock", "ix:continuation", "body", "html" ], "baseRef": "ipii_20f.htm", "contextRef": "From2020-12-01to2021-11-30", "decimals": "0", "first": true, "lang": null, "name": "ipci:Effectiveincometaxreconciliationtaxlossexpired", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000064 - Disclosure - Income taxes (Details 2)", "role": "http://intellipharmaceutics.com/role/IncomeTaxesDetails2", "shortName": "Income taxes (Details 2)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "ipci:Scheduleofeffectiveincometaxratereconciliationtabletextblock", "ix:continuation", "body", "html" ], "baseRef": "ipii_20f.htm", "contextRef": "From2020-12-01to2021-11-30", "decimals": "0", "first": true, "lang": null, "name": "ipci:Effectiveincometaxreconciliationtaxlossexpired", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R64": { "firstAnchor": { "ancestors": [ "p", "ix:continuation", "body", "html" ], "baseRef": "ipii_20f.htm", "contextRef": "AsOf2021-11-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:OperatingLossCarryforwards", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000065 - Disclosure - Income taxes (Details 3)", "role": "http://intellipharmaceutics.com/role/IncomeTaxesDetails3", "shortName": "Income taxes (Details 3)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "ipci:Scheduleofoperatinglossestabletextblock", "ix:continuation", "body", "html" ], "baseRef": "ipii_20f.htm", "contextRef": "AsOf2021-11-30_ipci_TaxYear2029Member", "decimals": "0", "lang": null, "name": "us-gaap:OperatingLossCarryforwards", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R65": { "firstAnchor": { "ancestors": [ "p", "ix:continuation", "body", "html" ], "baseRef": "ipii_20f.htm", "contextRef": "AsOf2021-11-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:OperatingLossCarryforwards", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000066 - Disclosure - Income taxes (Details Narrative)", "role": "http://intellipharmaceutics.com/role/IncomeTaxesDetailsNarrative", "shortName": "Income taxes (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "ix:continuation", "body", "html" ], "baseRef": "ipii_20f.htm", "contextRef": "AsOf2021-11-30", "decimals": "0", "lang": null, "name": "ipci:DeferredTaxAssetsTaxDeferredExpenseResearchAndExperimentalDevelopmentExpenditures", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R66": { "firstAnchor": { "ancestors": [ "p", "ix:continuation", "body", "html" ], "baseRef": "ipii_20f.htm", "contextRef": "From2021-10-10to2021-10-12", "decimals": "0", "first": true, "lang": null, "name": "ipci:PaymentForSettlement", "reportCount": 1, "unique": true, "unitRef": "CAD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000067 - Disclosure - Contingencies (Details Narrative)", "role": "http://intellipharmaceutics.com/role/ContingenciesDetailsNarrative", "shortName": "Contingencies (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "ix:continuation", "body", "html" ], "baseRef": "ipii_20f.htm", "contextRef": "From2021-10-10to2021-10-12", "decimals": "0", "first": true, "lang": null, "name": "ipci:PaymentForSettlement", "reportCount": 1, "unique": true, "unitRef": "CAD", "xsiNil": "false" } }, "R67": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "ipci:Fairvalueassetsmeasuredonnonrecurringbasistextblock", "ix:continuation", "body", "html" ], "baseRef": "ipii_20f.htm", "contextRef": "AsOf2021-11-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:ConvertibleDebt", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000068 - Disclosure - Financial Instruments (Details)", "role": "http://intellipharmaceutics.com/role/FinancialInstrumentsDetails", "shortName": "Financial Instruments (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "ipci:Fairvalueassetsmeasuredonnonrecurringbasistextblock", "ix:continuation", "body", "html" ], "baseRef": "ipii_20f.htm", "contextRef": "AsOf2021-11-30", "decimals": "0", "lang": null, "name": "us-gaap:NotesPayableFairValueDisclosure", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R68": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "ipci:Pastduefinancingreceivablestabletextblock", "ix:continuation", "body", "html" ], "baseRef": "ipii_20f.htm", "contextRef": "AsOf2021-11-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:AccountsReceivableGrossCurrent", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000069 - Disclosure - Financial Instruments (Details 1)", "role": "http://intellipharmaceutics.com/role/FinancialInstrumentsDetails1", "shortName": "Financial Instruments (Details 1)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "ipci:Pastduefinancingreceivablestabletextblock", "ix:continuation", "body", "html" ], "baseRef": "ipii_20f.htm", "contextRef": "AsOf2021-11-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:AccountsReceivableGrossCurrent", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R69": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "ipci:Contractualobligationfiscalyearmaturityscheduletabletextblock", "ix:continuation", "body", "html" ], "baseRef": "ipii_20f.htm", "contextRef": "From2020-12-01to2021-11-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:EffectOnFutureCashFlowsAmount", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000070 - Disclosure - Financial Instruments (Details 2)", "role": "http://intellipharmaceutics.com/role/FinancialInstrumentsDetails2", "shortName": "Financial Instruments (Details 2)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "ipci:Contractualobligationfiscalyearmaturityscheduletabletextblock", "ix:continuation", "body", "html" ], "baseRef": "ipii_20f.htm", "contextRef": "From2020-12-01to2021-11-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:EffectOnFutureCashFlowsAmount", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R7": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "ipii_20f.htm", "contextRef": "From2020-12-01to2021-11-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:NatureOfOperations", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000007 - Disclosure - Nature of Operations", "role": "http://intellipharmaceutics.com/role/NatureOfOperations", "shortName": "Nature of Operations", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "ipii_20f.htm", "contextRef": "From2020-12-01to2021-11-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:NatureOfOperations", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R70": { "firstAnchor": { "ancestors": [ "p", "ix:continuation", "body", "html" ], "baseRef": "ipii_20f.htm", "contextRef": "From2020-12-01to2021-11-30", "decimals": "-5", "first": true, "lang": null, "name": "ipci:ForeignExchangeRiskThresholdBalance", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000071 - Disclosure - Financial Instruments (Details Narrative)", "role": "http://intellipharmaceutics.com/role/FinancialInstrumentsDetailsNarrative", "shortName": "Financial Instruments (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "ix:continuation", "body", "html" ], "baseRef": "ipii_20f.htm", "contextRef": "From2020-12-01to2021-11-30", "decimals": "-5", "first": true, "lang": null, "name": "ipci:ForeignExchangeRiskThresholdBalance", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R71": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "body", "html" ], "baseRef": "ipii_20f.htm", "contextRef": "From2020-12-01to2021-11-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:Revenues", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000072 - Disclosure - Segmented Information (Details)", "role": "http://intellipharmaceutics.com/role/SegmentedInformationDetails", "shortName": "Segmented Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "ipci:Scheduleofrevenuesfromexternalcustomersandlonglivedassetsbygeographicalareastabletextblock", "us-gaap:SegmentReportingDisclosureTextBlock", "body", "html" ], "baseRef": "ipii_20f.htm", "contextRef": "From2020-12-01to2021-11-30_ipci_UnitedStateMember", "decimals": "0", "lang": null, "name": "us-gaap:Revenues", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R8": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "ipii_20f.htm", "contextRef": "From2020-12-01to2021-11-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000008 - Disclosure - Basis of Presentation", "role": "http://intellipharmaceutics.com/role/BasisOfPresentation", "shortName": "Basis of Presentation", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "ipii_20f.htm", "contextRef": "From2020-12-01to2021-11-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R9": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "ipii_20f.htm", "contextRef": "From2020-12-01to2021-11-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000009 - Disclosure - Significant Accounting Policies", "role": "http://intellipharmaceutics.com/role/SignificantAccountingPolicies", "shortName": "Significant Accounting Policies", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "ipii_20f.htm", "contextRef": "From2020-12-01to2021-11-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 75, "tag": { "dei_AddressTypeDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "An entity may have several addresses for different purposes and this domain represents all such types." } } }, "localname": "AddressTypeDomain", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://intellipharmaceutics.com/role/Cover" ], "xbrltype": "domainItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://intellipharmaceutics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AuditorLocation": { "auth_ref": [ "r535", "r536", "r537" ], "lang": { "en-us": { "role": { "label": "Auditor Location" } } }, "localname": "AuditorLocation", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://intellipharmaceutics.com/role/Cover" ], "xbrltype": "internationalNameItemType" }, "dei_AuditorName": { "auth_ref": [ "r535", "r536", "r537" ], "lang": { "en-us": { "role": { "label": "Auditor Name" } } }, "localname": "AuditorName", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://intellipharmaceutics.com/role/Cover" ], "xbrltype": "internationalNameItemType" }, "dei_BusinessContactMember": { "auth_ref": [ "r536", "r537" ], "lang": { "en-us": { "role": { "documentation": "Business contact for the entity", "label": "Business Contact [Member]" } } }, "localname": "BusinessContactMember", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://intellipharmaceutics.com/role/Cover" ], "xbrltype": "domainItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://intellipharmaceutics.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_ContactPersonnelName": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of contact personnel", "label": "Contact Personnel Name" } } }, "localname": "ContactPersonnelName", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://intellipharmaceutics.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://intellipharmaceutics.com/role/Cover" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentAccountingStandard": { "auth_ref": [ "r536" ], "lang": { "en-us": { "role": { "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.", "label": "Document Accounting Standard" } } }, "localname": "DocumentAccountingStandard", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://intellipharmaceutics.com/role/Cover" ], "xbrltype": "accountingStandardItemType" }, "dei_DocumentAnnualReport": { "auth_ref": [ "r535", "r536", "r537" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an annual report.", "label": "Document Annual Report" } } }, "localname": "DocumentAnnualReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://intellipharmaceutics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://intellipharmaceutics.com/role/Cover" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://intellipharmaceutics.com/role/Cover" ], "xbrltype": "gYearItemType" }, "dei_DocumentInformationLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "localname": "DocumentInformationLineItems", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://intellipharmaceutics.com/role/Cover" ], "xbrltype": "stringItemType" }, "dei_DocumentInformationTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package." } } }, "localname": "DocumentInformationTable", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://intellipharmaceutics.com/role/Cover" ], "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://intellipharmaceutics.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentRegistrationStatement": { "auth_ref": [ "r533" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a registration statement.", "label": "Document Registration Statement" } } }, "localname": "DocumentRegistrationStatement", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://intellipharmaceutics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentShellCompanyReport": { "auth_ref": [ "r536" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.", "label": "Document Shell Company Report" } } }, "localname": "DocumentShellCompanyReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://intellipharmaceutics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r538" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://intellipharmaceutics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://intellipharmaceutics.com/role/Cover" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address Address Line 1" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://intellipharmaceutics.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address City Or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://intellipharmaceutics.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://intellipharmaceutics.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressesAddressTypeAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The axis of a table defines the relationship between the domain members or categories in the table and the line items or concepts that complete the table.", "label": "Entity Addresses Address Type [Axis]" } } }, "localname": "EntityAddressesAddressTypeAxis", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://intellipharmaceutics.com/role/Cover" ], "xbrltype": "stringItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r534" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://intellipharmaceutics.com/role/Cover" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://intellipharmaceutics.com/role/Cover" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://intellipharmaceutics.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r534" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://intellipharmaceutics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://intellipharmaceutics.com/role/Cover" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r534" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://intellipharmaceutics.com/role/Cover" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation State Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://intellipharmaceutics.com/role/Cover" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r546" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://intellipharmaceutics.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r534" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://intellipharmaceutics.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r534" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://intellipharmaceutics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityVoluntaryFilers": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.", "label": "Entity Voluntary Filers" } } }, "localname": "EntityVoluntaryFilers", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://intellipharmaceutics.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityWellKnownSeasonedIssuer": { "auth_ref": [ "r547" ], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.", "label": "Entity Well Known Seasoned Issuer" } } }, "localname": "EntityWellKnownSeasonedIssuer", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://intellipharmaceutics.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_IcfrAuditorAttestationFlag": { "auth_ref": [ "r535", "r536", "r537" ], "lang": { "en-us": { "role": { "label": "Icfr Auditor Attestation Flag" } } }, "localname": "IcfrAuditorAttestationFlag", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://intellipharmaceutics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://intellipharmaceutics.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "ipci_Accountspayableandaccruedliabilitiesdisclosuretextblock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "[Accrued Liabilities]", "verboseLabel": "Accrued Liabilities" } } }, "localname": "Accountspayableandaccruedliabilitiesdisclosuretextblock", "nsuri": "http://intellipharmaceutics.com/20201130", "presentation": [ "http://intellipharmaceutics.com/role/AccruedLiabilities" ], "xbrltype": "textBlockItemType" }, "ipci_AccruedBoardOfDirectorsFees": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Board of Directors fees" } } }, "localname": "AccruedBoardOfDirectorsFees", "nsuri": "http://intellipharmaceutics.com/20201130", "presentation": [ "http://intellipharmaceutics.com/role/AccruedLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "ipci_AccruedInterest": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Interest" } } }, "localname": "AccruedInterest", "nsuri": "http://intellipharmaceutics.com/20201130", "presentation": [ "http://intellipharmaceutics.com/role/AccruedLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "ipci_AccruedLitigationSettlementFee": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Litigation settlement fee (Note 16)" } } }, "localname": "AccruedLitigationSettlementFee", "nsuri": "http://intellipharmaceutics.com/20201130", "presentation": [ "http://intellipharmaceutics.com/role/AccruedLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "ipci_AdditionalCommonStockSharesIssued": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Additional common stock shares issued" } } }, "localname": "AdditionalCommonStockSharesIssued", "nsuri": "http://intellipharmaceutics.com/20201130", "presentation": [ "http://intellipharmaceutics.com/role/WarrantsDetailsNarrative" ], "xbrltype": "sharesItemType" }, "ipci_AdditionalPaidInCapitalOneMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Additional Paid In Capital [Member]" } } }, "localname": "AdditionalPaidInCapitalOneMember", "nsuri": "http://intellipharmaceutics.com/20201130", "presentation": [ "http://intellipharmaceutics.com/role/CapitalStockDetailsNarrative" ], "xbrltype": "domainItemType" }, "ipci_Additionalcommonstockandwarrantsissued": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Additional common stock and Warrants Issued" } } }, "localname": "Additionalcommonstockandwarrantsissued", "nsuri": "http://intellipharmaceutics.com/20201130", "presentation": [ "http://intellipharmaceutics.com/role/CapitalStockDetailsNarrative" ], "xbrltype": "sharesItemType" }, "ipci_AggregateOfCommonSharesIssued": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Aggregate of common shares issued" } } }, "localname": "AggregateOfCommonSharesIssued", "nsuri": "http://intellipharmaceutics.com/20201130", "presentation": [ "http://intellipharmaceutics.com/role/WarrantsDetailsNarrative" ], "xbrltype": "sharesItemType" }, "ipci_BookAndTaxBasisDifferencesOnAssetsAndLiabilities": { "auth_ref": [], "calculation": { "http://intellipharmaceutics.com/role/IncomeTaxesDetails": { "order": 3.0, "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "label": "Book and tax basis differences on assets and liabilities" } } }, "localname": "BookAndTaxBasisDifferencesOnAssetsAndLiabilities", "nsuri": "http://intellipharmaceutics.com/20201130", "presentation": [ "http://intellipharmaceutics.com/role/IncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "ipci_CanadasMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Canada [Member]" } } }, "localname": "CanadasMember", "nsuri": "http://intellipharmaceutics.com/20201130", "presentation": [ "http://intellipharmaceutics.com/role/SegmentedInformationDetails" ], "xbrltype": "domainItemType" }, "ipci_CapitalUnitsOneMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Capital Units [Member]" } } }, "localname": "CapitalUnitsOneMember", "nsuri": "http://intellipharmaceutics.com/20201130", "presentation": [ "http://intellipharmaceutics.com/role/CapitalStockDetailsNarrative" ], "xbrltype": "domainItemType" }, "ipci_ChargesFromAdditionalPaidInCapitalToCommonSharesUnderCapitalStock": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "Charges from additional paid-in capital to common shares under Capital stock", "terseLabel": "Charges from additional paid-in capital to common shares under Capital stock", "verboseLabel": "Charges from additional paid-in capital to common shares under Capital stock" } } }, "localname": "ChargesFromAdditionalPaidInCapitalToCommonSharesUnderCapitalStock", "nsuri": "http://intellipharmaceutics.com/20201130", "presentation": [ "http://intellipharmaceutics.com/role/CapitalStockDetailsNarrative", "http://intellipharmaceutics.com/role/DeferredShareUnitsDetailsNarrative", "http://intellipharmaceutics.com/role/WarrantsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "ipci_Classofwarrantorrightexercisepriceofwarrantsorrights1": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Warrants, exercise price" } } }, "localname": "Classofwarrantorrightexercisepriceofwarrantsorrights1", "nsuri": "http://intellipharmaceutics.com/20201130", "presentation": [ "http://intellipharmaceutics.com/role/CapitalStockDetailsNarrative" ], "xbrltype": "perShareItemType" }, "ipci_Classofwarrantorrightnumberofsecuritiescalledbywarrantsorrights": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Number of securities called by warrants or rights" } } }, "localname": "Classofwarrantorrightnumberofsecuritiescalledbywarrantsorrights", "nsuri": "http://intellipharmaceutics.com/20201130", "presentation": [ "http://intellipharmaceutics.com/role/CapitalStockDetailsNarrative" ], "xbrltype": "sharesItemType" }, "ipci_CommonSharesIssuedDuringPeriodUponExercise": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Common shares issued during period upon exercise", "verboseLabel": "Common shares issued during period upon exercise" } } }, "localname": "CommonSharesIssuedDuringPeriodUponExercise", "nsuri": "http://intellipharmaceutics.com/20201130", "presentation": [ "http://intellipharmaceutics.com/role/CapitalStockDetailsNarrative", "http://intellipharmaceutics.com/role/WarrantsDetailsNarrative" ], "xbrltype": "sharesItemType" }, "ipci_CommonStockOneMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Common Stock [Member]" } } }, "localname": "CommonStockOneMember", "nsuri": "http://intellipharmaceutics.com/20201130", "presentation": [ "http://intellipharmaceutics.com/role/CapitalStockDetailsNarrative" ], "xbrltype": "domainItemType" }, "ipci_Commonstockvalue": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Common stock value, issued" } } }, "localname": "Commonstockvalue", "nsuri": "http://intellipharmaceutics.com/20201130", "presentation": [ "http://intellipharmaceutics.com/role/CapitalStockDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "ipci_ComputerSoftwareMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Computer Software" } } }, "localname": "ComputerSoftwareMember", "nsuri": "http://intellipharmaceutics.com/20201130", "presentation": [ "http://intellipharmaceutics.com/role/PropertyAndEquipmentDetails" ], "xbrltype": "domainItemType" }, "ipci_Contractualobligationfiscalyearmaturityscheduletabletextblock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Contractual obligation, fiscal year maturity schedule" } } }, "localname": "Contractualobligationfiscalyearmaturityscheduletabletextblock", "nsuri": "http://intellipharmaceutics.com/20201130", "presentation": [ "http://intellipharmaceutics.com/role/FinancialInstrumentsTables" ], "xbrltype": "textBlockItemType" }, "ipci_ContributionToSettlementFund": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "Contribution to settlement fund" } } }, "localname": "ContributionToSettlementFund", "nsuri": "http://intellipharmaceutics.com/20201130", "presentation": [ "http://intellipharmaceutics.com/role/ContingenciesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "ipci_ConversionPricePerShare": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Conversion price per share" } } }, "localname": "ConversionPricePerShare", "nsuri": "http://intellipharmaceutics.com/20201130", "presentation": [ "http://intellipharmaceutics.com/role/SignificantAccountingPoliciesDetailsNarratives" ], "xbrltype": "perShareItemType" }, "ipci_ConvertibleDebenturesAndPromissoryNotesPayableDetails1": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Convertible Debentures and Promissory Notes Payable (Details 1)" } } }, "localname": "ConvertibleDebenturesAndPromissoryNotesPayableDetails1", "nsuri": "http://intellipharmaceutics.com/20201130", "xbrltype": "stringItemType" }, "ipci_ConvertibleDebtPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the policy for convertible debt.", "label": "Convertible debentures" } } }, "localname": "ConvertibleDebtPolicyTextBlock", "nsuri": "http://intellipharmaceutics.com/20201130", "presentation": [ "http://intellipharmaceutics.com/role/SignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "ipci_ConvertibleNotesPayable1": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Convertible debenture payable to two directors and officers of the Company, unsecured, 10% annual interest rate, payable monthly (\"2018 Debenture\")" } } }, "localname": "ConvertibleNotesPayable1", "nsuri": "http://intellipharmaceutics.com/20201130", "presentation": [ "http://intellipharmaceutics.com/role/ConvertibleDebenturesAndPromissoryNotesPayableDetails" ], "xbrltype": "monetaryItemType" }, "ipci_ConvertibleNotesPayable2": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Convertible debenture payable to two directors and officers of the Company, unsecured, 12% annual interest rate, payable monthly (\"May 2019 Debenture\")" } } }, "localname": "ConvertibleNotesPayable2", "nsuri": "http://intellipharmaceutics.com/20201130", "presentation": [ "http://intellipharmaceutics.com/role/ConvertibleDebenturesAndPromissoryNotesPayableDetails" ], "xbrltype": "monetaryItemType" }, "ipci_ConvertibleNotesPayable3": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Convertible debenture payable to two directors and officers of the Company, unsecured, 12% annual interest rate, payable monthly (\"November 2019 Debenture\")" } } }, "localname": "ConvertibleNotesPayable3", "nsuri": "http://intellipharmaceutics.com/20201130", "presentation": [ "http://intellipharmaceutics.com/role/ConvertibleDebenturesAndPromissoryNotesPayableDetails" ], "xbrltype": "monetaryItemType" }, "ipci_CovidActReliefFund": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Relief fund offset" } } }, "localname": "CovidActReliefFund", "nsuri": "http://intellipharmaceutics.com/20201130", "presentation": [ "http://intellipharmaceutics.com/role/LeaseDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "ipci_CurrentTaxExpense": { "auth_ref": [], "calculation": { "http://intellipharmaceutics.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss": { "order": 22.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after tax of income (loss) from continuing operations including portion attributable to the noncontrolling interest.", "label": "Current tax expense" } } }, "localname": "CurrentTaxExpense", "nsuri": "http://intellipharmaceutics.com/20201130", "presentation": [ "http://intellipharmaceutics.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "ipci_Currentincometaxexpensebenefit": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "[Current tax expense]", "verboseLabel": "Current tax expense" } } }, "localname": "Currentincometaxexpensebenefit", "nsuri": "http://intellipharmaceutics.com/20201130", "presentation": [ "http://intellipharmaceutics.com/role/IncomeTaxesDetails2" ], "xbrltype": "monetaryItemType" }, "ipci_DebtConvertibleCommonShares": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Debt convertible common shares" } } }, "localname": "DebtConvertibleCommonShares", "nsuri": "http://intellipharmaceutics.com/20201130", "presentation": [ "http://intellipharmaceutics.com/role/SignificantAccountingPoliciesDetailsNarratives" ], "xbrltype": "sharesItemType" }, "ipci_DebtInstrumentCarryingValue": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Debt instrument carrying value" } } }, "localname": "DebtInstrumentCarryingValue", "nsuri": "http://intellipharmaceutics.com/20201130", "presentation": [ "http://intellipharmaceutics.com/role/ConvertibleDebenturesAndPromissoryNotesPayableDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "ipci_DebtPrincipalAmount": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount of the original debt being converted in a noncash (or part noncash) transaction. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.", "label": "Debt principal amount" } } }, "localname": "DebtPrincipalAmount", "nsuri": "http://intellipharmaceutics.com/20201130", "presentation": [ "http://intellipharmaceutics.com/role/ConvertibleDebenturesAndPromissoryNotesPayableDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "ipci_DecliningBalanceDepreciationRate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the declining balance depreciation rate.", "label": "Declining balance depreciation rate" } } }, "localname": "DecliningBalanceDepreciationRate", "nsuri": "http://intellipharmaceutics.com/20201130", "presentation": [ "http://intellipharmaceutics.com/role/SignificantAccountingPoliciesDetail" ], "xbrltype": "percentItemType" }, "ipci_DecliningBalanceMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Declining Balance" } } }, "localname": "DecliningBalanceMember", "nsuri": "http://intellipharmaceutics.com/20201130", "presentation": [ "http://intellipharmaceutics.com/role/SignificantAccountingPoliciesDetail" ], "xbrltype": "domainItemType" }, "ipci_DeferredCompensationArrangementsDisclosureTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for deferred compensation arrangements.", "label": "[Deferred Share Units]", "verboseLabel": "Deferred Share Units" } } }, "localname": "DeferredCompensationArrangementsDisclosureTextBlock", "nsuri": "http://intellipharmaceutics.com/20201130", "presentation": [ "http://intellipharmaceutics.com/role/DeferredShareUnits" ], "xbrltype": "textBlockItemType" }, "ipci_DeferredIncomeTaxRecovery": { "auth_ref": [], "calculation": { "http://intellipharmaceutics.com/role/ConsolidatedStatementsOfCashFlows": { "order": 16.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Deferred income tax recovery.", "label": "Deferred income tax recovery (Note 15)" } } }, "localname": "DeferredIncomeTaxRecovery", "nsuri": "http://intellipharmaceutics.com/20201130", "presentation": [ "http://intellipharmaceutics.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "ipci_DeferredShareUnitsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Deferred Share Units" } } }, "localname": "DeferredShareUnitsAbstract", "nsuri": "http://intellipharmaceutics.com/20201130", "xbrltype": "stringItemType" }, "ipci_DeferredShareUnitsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "[Deferred Share Units 2]", "verboseLabel": "Deferred Share Units" } } }, "localname": "DeferredShareUnitsMember", "nsuri": "http://intellipharmaceutics.com/20201130", "presentation": [ "http://intellipharmaceutics.com/role/DeferredShareUnitsDetailsNarrative" ], "xbrltype": "domainItemType" }, "ipci_DeferredShareUnitsPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the policy for deferred share units.", "label": "[Deferred Share Units 1]", "verboseLabel": "Deferred Share Units" } } }, "localname": "DeferredShareUnitsPolicyTextBlock", "nsuri": "http://intellipharmaceutics.com/20201130", "presentation": [ "http://intellipharmaceutics.com/role/SignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "ipci_DeferredTaxAssetsTaxDeferredExpenseResearchAndExperimentalDevelopmentExpenditures": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "Research and experimental development expenditures, cumulative carry-forwards" } } }, "localname": "DeferredTaxAssetsTaxDeferredExpenseResearchAndExperimentalDevelopmentExpenditures", "nsuri": "http://intellipharmaceutics.com/20201130", "presentation": [ "http://intellipharmaceutics.com/role/IncomeTaxesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "ipci_DeferredTaxAssetsTaxDeferredExpenseUndeductedResearchAndDevelopmentExpenditures": { "auth_ref": [], "calculation": { "http://intellipharmaceutics.com/role/IncomeTaxesDetails": { "order": 6.0, "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "label": "Undeducted research and development expenditures" } } }, "localname": "DeferredTaxAssetsTaxDeferredExpenseUndeductedResearchAndDevelopmentExpenditures", "nsuri": "http://intellipharmaceutics.com/20201130", "presentation": [ "http://intellipharmaceutics.com/role/IncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "ipci_DeferredTaxAssetsUnclaimedInvestmentTaxCredits": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "Unclaimed investment tax credits" } } }, "localname": "DeferredTaxAssetsUnclaimedInvestmentTaxCredits", "nsuri": "http://intellipharmaceutics.com/20201130", "presentation": [ "http://intellipharmaceutics.com/role/IncomeTaxesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "ipci_DeferredTaxLiabilitiesConvertibleDebentures": { "auth_ref": [], "calculation": { "http://intellipharmaceutics.com/role/IncomeTaxesDetails": { "order": 10.0, "parentTag": "us-gaap_DeferredTaxLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "label": "[Convertible debentures]", "verboseLabel": "Convertible debentures" } } }, "localname": "DeferredTaxLiabilitiesConvertibleDebentures", "nsuri": "http://intellipharmaceutics.com/20201130", "presentation": [ "http://intellipharmaceutics.com/role/IncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "ipci_DeferredTaxRecovery": { "auth_ref": [], "calculation": { "http://intellipharmaceutics.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss": { "order": 21.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "label": "Deferred tax recovery" } } }, "localname": "DeferredTaxRecovery", "nsuri": "http://intellipharmaceutics.com/20201130", "presentation": [ "http://intellipharmaceutics.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "ipci_Deferredincometaxexpensebenefit": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "[Deferred tax recovery]", "verboseLabel": "Deferred tax recovery" } } }, "localname": "Deferredincometaxexpensebenefit", "nsuri": "http://intellipharmaceutics.com/20201130", "presentation": [ "http://intellipharmaceutics.com/role/IncomeTaxesDetails2" ], "xbrltype": "monetaryItemType" }, "ipci_Effectiveincometaxratereconciliationatfederalstatutoryincometaxrate": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statutory income tax rate" } } }, "localname": "Effectiveincometaxratereconciliationatfederalstatutoryincometaxrate", "nsuri": "http://intellipharmaceutics.com/20201130", "presentation": [ "http://intellipharmaceutics.com/role/IncomeTaxesDetails2" ], "xbrltype": "percentItemType" }, "ipci_Effectiveincometaxreconciliationglobalintangiblelowtaxedincome": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Global intangible low-taxed income (GILTI)" } } }, "localname": "Effectiveincometaxreconciliationglobalintangiblelowtaxedincome", "nsuri": "http://intellipharmaceutics.com/20201130", "presentation": [ "http://intellipharmaceutics.com/role/IncomeTaxesDetails2" ], "xbrltype": "monetaryItemType" }, "ipci_Effectiveincometaxreconciliationtaxlossexpired": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "Tax loss expired and other" } } }, "localname": "Effectiveincometaxreconciliationtaxlossexpired", "nsuri": "http://intellipharmaceutics.com/20201130", "presentation": [ "http://intellipharmaceutics.com/role/IncomeTaxesDetails2" ], "xbrltype": "monetaryItemType" }, "ipci_EmployeeCostsPayableMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Employee Costs Payable" } } }, "localname": "EmployeeCostsPayableMember", "nsuri": "http://intellipharmaceutics.com/20201130", "presentation": [ "http://intellipharmaceutics.com/role/FinancialInstrumentsDetails2" ], "xbrltype": "domainItemType" }, "ipci_EquipmentBookValue": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "Equipment book value" } } }, "localname": "EquipmentBookValue", "nsuri": "http://intellipharmaceutics.com/20201130", "presentation": [ "http://intellipharmaceutics.com/role/PropertyAndEquipmentDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "ipci_EquipmentNotInUse": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "Equipment not in use" } } }, "localname": "EquipmentNotInUse", "nsuri": "http://intellipharmaceutics.com/20201130", "presentation": [ "http://intellipharmaceutics.com/role/PropertyAndEquipmentDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "ipci_ExerciseOfOverallotmentOptionPerShare": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Exercise of overallotment option per share" } } }, "localname": "ExerciseOfOverallotmentOptionPerShare", "nsuri": "http://intellipharmaceutics.com/20201130", "presentation": [ "http://intellipharmaceutics.com/role/WarrantsDetailsNarrative" ], "xbrltype": "perShareItemType" }, "ipci_FairValueOfPreFundedWarrants": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Fair value of Pre funded warrants" } } }, "localname": "FairValueOfPreFundedWarrants", "nsuri": "http://intellipharmaceutics.com/20201130", "presentation": [ "http://intellipharmaceutics.com/role/WarrantsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "ipci_Fairvalueassetsmeasuredonnonrecurringbasistextblock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Schedule of fair value measurements, nonrecurring" } } }, "localname": "Fairvalueassetsmeasuredonnonrecurringbasistextblock", "nsuri": "http://intellipharmaceutics.com/20201130", "presentation": [ "http://intellipharmaceutics.com/role/FinancialInstrumentsTables" ], "xbrltype": "textBlockItemType" }, "ipci_FinancialLiabilitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Financial Liabilities" } } }, "localname": "FinancialLiabilitiesAbstract", "nsuri": "http://intellipharmaceutics.com/20201130", "presentation": [ "http://intellipharmaceutics.com/role/FinancialInstrumentsDetails" ], "xbrltype": "stringItemType" }, "ipci_FinancingReceivableNotPastDue": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "Not past due" } } }, "localname": "FinancingReceivableNotPastDue", "nsuri": "http://intellipharmaceutics.com/20201130", "presentation": [ "http://intellipharmaceutics.com/role/FinancialInstrumentsDetails1" ], "xbrltype": "monetaryItemType" }, "ipci_FinancingReceivablePastDue": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "Past due" } } }, "localname": "FinancingReceivablePastDue", "nsuri": "http://intellipharmaceutics.com/20201130", "presentation": [ "http://intellipharmaceutics.com/role/FinancialInstrumentsDetails1" ], "xbrltype": "monetaryItemType" }, "ipci_FinishedGoodsWriteOff": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Finished goods write off" } } }, "localname": "FinishedGoodsWriteOff", "nsuri": "http://intellipharmaceutics.com/20201130", "presentation": [ "http://intellipharmaceutics.com/role/SignificantAccountingPoliciesDetailsNarratives" ], "xbrltype": "monetaryItemType" }, "ipci_FirmWarrants2018Member": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "2018 Firm Warrants" } } }, "localname": "FirmWarrants2018Member", "nsuri": "http://intellipharmaceutics.com/20201130", "presentation": [ "http://intellipharmaceutics.com/role/WarrantsDetails", "http://intellipharmaceutics.com/role/WarrantsDetails1" ], "xbrltype": "domainItemType" }, "ipci_ForeignExchangeRiskLossAndOtherComprehensiveLossAmountAffected": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Foreign exchange risk loss and other comprehensive loss amount affected" } } }, "localname": "ForeignExchangeRiskLossAndOtherComprehensiveLossAmountAffected", "nsuri": "http://intellipharmaceutics.com/20201130", "presentation": [ "http://intellipharmaceutics.com/role/FinancialInstrumentsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "ipci_ForeignExchangeRiskMovementInCurrencyPercentage": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Foreign exchange risk movement in currency percentage" } } }, "localname": "ForeignExchangeRiskMovementInCurrencyPercentage", "nsuri": "http://intellipharmaceutics.com/20201130", "presentation": [ "http://intellipharmaceutics.com/role/FinancialInstrumentsDetailsNarrative" ], "xbrltype": "percentItemType" }, "ipci_ForeignExchangeRiskThresholdBalance": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Foreign exchange risk threshold balance" } } }, "localname": "ForeignExchangeRiskThresholdBalance", "nsuri": "http://intellipharmaceutics.com/20201130", "presentation": [ "http://intellipharmaceutics.com/role/FinancialInstrumentsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "ipci_GreaterThanOneYearMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Greater Than One Year" } } }, "localname": "GreaterThanOneYearMember", "nsuri": "http://intellipharmaceutics.com/20201130", "presentation": [ "http://intellipharmaceutics.com/role/FinancialInstrumentsDetails2" ], "xbrltype": "domainItemType" }, "ipci_GrossProceedsFromCommonSharesAndWarrants": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Gross proceeds from common shares and warrants" } } }, "localname": "GrossProceedsFromCommonSharesAndWarrants", "nsuri": "http://intellipharmaceutics.com/20201130", "presentation": [ "http://intellipharmaceutics.com/role/WarrantsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "ipci_IncomeLossPerCommonShareBasicAndDiluted": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Loss per common share, basic and diluted" } } }, "localname": "IncomeLossPerCommonShareBasicAndDiluted", "nsuri": "http://intellipharmaceutics.com/20201130", "presentation": [ "http://intellipharmaceutics.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "perShareItemType" }, "ipci_Incometaxexpensebenefit": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "Income tax expense (recovery)" } } }, "localname": "Incometaxexpensebenefit", "nsuri": "http://intellipharmaceutics.com/20201130", "presentation": [ "http://intellipharmaceutics.com/role/IncomeTaxesDetails2" ], "xbrltype": "monetaryItemType" }, "ipci_Incometaxreconciliationchangeindeferredtaxassetsvaluationallowance": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "Change in valuation allowance" } } }, "localname": "Incometaxreconciliationchangeindeferredtaxassetsvaluationallowance", "nsuri": "http://intellipharmaceutics.com/20201130", "presentation": [ "http://intellipharmaceutics.com/role/IncomeTaxesDetails2" ], "xbrltype": "monetaryItemType" }, "ipci_Incometaxreconciliationdeductionsother": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Financing costs booked to equity" } } }, "localname": "Incometaxreconciliationdeductionsother", "nsuri": "http://intellipharmaceutics.com/20201130", "presentation": [ "http://intellipharmaceutics.com/role/IncomeTaxesDetails2" ], "xbrltype": "monetaryItemType" }, "ipci_Incometaxreconciliationforeignexchangechange": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Difference in foreign tax rates" } } }, "localname": "Incometaxreconciliationforeignexchangechange", "nsuri": "http://intellipharmaceutics.com/20201130", "presentation": [ "http://intellipharmaceutics.com/role/IncomeTaxesDetails2" ], "xbrltype": "monetaryItemType" }, "ipci_Incometaxreconciliationincometaxexpensebenefitatfederalstatutoryincometaxrate": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "Statutory income tax recovery" } } }, "localname": "Incometaxreconciliationincometaxexpensebenefitatfederalstatutoryincometaxrate", "nsuri": "http://intellipharmaceutics.com/20201130", "presentation": [ "http://intellipharmaceutics.com/role/IncomeTaxesDetails2" ], "xbrltype": "monetaryItemType" }, "ipci_Incometaxreconciliationnondeductibleexpense": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "Non-deductible expenses/ non-taxable income" } } }, "localname": "Incometaxreconciliationnondeductibleexpense", "nsuri": "http://intellipharmaceutics.com/20201130", "presentation": [ "http://intellipharmaceutics.com/role/IncomeTaxesDetails2" ], "xbrltype": "monetaryItemType" }, "ipci_Incometaxreconciliationotheradjustments": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "True up of tax returns" } } }, "localname": "Incometaxreconciliationotheradjustments", "nsuri": "http://intellipharmaceutics.com/20201130", "presentation": [ "http://intellipharmaceutics.com/role/IncomeTaxesDetails2" ], "xbrltype": "monetaryItemType" }, "ipci_Incometaxreconciliationtaxcreditsinvestment": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "[Investment tax credit]", "verboseLabel": "Investment tax credit" } } }, "localname": "Incometaxreconciliationtaxcreditsinvestment", "nsuri": "http://intellipharmaceutics.com/20201130", "presentation": [ "http://intellipharmaceutics.com/role/IncomeTaxesDetails2" ], "xbrltype": "monetaryItemType" }, "ipci_IncreaseDecreaseInDeferredTaxAssetsLiabilitiesNetDueToRecognizationInProfitOrLoss": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "Recognized in profit/loss" } } }, "localname": "IncreaseDecreaseInDeferredTaxAssetsLiabilitiesNetDueToRecognizationInProfitOrLoss", "nsuri": "http://intellipharmaceutics.com/20201130", "presentation": [ "http://intellipharmaceutics.com/role/IncomeTaxesDetails1" ], "xbrltype": "monetaryItemType" }, "ipci_IncreaseDecreaseInDeferredTaxAssetsLiabilitiesNetDueToRecognizationInShareholdersEquity": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "Recognized in shareholders' equity" } } }, "localname": "IncreaseDecreaseInDeferredTaxAssetsLiabilitiesNetDueToRecognizationInShareholdersEquity", "nsuri": "http://intellipharmaceutics.com/20201130", "presentation": [ "http://intellipharmaceutics.com/role/IncomeTaxesDetails1" ], "xbrltype": "monetaryItemType" }, "ipci_IncreaseDecreaseInPrepaidExpensesSundryAndOtherAssets": { "auth_ref": [], "calculation": { "http://intellipharmaceutics.com/role/ConsolidatedStatementsOfCashFlows": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "label": "[Prepaid expenses, sundry and other assets 1]", "verboseLabel": "Prepaid expenses, sundry and other assets" } } }, "localname": "IncreaseDecreaseInPrepaidExpensesSundryAndOtherAssets", "nsuri": "http://intellipharmaceutics.com/20201130", "presentation": [ "http://intellipharmaceutics.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "ipci_IncreaseDecreaseOperatingLeaseLiability": { "auth_ref": [], "calculation": { "http://intellipharmaceutics.com/role/ConsolidatedStatementsOfCashFlows": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "label": "Operating lease liability" } } }, "localname": "IncreaseDecreaseOperatingLeaseLiability", "nsuri": "http://intellipharmaceutics.com/20201130", "presentation": [ "http://intellipharmaceutics.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "ipci_ItemsNotAffectingCashAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Items not affecting cash" } } }, "localname": "ItemsNotAffectingCashAbstract", "nsuri": "http://intellipharmaceutics.com/20201130", "presentation": [ "http://intellipharmaceutics.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "ipci_June2016WarrantsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "June 2016 Warrants" } } }, "localname": "June2016WarrantsMember", "nsuri": "http://intellipharmaceutics.com/20201130", "presentation": [ "http://intellipharmaceutics.com/role/WarrantsDetails1" ], "xbrltype": "domainItemType" }, "ipci_LaboratoryEquipmentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Laboratory Equipment", "verboseLabel": "Laboratory Equipment" } } }, "localname": "LaboratoryEquipmentMember", "nsuri": "http://intellipharmaceutics.com/20201130", "presentation": [ "http://intellipharmaceutics.com/role/PropertyAndEquipmentDetails", "http://intellipharmaceutics.com/role/PropertyAndEquipmentDetailsNarrative", "http://intellipharmaceutics.com/role/SignificantAccountingPoliciesDetail" ], "xbrltype": "domainItemType" }, "ipci_LessThan3MonthsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Less Than 3 Months" } } }, "localname": "LessThan3MonthsMember", "nsuri": "http://intellipharmaceutics.com/20201130", "presentation": [ "http://intellipharmaceutics.com/role/FinancialInstrumentsDetails2" ], "xbrltype": "domainItemType" }, "ipci_LicensingRevenue": { "auth_ref": [], "calculation": { "http://intellipharmaceutics.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss": { "order": 2.0, "parentTag": "us-gaap_Revenues", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "label": "Licensing (Note 3)" } } }, "localname": "LicensingRevenue", "nsuri": "http://intellipharmaceutics.com/20201130", "presentation": [ "http://intellipharmaceutics.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "ipci_LongLivedAssetsWriteDown": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "Write-down of long lived assets" } } }, "localname": "LongLivedAssetsWriteDown", "nsuri": "http://intellipharmaceutics.com/20201130", "presentation": [ "http://intellipharmaceutics.com/role/PropertyAndEquipmentDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "ipci_MallinckrodtLLCMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Mallinckrodt LLC [Member]" } } }, "localname": "MallinckrodtLLCMember", "nsuri": "http://intellipharmaceutics.com/20201130", "presentation": [ "http://intellipharmaceutics.com/role/SignificantAccountingPoliciesDetailsNarratives" ], "xbrltype": "domainItemType" }, "ipci_March2018PlacementAgentWarrantsTotalMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "March 2018 Placement Agent Warrants" } } }, "localname": "March2018PlacementAgentWarrantsTotalMember", "nsuri": "http://intellipharmaceutics.com/20201130", "presentation": [ "http://intellipharmaceutics.com/role/WarrantsDetails1" ], "xbrltype": "domainItemType" }, "ipci_March2018WarrantsTotalMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "March 2018 Warrants" } } }, "localname": "March2018WarrantsTotalMember", "nsuri": "http://intellipharmaceutics.com/20201130", "presentation": [ "http://intellipharmaceutics.com/role/WarrantsDetails1" ], "xbrltype": "domainItemType" }, "ipci_NetCashLeasePayments": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Net cash lease payments" } } }, "localname": "NetCashLeasePayments", "nsuri": "http://intellipharmaceutics.com/20201130", "presentation": [ "http://intellipharmaceutics.com/role/LeaseDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "ipci_NineMonthsToOneYearMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Nine Months To One Year" } } }, "localname": "NineMonthsToOneYearMember", "nsuri": "http://intellipharmaceutics.com/20201130", "presentation": [ "http://intellipharmaceutics.com/role/FinancialInstrumentsDetails2" ], "xbrltype": "domainItemType" }, "ipci_NonCashLeaseExpense": { "auth_ref": [], "calculation": { "http://intellipharmaceutics.com/role/ConsolidatedStatementsOfCashFlows": { "order": 12.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "label": "Non-cash lease expense" } } }, "localname": "NonCashLeaseExpense", "nsuri": "http://intellipharmaceutics.com/20201130", "presentation": [ "http://intellipharmaceutics.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "ipci_November2019DebentureMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "November 2019 Debenture [Member]" } } }, "localname": "November2019DebentureMember", "nsuri": "http://intellipharmaceutics.com/20201130", "presentation": [ "http://intellipharmaceutics.com/role/ConvertibleDebenturesAndPromissoryNotesPayableDetailsNarrative" ], "xbrltype": "domainItemType" }, "ipci_October2017PlacementAgentWarrantsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "October 2017 Placement Agent Warrants" } } }, "localname": "October2017PlacementAgentWarrantsMember", "nsuri": "http://intellipharmaceutics.com/20201130", "presentation": [ "http://intellipharmaceutics.com/role/WarrantsDetails1" ], "xbrltype": "domainItemType" }, "ipci_October2017WarrantsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "October 2017 Warrants" } } }, "localname": "October2017WarrantsMember", "nsuri": "http://intellipharmaceutics.com/20201130", "presentation": [ "http://intellipharmaceutics.com/role/WarrantsDetails1" ], "xbrltype": "domainItemType" }, "ipci_October2018PlacementAgentWarrantsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "October 2018 Placement Agent Warrants" } } }, "localname": "October2018PlacementAgentWarrantsMember", "nsuri": "http://intellipharmaceutics.com/20201130", "presentation": [ "http://intellipharmaceutics.com/role/WarrantsDetails", "http://intellipharmaceutics.com/role/WarrantsDetails1" ], "xbrltype": "domainItemType" }, "ipci_OctoberTwoThousandAndEighteenPlacementAgentWarrantsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "October 2018 Placement Agent Warrants [Member]" } } }, "localname": "OctoberTwoThousandAndEighteenPlacementAgentWarrantsMember", "nsuri": "http://intellipharmaceutics.com/20201130", "presentation": [ "http://intellipharmaceutics.com/role/CapitalStockDetailsNarrative" ], "xbrltype": "domainItemType" }, "ipci_OfficersAndDirectorsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Officers and Directors" } } }, "localname": "OfficersAndDirectorsMember", "nsuri": "http://intellipharmaceutics.com/20201130", "presentation": [ "http://intellipharmaceutics.com/role/CapitalStockDetailsNarrative" ], "xbrltype": "domainItemType" }, "ipci_Operatingleasesoflesseedisclosuretextblock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Schedule of operating lease assets and liabilities" } } }, "localname": "Operatingleasesoflesseedisclosuretextblock", "nsuri": "http://intellipharmaceutics.com/20201130", "presentation": [ "http://intellipharmaceutics.com/role/LeaseTables" ], "xbrltype": "textBlockItemType" }, "ipci_OptionsOutstandingEn": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of options outstanding, including both vested and non-vested options.", "label": "[Options outstanding, ending]", "verboseLabel": "Options outstanding, ending" } } }, "localname": "OptionsOutstandingEn", "nsuri": "http://intellipharmaceutics.com/20201130", "presentation": [ "http://intellipharmaceutics.com/role/OptionsDetails2" ], "xbrltype": "sharesItemType" }, "ipci_PastDueForMoreThan120DaysMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Past due for more than 120 days" } } }, "localname": "PastDueForMoreThan120DaysMember", "nsuri": "http://intellipharmaceutics.com/20201130", "presentation": [ "http://intellipharmaceutics.com/role/FinancialInstrumentsDetails1" ], "xbrltype": "domainItemType" }, "ipci_PastDueForMoreThan31DaysButNoMoreThan120DaysMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Past due for more than 31 days but no more than 120 days" } } }, "localname": "PastDueForMoreThan31DaysButNoMoreThan120DaysMember", "nsuri": "http://intellipharmaceutics.com/20201130", "presentation": [ "http://intellipharmaceutics.com/role/FinancialInstrumentsDetails1" ], "xbrltype": "domainItemType" }, "ipci_Pastduefinancingreceivablestabletextblock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Schedule of past due financing receivables" } } }, "localname": "Pastduefinancingreceivablestabletextblock", "nsuri": "http://intellipharmaceutics.com/20201130", "presentation": [ "http://intellipharmaceutics.com/role/FinancialInstrumentsTables" ], "xbrltype": "textBlockItemType" }, "ipci_PaymentForSettlement": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Payment for settlement" } } }, "localname": "PaymentForSettlement", "nsuri": "http://intellipharmaceutics.com/20201130", "presentation": [ "http://intellipharmaceutics.com/role/ContingenciesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "ipci_PaymentForSettlementFromInsuranceCoverage": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Payment for settlement from insurance coverage" } } }, "localname": "PaymentForSettlementFromInsuranceCoverage", "nsuri": "http://intellipharmaceutics.com/20201130", "presentation": [ "http://intellipharmaceutics.com/role/ContingenciesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "ipci_Paymentsofstockissuancecosts": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Payment of stock issuance costs" } } }, "localname": "Paymentsofstockissuancecosts", "nsuri": "http://intellipharmaceutics.com/20201130", "presentation": [ "http://intellipharmaceutics.com/role/CapitalStockDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "ipci_PlacementAgentWarrantsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Placement Agent Warrants [Member]" } } }, "localname": "PlacementAgentWarrantsMember", "nsuri": "http://intellipharmaceutics.com/20201130", "presentation": [ "http://intellipharmaceutics.com/role/WarrantsDetailsNarrative" ], "xbrltype": "domainItemType" }, "ipci_PlacementAgentsToPurchaseCommonShares": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Placement agents to purchase common shares" } } }, "localname": "PlacementAgentsToPurchaseCommonShares", "nsuri": "http://intellipharmaceutics.com/20201130", "presentation": [ "http://intellipharmaceutics.com/role/WarrantsDetailsNarrative" ], "xbrltype": "sharesItemType" }, "ipci_PlacementAgentsToPurchaseCommonSharesPerShare": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Placement agents to purchase common shares per share" } } }, "localname": "PlacementAgentsToPurchaseCommonSharesPerShare", "nsuri": "http://intellipharmaceutics.com/20201130", "presentation": [ "http://intellipharmaceutics.com/role/WarrantsDetailsNarrative" ], "xbrltype": "perShareItemType" }, "ipci_PreFundedWarrantDescriptionPerShare": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Pre-Funded warrant description per share" } } }, "localname": "PreFundedWarrantDescriptionPerShare", "nsuri": "http://intellipharmaceutics.com/20201130", "presentation": [ "http://intellipharmaceutics.com/role/WarrantsDetailsNarrative" ], "xbrltype": "stringItemType" }, "ipci_PreFundedWarrantIssued": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Pre funded warrant issued" } } }, "localname": "PreFundedWarrantIssued", "nsuri": "http://intellipharmaceutics.com/20201130", "presentation": [ "http://intellipharmaceutics.com/role/WarrantsDetailsNarrative" ], "xbrltype": "sharesItemType" }, "ipci_PreFundedWarrants2018Member": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "2018 Pre-Funded Warrants" } } }, "localname": "PreFundedWarrants2018Member", "nsuri": "http://intellipharmaceutics.com/20201130", "presentation": [ "http://intellipharmaceutics.com/role/WarrantsDetails1" ], "xbrltype": "domainItemType" }, "ipci_PreFundedWarrantsExercised": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Pre-Funded Warrants exercised" } } }, "localname": "PreFundedWarrantsExercised", "nsuri": "http://intellipharmaceutics.com/20201130", "presentation": [ "http://intellipharmaceutics.com/role/WarrantsDetailsNarrative" ], "xbrltype": "sharesItemType" }, "ipci_Prefundedunitsissued": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Prefunded units, issued" } } }, "localname": "Prefundedunitsissued", "nsuri": "http://intellipharmaceutics.com/20201130", "presentation": [ "http://intellipharmaceutics.com/role/CapitalStockDetailsNarrative" ], "xbrltype": "sharesItemType" }, "ipci_PrepaidExpensesSundryAndOtherAssets": { "auth_ref": [], "calculation": { "http://intellipharmaceutics.com/role/ConsolidatedStatementsOfCashFlows": { "order": 11.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Prepaid expenses, sundry and other assets.", "label": "[Prepaid expenses, sundry and other assets]", "verboseLabel": "Prepaid expenses, sundry and other assets" } } }, "localname": "PrepaidExpensesSundryAndOtherAssets", "nsuri": "http://intellipharmaceutics.com/20201130", "presentation": [ "http://intellipharmaceutics.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "ipci_PrivatePlacementOfferingOfAnAggregateOfCommonShares": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Private placement offering of an aggregate of common shares" } } }, "localname": "PrivatePlacementOfferingOfAnAggregateOfCommonShares", "nsuri": "http://intellipharmaceutics.com/20201130", "presentation": [ "http://intellipharmaceutics.com/role/CapitalStockDetailsNarrative" ], "xbrltype": "sharesItemType" }, "ipci_PrivatePlacementOfferingOfAnAggregateOfCommonValue": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "Private placement offering of an aggregate of common value" } } }, "localname": "PrivatePlacementOfferingOfAnAggregateOfCommonValue", "nsuri": "http://intellipharmaceutics.com/20201130", "presentation": [ "http://intellipharmaceutics.com/role/CapitalStockDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "ipci_ProceedsFromCommonSharesIssuedDuringPeriodUponExercise": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Proceeds from common shares issued during period upon exercise" } } }, "localname": "ProceedsFromCommonSharesIssuedDuringPeriodUponExercise", "nsuri": "http://intellipharmaceutics.com/20201130", "presentation": [ "http://intellipharmaceutics.com/role/CapitalStockDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "ipci_ProceedsFromPrivatePlacemtnFinancingNote10Amount": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Proceeds from private placemtn financing (Note 10), amount" } } }, "localname": "ProceedsFromPrivatePlacemtnFinancingNote10Amount", "nsuri": "http://intellipharmaceutics.com/20201130", "presentation": [ "http://intellipharmaceutics.com/role/ConsolidatedStatementsOfShareholdersEquityDeficiency" ], "xbrltype": "monetaryItemType" }, "ipci_ProceedsFromPrivatePlacemtnFinancingNote10Shares": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Proceeds from private placemtn financing (Note 10), shares" } } }, "localname": "ProceedsFromPrivatePlacemtnFinancingNote10Shares", "nsuri": "http://intellipharmaceutics.com/20201130", "presentation": [ "http://intellipharmaceutics.com/role/ConsolidatedStatementsOfShareholdersEquityDeficiency" ], "xbrltype": "sharesItemType" }, "ipci_Proceedsfromissuanceorsaleofequity": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "Proceeds from issuance or sale of equity" } } }, "localname": "Proceedsfromissuanceorsaleofequity", "nsuri": "http://intellipharmaceutics.com/20201130", "presentation": [ "http://intellipharmaceutics.com/role/CapitalStockDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "ipci_PromissoryNoteMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Promissory Notes Payable" } } }, "localname": "PromissoryNoteMember", "nsuri": "http://intellipharmaceutics.com/20201130", "presentation": [ "http://intellipharmaceutics.com/role/FinancialInstrumentsDetails2" ], "xbrltype": "domainItemType" }, "ipci_PromissoryNotesPayableMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Promissory Notes Payable 1" } } }, "localname": "PromissoryNotesPayableMember", "nsuri": "http://intellipharmaceutics.com/20201130", "presentation": [ "http://intellipharmaceutics.com/role/ConvertibleDebenturesAndPromissoryNotesPayableDetails1" ], "xbrltype": "domainItemType" }, "ipci_Propertyplantandequipmenttextblock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Schedule of property and equipment" } } }, "localname": "Propertyplantandequipmenttextblock", "nsuri": "http://intellipharmaceutics.com/20201130", "presentation": [ "http://intellipharmaceutics.com/role/PropertyAndEquipmentTables" ], "xbrltype": "textBlockItemType" }, "ipci_PurchasePricePerShareOfWarrants": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Purchase price per share of warrants" } } }, "localname": "PurchasePricePerShareOfWarrants", "nsuri": "http://intellipharmaceutics.com/20201130", "presentation": [ "http://intellipharmaceutics.com/role/WarrantsDetailsNarrative" ], "xbrltype": "perShareItemType" }, "ipci_RawMaterialWriteOff": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "Raw material write off" } } }, "localname": "RawMaterialWriteOff", "nsuri": "http://intellipharmaceutics.com/20201130", "presentation": [ "http://intellipharmaceutics.com/role/SignificantAccountingPoliciesDetailsNarratives" ], "xbrltype": "monetaryItemType" }, "ipci_RemainingLeaseTermMonths": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Remaining lease term of operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Remaining lease term (months)" } } }, "localname": "RemainingLeaseTermMonths", "nsuri": "http://intellipharmaceutics.com/20201130", "presentation": [ "http://intellipharmaceutics.com/role/LeaseDetails1" ], "xbrltype": "durationItemType" }, "ipci_RestrictedShareUnitReservedMaximumForIssuanceUnderThePlan": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Aggregate number of common shares reserved for future issuance.", "label": "Restricted Share Unit reserved maximum for issuance under the plan" } } }, "localname": "RestrictedShareUnitReservedMaximumForIssuanceUnderThePlan", "nsuri": "http://intellipharmaceutics.com/20201130", "presentation": [ "http://intellipharmaceutics.com/role/RestrictedShareUnitsDetailsNarrative" ], "xbrltype": "sharesItemType" }, "ipci_RestrictedShareUnitsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Restricted share units" } } }, "localname": "RestrictedShareUnitsAbstract", "nsuri": "http://intellipharmaceutics.com/20201130", "xbrltype": "stringItemType" }, "ipci_RestrictedShareUnitsDisclosureTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "[Restricted share units]", "verboseLabel": "Restricted share units" } } }, "localname": "RestrictedShareUnitsDisclosureTextBlock", "nsuri": "http://intellipharmaceutics.com/20201130", "presentation": [ "http://intellipharmaceutics.com/role/RestrictedShareUnits" ], "xbrltype": "textBlockItemType" }, "ipci_ReturnOfEquipment": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "Return of equipment" } } }, "localname": "ReturnOfEquipment", "nsuri": "http://intellipharmaceutics.com/20201130", "presentation": [ "http://intellipharmaceutics.com/role/PropertyAndEquipmentDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "ipci_Saleofstocknumberofsharesissuedintransaction": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Sale of stock" } } }, "localname": "Saleofstocknumberofsharesissuedintransaction", "nsuri": "http://intellipharmaceutics.com/20201130", "presentation": [ "http://intellipharmaceutics.com/role/CapitalStockDetailsNarrative" ], "xbrltype": "sharesItemType" }, "ipci_Scheduleofaccruedliabilitiestabletextblock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Schedule of accrued liabilities" } } }, "localname": "Scheduleofaccruedliabilitiestabletextblock", "nsuri": "http://intellipharmaceutics.com/20201130", "presentation": [ "http://intellipharmaceutics.com/role/AccruedLiabilitiesTables" ], "xbrltype": "textBlockItemType" }, "ipci_Scheduleofdeferredtaxassetsandliabilitiestabletextblock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Schedule of deferred tax assets and liabilities" } } }, "localname": "Scheduleofdeferredtaxassetsandliabilitiestabletextblock", "nsuri": "http://intellipharmaceutics.com/20201130", "presentation": [ "http://intellipharmaceutics.com/role/IncomeTaxesTables" ], "xbrltype": "textBlockItemType" }, "ipci_Scheduleofdepreciationratestabletextblock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Schedule of depreciation rates" } } }, "localname": "Scheduleofdepreciationratestabletextblock", "nsuri": "http://intellipharmaceutics.com/20201130", "presentation": [ "http://intellipharmaceutics.com/role/SignificantAccountingPoliciesTables" ], "xbrltype": "textBlockItemType" }, "ipci_Scheduleofeffectiveincometaxratereconciliationtabletextblock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Schedule of effective income tax rate reconciliation" } } }, "localname": "Scheduleofeffectiveincometaxratereconciliationtabletextblock", "nsuri": "http://intellipharmaceutics.com/20201130", "presentation": [ "http://intellipharmaceutics.com/role/IncomeTaxesTables" ], "xbrltype": "textBlockItemType" }, "ipci_Scheduleofemployeeservicesharebasedcompensationallocationofrecognizedperiodcoststextblock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Schedule of employee service share-based compensation, allocation of recognized period costs" } } }, "localname": "Scheduleofemployeeservicesharebasedcompensationallocationofrecognizedperiodcoststextblock", "nsuri": "http://intellipharmaceutics.com/20201130", "presentation": [ "http://intellipharmaceutics.com/role/OptionsTables" ], "xbrltype": "textBlockItemType" }, "ipci_Scheduleofoperatinglossestabletextblock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Schedule of operating losses" } } }, "localname": "Scheduleofoperatinglossestabletextblock", "nsuri": "http://intellipharmaceutics.com/20201130", "presentation": [ "http://intellipharmaceutics.com/role/IncomeTaxesTables" ], "xbrltype": "textBlockItemType" }, "ipci_Scheduleofregulatoryassetsandliabilitiestextblock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Schedule of assets and liabilities related to operating leases" } } }, "localname": "Scheduleofregulatoryassetsandliabilitiestextblock", "nsuri": "http://intellipharmaceutics.com/20201130", "presentation": [ "http://intellipharmaceutics.com/role/ConvertibleDebenturesAndPromissoryNotesPayableTables" ], "xbrltype": "textBlockItemType" }, "ipci_Scheduleofrelatedpartytransactionstabletextblock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Schedule of related party transactions" } } }, "localname": "Scheduleofrelatedpartytransactionstabletextblock", "nsuri": "http://intellipharmaceutics.com/20201130", "presentation": [ "http://intellipharmaceutics.com/role/ConvertibleDebenturesAndPromissoryNotesPayableTables" ], "xbrltype": "textBlockItemType" }, "ipci_Scheduleofrevenuesfromexternalcustomersandlonglivedassetsbygeographicalareastabletextblock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Schedule of revenue from external customers and long-lived assets, by geographical areas" } } }, "localname": "Scheduleofrevenuesfromexternalcustomersandlonglivedassetsbygeographicalareastabletextblock", "nsuri": "http://intellipharmaceutics.com/20201130", "presentation": [ "http://intellipharmaceutics.com/role/SegmentedInformationTables" ], "xbrltype": "textBlockItemType" }, "ipci_Scheduleofsharebasedcompensationsharesauthorizedunderstockoptionplansbyexercisepricerangetextblock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Schedule of share-based compensation, shares authorized under stock option plans, by exercise price range" } } }, "localname": "Scheduleofsharebasedcompensationsharesauthorizedunderstockoptionplansbyexercisepricerangetextblock", "nsuri": "http://intellipharmaceutics.com/20201130", "presentation": [ "http://intellipharmaceutics.com/role/OptionsTables" ], "xbrltype": "textBlockItemType" }, "ipci_Scheduleofsharebasedcompensationstockoptionsactivitytabletextblock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Schedule of share-based compensation, stock options, activity" } } }, "localname": "Scheduleofsharebasedcompensationstockoptionsactivitytabletextblock", "nsuri": "http://intellipharmaceutics.com/20201130", "presentation": [ "http://intellipharmaceutics.com/role/OptionsTables" ], "xbrltype": "textBlockItemType" }, "ipci_Scheduleofsharebasedpaymentawardstockoptionsvaluationassumptionstabletextblock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Schedule of share-based payment award, stock options, valuation assumptions" } } }, "localname": "Scheduleofsharebasedpaymentawardstockoptionsvaluationassumptionstabletextblock", "nsuri": "http://intellipharmaceutics.com/20201130", "presentation": [ "http://intellipharmaceutics.com/role/OptionsTables" ], "xbrltype": "textBlockItemType" }, "ipci_Scheduleofstockholdersequitynotewarrantsorrightstextblock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Schedule of stockholders' equity note, warrants or rights" } } }, "localname": "Scheduleofstockholdersequitynotewarrantsorrightstextblock", "nsuri": "http://intellipharmaceutics.com/20201130", "presentation": [ "http://intellipharmaceutics.com/role/WarrantsTables" ], "xbrltype": "textBlockItemType" }, "ipci_Scheduleofwarranttransactionstabletextblock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Schedule of warrant transactions" } } }, "localname": "Scheduleofwarranttransactionstabletextblock", "nsuri": "http://intellipharmaceutics.com/20201130", "presentation": [ "http://intellipharmaceutics.com/role/WarrantsTables" ], "xbrltype": "textBlockItemType" }, "ipci_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancelledInPeriod": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "[Cancelled]", "negatedLabel": "Cancelled", "verboseLabel": "Cancelled" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancelledInPeriod", "nsuri": "http://intellipharmaceutics.com/20201130", "presentation": [ "http://intellipharmaceutics.com/role/OptionsDetails1", "http://intellipharmaceutics.com/role/OptionsDetails2" ], "xbrltype": "sharesItemType" }, "ipci_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancelledInPeriodWeightedAverageFairValue": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "[Cancelled 2]", "verboseLabel": "Cancelled" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancelledInPeriodWeightedAverageFairValue", "nsuri": "http://intellipharmaceutics.com/20201130", "presentation": [ "http://intellipharmaceutics.com/role/OptionsDetails1" ], "xbrltype": "perShareItemType" }, "ipci_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationInPeriod": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements.", "label": "[Expired]", "negatedLabel": "Expired", "verboseLabel": "Expired" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationInPeriod", "nsuri": "http://intellipharmaceutics.com/20201130", "presentation": [ "http://intellipharmaceutics.com/role/OptionsDetails1", "http://intellipharmaceutics.com/role/OptionsDetails2" ], "xbrltype": "sharesItemType" }, "ipci_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageIntrinsicValue": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "[Forfeited]", "verboseLabel": "Forfeited" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageIntrinsicValue", "nsuri": "http://intellipharmaceutics.com/20201130", "presentation": [ "http://intellipharmaceutics.com/role/OptionsDetails1" ], "xbrltype": "perShareItemType" }, "ipci_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageGrantDateFairValue": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "[Weighted average grant date fair value, ending]", "periodEndLabel": "Weighted average grant date fair value, ending" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageGrantDateFairValue", "nsuri": "http://intellipharmaceutics.com/20201130", "presentation": [ "http://intellipharmaceutics.com/role/OptionsDetails1" ], "xbrltype": "perShareItemType" }, "ipci_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsCancelledInPeriodWeightedAverageExercisePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "[Cancelled 1]", "verboseLabel": "Cancelled" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsCancelledInPeriodWeightedAverageExercisePrice", "nsuri": "http://intellipharmaceutics.com/20201130", "presentation": [ "http://intellipharmaceutics.com/role/OptionsDetails1" ], "xbrltype": "perShareItemType" }, "ipci_ShareIssuedPricePerShare": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Share issued, price per share" } } }, "localname": "ShareIssuedPricePerShare", "nsuri": "http://intellipharmaceutics.com/20201130", "presentation": [ "http://intellipharmaceutics.com/role/CapitalStockDetailsNarrative" ], "xbrltype": "perShareItemType" }, "ipci_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageGrantDateFairValue": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Weighted average grant date fair value exercisable" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageGrantDateFairValue", "nsuri": "http://intellipharmaceutics.com/20201130", "presentation": [ "http://intellipharmaceutics.com/role/OptionsDetails1" ], "xbrltype": "perShareItemType" }, "ipci_SharesIssuedUponExerciseOf2018PreFundedWarrantsNote14Amount": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Shares issued upon exercise of 2018 Pre-Funded Warrants (Note 14), amount" } } }, "localname": "SharesIssuedUponExerciseOf2018PreFundedWarrantsNote14Amount", "nsuri": "http://intellipharmaceutics.com/20201130", "presentation": [ "http://intellipharmaceutics.com/role/ConsolidatedStatementsOfShareholdersEquityDeficiency" ], "xbrltype": "monetaryItemType" }, "ipci_SharesIssuedUponExerciseOf2018PreFundedWarrantsNote14Shares": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Shares issued upon exercise of 2018 Pre-Funded Warrants (Note 14), shares" } } }, "localname": "SharesIssuedUponExerciseOf2018PreFundedWarrantsNote14Shares", "nsuri": "http://intellipharmaceutics.com/20201130", "presentation": [ "http://intellipharmaceutics.com/role/ConsolidatedStatementsOfShareholdersEquityDeficiency" ], "xbrltype": "sharesItemType" }, "ipci_SharesIssuedUponExerciseOfDsuShares": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Shares issued upon exercise of DSUs (Note 12), shares" } } }, "localname": "SharesIssuedUponExerciseOfDsuShares", "nsuri": "http://intellipharmaceutics.com/20201130", "presentation": [ "http://intellipharmaceutics.com/role/ConsolidatedStatementsOfShareholdersEquityDeficiency" ], "xbrltype": "sharesItemType" }, "ipci_SharesIssuedUponExerciseOfDsusNote12Amount": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Shares issued upon exercise of DSUs (Note 12), amount" } } }, "localname": "SharesIssuedUponExerciseOfDsusNote12Amount", "nsuri": "http://intellipharmaceutics.com/20201130", "presentation": [ "http://intellipharmaceutics.com/role/ConsolidatedStatementsOfShareholdersEquityDeficiency" ], "xbrltype": "monetaryItemType" }, "ipci_SixToNineMonthsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Six To Nine Months" } } }, "localname": "SixToNineMonthsMember", "nsuri": "http://intellipharmaceutics.com/20201130", "presentation": [ "http://intellipharmaceutics.com/role/FinancialInstrumentsDetails2" ], "xbrltype": "domainItemType" }, "ipci_StockOptionSharebasedCompensationForfeitureRate": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Stock option share-based compensation forfeiture rate" } } }, "localname": "StockOptionSharebasedCompensationForfeitureRate", "nsuri": "http://intellipharmaceutics.com/20201130", "presentation": [ "http://intellipharmaceutics.com/role/OptionsDetailsNarrative" ], "xbrltype": "percentItemType" }, "ipci_Stockissuancecosts": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Stock issuance costs" } } }, "localname": "Stockissuancecosts", "nsuri": "http://intellipharmaceutics.com/20201130", "presentation": [ "http://intellipharmaceutics.com/role/CapitalStockDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "ipci_StraightLineMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Straight Line" } } }, "localname": "StraightLineMember", "nsuri": "http://intellipharmaceutics.com/20201130", "presentation": [ "http://intellipharmaceutics.com/role/SignificantAccountingPoliciesDetail" ], "xbrltype": "domainItemType" }, "ipci_TaxYear2029Member": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "2029" } } }, "localname": "TaxYear2029Member", "nsuri": "http://intellipharmaceutics.com/20201130", "presentation": [ "http://intellipharmaceutics.com/role/IncomeTaxesDetails3" ], "xbrltype": "domainItemType" }, "ipci_TaxYear2030Member": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "2030" } } }, "localname": "TaxYear2030Member", "nsuri": "http://intellipharmaceutics.com/20201130", "presentation": [ "http://intellipharmaceutics.com/role/IncomeTaxesDetails3" ], "xbrltype": "domainItemType" }, "ipci_TaxYear2031Member": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "2031" } } }, "localname": "TaxYear2031Member", "nsuri": "http://intellipharmaceutics.com/20201130", "presentation": [ "http://intellipharmaceutics.com/role/IncomeTaxesDetails3" ], "xbrltype": "domainItemType" }, "ipci_TaxYear2032Member": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "2032" } } }, "localname": "TaxYear2032Member", "nsuri": "http://intellipharmaceutics.com/20201130", "presentation": [ "http://intellipharmaceutics.com/role/IncomeTaxesDetails3" ], "xbrltype": "domainItemType" }, "ipci_TaxYear2033Member": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "2033" } } }, "localname": "TaxYear2033Member", "nsuri": "http://intellipharmaceutics.com/20201130", "presentation": [ "http://intellipharmaceutics.com/role/IncomeTaxesDetails3" ], "xbrltype": "domainItemType" }, "ipci_TaxYear2034Member": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "2034" } } }, "localname": "TaxYear2034Member", "nsuri": "http://intellipharmaceutics.com/20201130", "presentation": [ "http://intellipharmaceutics.com/role/IncomeTaxesDetails3" ], "xbrltype": "domainItemType" }, "ipci_TaxYear2035Member": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "2035" } } }, "localname": "TaxYear2035Member", "nsuri": "http://intellipharmaceutics.com/20201130", "presentation": [ "http://intellipharmaceutics.com/role/IncomeTaxesDetails3" ], "xbrltype": "domainItemType" }, "ipci_TaxYear2036Member": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "2036" } } }, "localname": "TaxYear2036Member", "nsuri": "http://intellipharmaceutics.com/20201130", "presentation": [ "http://intellipharmaceutics.com/role/IncomeTaxesDetails3" ], "xbrltype": "domainItemType" }, "ipci_TaxYear2037Member": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "2037" } } }, "localname": "TaxYear2037Member", "nsuri": "http://intellipharmaceutics.com/20201130", "presentation": [ "http://intellipharmaceutics.com/role/IncomeTaxesDetails3" ], "xbrltype": "domainItemType" }, "ipci_TaxYear2038Member": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "2038" } } }, "localname": "TaxYear2038Member", "nsuri": "http://intellipharmaceutics.com/20201130", "presentation": [ "http://intellipharmaceutics.com/role/IncomeTaxesDetails3" ], "xbrltype": "domainItemType" }, "ipci_TaxYear2039Member": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "2039" } } }, "localname": "TaxYear2039Member", "nsuri": "http://intellipharmaceutics.com/20201130", "presentation": [ "http://intellipharmaceutics.com/role/IncomeTaxesDetails3" ], "xbrltype": "domainItemType" }, "ipci_TaxYear2040Member": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "2040" } } }, "localname": "TaxYear2040Member", "nsuri": "http://intellipharmaceutics.com/20201130", "presentation": [ "http://intellipharmaceutics.com/role/IncomeTaxesDetails3" ], "xbrltype": "domainItemType" }, "ipci_TaxYear2041Member": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "2041" } } }, "localname": "TaxYear2041Member", "nsuri": "http://intellipharmaceutics.com/20201130", "presentation": [ "http://intellipharmaceutics.com/role/IncomeTaxesDetails3" ], "xbrltype": "domainItemType" }, "ipci_ThreeToSixMonthsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Three To Six Months" } } }, "localname": "ThreeToSixMonthsMember", "nsuri": "http://intellipharmaceutics.com/20201130", "presentation": [ "http://intellipharmaceutics.com/role/FinancialInstrumentsDetails2" ], "xbrltype": "domainItemType" }, "ipci_TradeAndOtherReceivablesDisclosureTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "[Trade and other receivables]", "verboseLabel": "Trade and other receivables" } } }, "localname": "TradeAndOtherReceivablesDisclosureTextBlock", "nsuri": "http://intellipharmaceutics.com/20201130", "presentation": [ "http://intellipharmaceutics.com/role/TradeAndOtherReceivables" ], "xbrltype": "textBlockItemType" }, "ipci_TwoThousandAndEighteenFirmWarrantsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "2018 Firm Warrants [Member]" } } }, "localname": "TwoThousandAndEighteenFirmWarrantsMember", "nsuri": "http://intellipharmaceutics.com/20201130", "presentation": [ "http://intellipharmaceutics.com/role/CapitalStockDetailsNarrative" ], "xbrltype": "domainItemType" }, "ipci_TwoThousandAndEighteenOptionWarrantsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "2018 Option Warrants [Member]" } } }, "localname": "TwoThousandAndEighteenOptionWarrantsMember", "nsuri": "http://intellipharmaceutics.com/20201130", "presentation": [ "http://intellipharmaceutics.com/role/CapitalStockDetailsNarrative" ], "xbrltype": "domainItemType" }, "ipci_TwoThousandAndEighteenPreFundedUnitsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "2018 Pre-Funded Units [Member]" } } }, "localname": "TwoThousandAndEighteenPreFundedUnitsMember", "nsuri": "http://intellipharmaceutics.com/20201130", "presentation": [ "http://intellipharmaceutics.com/role/CapitalStockDetailsNarrative" ], "xbrltype": "domainItemType" }, "ipci_TwoThousandAndEighteenPreFundedWarrantsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "2018 Pre-Funded Warrants [Member]" } } }, "localname": "TwoThousandAndEighteenPreFundedWarrantsMember", "nsuri": "http://intellipharmaceutics.com/20201130", "presentation": [ "http://intellipharmaceutics.com/role/CapitalStockDetailsNarrative" ], "xbrltype": "domainItemType" }, "ipci_TwoThousandAndEighteenUnitWarrantsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "2018 Unit Warrants [Member]" } } }, "localname": "TwoThousandAndEighteenUnitWarrantsMember", "nsuri": "http://intellipharmaceutics.com/20201130", "presentation": [ "http://intellipharmaceutics.com/role/CapitalStockDetailsNarrative" ], "xbrltype": "domainItemType" }, "ipci_TwoThousandDebentureMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "2018 Debenture [Member]" } } }, "localname": "TwoThousandDebentureMember", "nsuri": "http://intellipharmaceutics.com/20201130", "presentation": [ "http://intellipharmaceutics.com/role/ConvertibleDebenturesAndPromissoryNotesPayableDetailsNarrative" ], "xbrltype": "domainItemType" }, "ipci_TwoThousandEighteenFirmWarrantsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "[2018 Firm Warrants [Member]]", "verboseLabel": "2018 Firm Warrants [Member]" } } }, "localname": "TwoThousandEighteenFirmWarrantsMember", "nsuri": "http://intellipharmaceutics.com/20201130", "presentation": [ "http://intellipharmaceutics.com/role/WarrantsDetailsNarrative" ], "xbrltype": "domainItemType" }, "ipci_UnderwrittenPublicOfferingPerUnits": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Underwritten public offering per units" } } }, "localname": "UnderwrittenPublicOfferingPerUnits", "nsuri": "http://intellipharmaceutics.com/20201130", "presentation": [ "http://intellipharmaceutics.com/role/WarrantsDetailsNarrative" ], "xbrltype": "perShareItemType" }, "ipci_UnitedStateMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "United States [Member]" } } }, "localname": "UnitedStateMember", "nsuri": "http://intellipharmaceutics.com/20201130", "presentation": [ "http://intellipharmaceutics.com/role/SegmentedInformationDetails" ], "xbrltype": "domainItemType" }, "ipci_UnsecuredConvertibleDebenturesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "[Convertible Debentures]", "verboseLabel": "Convertible Debentures" } } }, "localname": "UnsecuredConvertibleDebenturesMember", "nsuri": "http://intellipharmaceutics.com/20201130", "presentation": [ "http://intellipharmaceutics.com/role/FinancialInstrumentsDetails2" ], "xbrltype": "domainItemType" }, "ipci_UnsecuredConvertibleDebtInterestRate": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Unsecured Convertible debt interest rate" } } }, "localname": "UnsecuredConvertibleDebtInterestRate", "nsuri": "http://intellipharmaceutics.com/20201130", "presentation": [ "http://intellipharmaceutics.com/role/SignificantAccountingPoliciesDetailsNarratives" ], "xbrltype": "percentItemType" }, "ipci_UpFrontPaymentReceived": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "Up front payment received" } } }, "localname": "UpFrontPaymentReceived", "nsuri": "http://intellipharmaceutics.com/20201130", "presentation": [ "http://intellipharmaceutics.com/role/SignificantAccountingPoliciesDetailsNarratives" ], "xbrltype": "monetaryItemType" }, "ipci_UpfrontFees": { "auth_ref": [], "calculation": { "http://intellipharmaceutics.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss": { "order": 3.0, "parentTag": "us-gaap_Revenues", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "label": "Up-front fees (Note 3)" } } }, "localname": "UpfrontFees", "nsuri": "http://intellipharmaceutics.com/20201130", "presentation": [ "http://intellipharmaceutics.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "ipci_WarrantOneMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Warrant [Member]" } } }, "localname": "WarrantOneMember", "nsuri": "http://intellipharmaceutics.com/20201130", "presentation": [ "http://intellipharmaceutics.com/role/CapitalStockDetailsNarrative" ], "xbrltype": "domainItemType" }, "ipci_WarrantToAcquireCommonShares": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Warrant to acquire common shares" } } }, "localname": "WarrantToAcquireCommonShares", "nsuri": "http://intellipharmaceutics.com/20201130", "presentation": [ "http://intellipharmaceutics.com/role/WarrantsDetailsNarrative" ], "xbrltype": "sharesItemType" }, "ipci_WarrantsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Warrants" } } }, "localname": "WarrantsAbstract", "nsuri": "http://intellipharmaceutics.com/20201130", "xbrltype": "stringItemType" }, "ipci_WarrantsExercisablePricePerShare": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Warrants exercisable price per share" } } }, "localname": "WarrantsExercisablePricePerShare", "nsuri": "http://intellipharmaceutics.com/20201130", "presentation": [ "http://intellipharmaceutics.com/role/WarrantsDetailsNarrative" ], "xbrltype": "perShareItemType" }, "ipci_WarrantsExercisableTerm": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Warrants exercisable term" } } }, "localname": "WarrantsExercisableTerm", "nsuri": "http://intellipharmaceutics.com/20201130", "presentation": [ "http://intellipharmaceutics.com/role/WarrantsDetailsNarrative" ], "xbrltype": "durationItemType" }, "ipci_WarrantsExercisedInPeriod": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Exercised" } } }, "localname": "WarrantsExercisedInPeriod", "nsuri": "http://intellipharmaceutics.com/20201130", "presentation": [ "http://intellipharmaceutics.com/role/WarrantsDetails1" ], "xbrltype": "sharesItemType" }, "ipci_WarrantsExpirationDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Expiration date of warrants.", "label": "Expiry" } } }, "localname": "WarrantsExpirationDate", "nsuri": "http://intellipharmaceutics.com/20201130", "presentation": [ "http://intellipharmaceutics.com/role/WarrantsDetails" ], "xbrltype": "dateItemType" }, "ipci_WarrantsExpiredInPeriod": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "[Expired 1]", "verboseLabel": "Expired" } } }, "localname": "WarrantsExpiredInPeriod", "nsuri": "http://intellipharmaceutics.com/20201130", "presentation": [ "http://intellipharmaceutics.com/role/WarrantsDetails1" ], "xbrltype": "sharesItemType" }, "ipci_WarrantsIssuedInPeriod": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Issued" } } }, "localname": "WarrantsIssuedInPeriod", "nsuri": "http://intellipharmaceutics.com/20201130", "presentation": [ "http://intellipharmaceutics.com/role/WarrantsDetails1" ], "xbrltype": "sharesItemType" }, "ipci_WarrantsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Warrants [Member]" } } }, "localname": "WarrantsMember", "nsuri": "http://intellipharmaceutics.com/20201130", "presentation": [ "http://intellipharmaceutics.com/role/WarrantsDetailsNarrative" ], "xbrltype": "domainItemType" }, "ipci_WarrantsPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the warrants significant accounting policy.", "label": "[Warrants 1]", "verboseLabel": "Warrants" } } }, "localname": "WarrantsPolicyTextBlock", "nsuri": "http://intellipharmaceutics.com/20201130", "presentation": [ "http://intellipharmaceutics.com/role/SignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "ipci_WarrantsTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the entire disclosure of Warrants.", "label": "[Warrants]", "verboseLabel": "Warrants" } } }, "localname": "WarrantsTextBlock", "nsuri": "http://intellipharmaceutics.com/20201130", "presentation": [ "http://intellipharmaceutics.com/role/Warrants" ], "xbrltype": "textBlockItemType" }, "ipci_WarrantsToPurchaseAdditionalCommonStockShares": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Warrants to purchase additional common stock shares" } } }, "localname": "WarrantsToPurchaseAdditionalCommonStockShares", "nsuri": "http://intellipharmaceutics.com/20201130", "presentation": [ "http://intellipharmaceutics.com/role/WarrantsDetailsNarrative" ], "xbrltype": "sharesItemType" }, "ipci_Warrantsissued": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Warrants, issued" } } }, "localname": "Warrantsissued", "nsuri": "http://intellipharmaceutics.com/20201130", "presentation": [ "http://intellipharmaceutics.com/role/CapitalStockDetailsNarrative" ], "xbrltype": "sharesItemType" }, "ipci_Warrantsissuedvalue": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Warrants issued value" } } }, "localname": "Warrantsissuedvalue", "nsuri": "http://intellipharmaceutics.com/20201130", "presentation": [ "http://intellipharmaceutics.com/role/CapitalStockDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "ipci_WeightedAverageGrantDateFairValueOfOptionsGranted": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "The weighted average grant date fair value of options granted" } } }, "localname": "WeightedAverageGrantDateFairValueOfOptionsGranted", "nsuri": "http://intellipharmaceutics.com/20201130", "presentation": [ "http://intellipharmaceutics.com/role/OptionsDetails" ], "xbrltype": "perShareItemType" }, "ipci_WeightedAverageNumberOfSharesOutstandingBasicAndDiluted": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Weighted average number of common shares outstanding, basic and diluted" } } }, "localname": "WeightedAverageNumberOfSharesOutstandingBasicAndDiluted", "nsuri": "http://intellipharmaceutics.com/20201130", "presentation": [ "http://intellipharmaceutics.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "sharesItemType" }, "ipci_WorkInProgressWriteOff": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "Work in progress write off" } } }, "localname": "WorkInProgressWriteOff", "nsuri": "http://intellipharmaceutics.com/20201130", "presentation": [ "http://intellipharmaceutics.com/role/SignificantAccountingPoliciesDetailsNarratives" ], "xbrltype": "monetaryItemType" }, "ipci_WorkingCapitalDeficit": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Working capital deficiency" } } }, "localname": "WorkingCapitalDeficit", "nsuri": "http://intellipharmaceutics.com/20201130", "presentation": [ "http://intellipharmaceutics.com/role/NatureOfOperationsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "ipci_WriteDownOfInvestmentTaxCredits": { "auth_ref": [], "calculation": { "http://intellipharmaceutics.com/role/ConsolidatedStatementsOfCashFlows": { "order": 14.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Write-down of investment tax credits.", "label": "Write-down of investment tax credits" } } }, "localname": "WriteDownOfInvestmentTaxCredits", "nsuri": "http://intellipharmaceutics.com/20201130", "presentation": [ "http://intellipharmaceutics.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "srt_BoardOfDirectorsChairmanMember": { "auth_ref": [ "r171" ], "lang": { "en-us": { "role": { "label": "Board Of Directors Chairman [Member]" } } }, "localname": "BoardOfDirectorsChairmanMember", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://intellipharmaceutics.com/role/OptionsDetailsNarrative" ], "xbrltype": "domainItemType" }, "srt_MaximumMember": { "auth_ref": [ "r254", "r284", "r310", "r311", "r428", "r429", "r430", "r431", "r432", "r433", "r452", "r498", "r500", "r528", "r529" ], "lang": { "en-us": { "role": { "label": "Maximum [Member]" } } }, "localname": "MaximumMember", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://intellipharmaceutics.com/role/OptionsDetails" ], "xbrltype": "domainItemType" }, "srt_MinimumMember": { "auth_ref": [ "r254", "r284", "r310", "r311", "r428", "r429", "r430", "r431", "r432", "r433", "r452", "r498", "r500", "r528", "r529" ], "lang": { "en-us": { "role": { "label": "Minimum [Member]" } } }, "localname": "MinimumMember", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://intellipharmaceutics.com/role/OptionsDetails" ], "xbrltype": "domainItemType" }, "srt_RangeAxis": { "auth_ref": [ "r254", "r284", "r308", "r310", "r311", "r428", "r429", "r430", "r431", "r432", "r433", "r452", "r498", "r500", "r528", "r529" ], "lang": { "en-us": { "role": { "label": "Statistical Measurement [Axis]" } } }, "localname": "RangeAxis", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://intellipharmaceutics.com/role/OptionsDetails" ], "xbrltype": "stringItemType" }, "srt_RangeMember": { "auth_ref": [ "r254", "r284", "r308", "r310", "r311", "r428", "r429", "r430", "r431", "r432", "r433", "r452", "r498", "r500", "r528", "r529" ], "localname": "RangeMember", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://intellipharmaceutics.com/role/OptionsDetails" ], "xbrltype": "domainItemType" }, "srt_SegmentGeographicalDomain": { "auth_ref": [ "r166", "r167", "r304", "r305", "r499", "r519", "r520", "r521", "r522", "r523", "r524", "r525", "r526", "r527" ], "localname": "SegmentGeographicalDomain", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://intellipharmaceutics.com/role/SegmentedInformationDetails" ], "xbrltype": "domainItemType" }, "srt_StatementGeographicalAxis": { "auth_ref": [ "r166", "r167", "r304", "r305", "r499", "r513", "r519", "r520", "r521", "r522", "r523", "r524", "r525", "r526", "r527" ], "lang": { "en-us": { "role": { "label": "Geographical [Axis]" } } }, "localname": "StatementGeographicalAxis", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://intellipharmaceutics.com/role/SegmentedInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AccountingPoliciesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Significant Accounting Policies" } } }, "localname": "AccountingPoliciesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_AccountsPayableCurrent": { "auth_ref": [ "r40", "r421" ], "calculation": { "http://intellipharmaceutics.com/role/ConsolidatedBalanceSheets": { "order": 10.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accounts payable" } } }, "localname": "AccountsPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://intellipharmaceutics.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccountsPayableMember": { "auth_ref": [ "r12" ], "lang": { "en-us": { "role": { "documentation": "Obligations incurred and payable to vendors for goods and services received.", "label": "Accounts Payable" } } }, "localname": "AccountsPayableMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://intellipharmaceutics.com/role/FinancialInstrumentsDetails2" ], "xbrltype": "domainItemType" }, "us-gaap_AccountsReceivableGross": { "auth_ref": [ "r172" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, before allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business.", "label": "Total accounts receivable, gross" } } }, "localname": "AccountsReceivableGross", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://intellipharmaceutics.com/role/FinancialInstrumentsDetails1" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccountsReceivableGrossCurrent": { "auth_ref": [ "r172", "r173" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, before allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.", "label": "Total accounts receivable" } } }, "localname": "AccountsReceivableGrossCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://intellipharmaceutics.com/role/FinancialInstrumentsDetails1" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccountsReceivableNet": { "auth_ref": [ "r24", "r485", "r514" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business.", "label": "Account receivable" } } }, "localname": "AccountsReceivableNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://intellipharmaceutics.com/role/TradeAndOtherReceivablesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccountsReceivableNetCurrent": { "auth_ref": [ "r5", "r24", "r172", "r173" ], "calculation": { "http://intellipharmaceutics.com/role/ConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.", "label": "Trade and other receivables, net", "verboseLabel": "Total accounts receivable, net" } } }, "localname": "AccountsReceivableNetCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://intellipharmaceutics.com/role/ConsolidatedBalanceSheets", "http://intellipharmaceutics.com/role/FinancialInstrumentsDetails1" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccretionExpense": { "auth_ref": [ "r228", "r229", "r230" ], "calculation": { "http://intellipharmaceutics.com/role/ConsolidatedStatementsOfCashFlows": { "order": 18.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount recognized for the passage of time, typically for liabilities, that have been discounted to their net present values. Excludes accretion associated with asset retirement obligations.", "label": "Debenture financing, net (Note 7)", "verboseLabel": "Accrued interest expense" } } }, "localname": "AccretionExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://intellipharmaceutics.com/role/ConsolidatedStatementsOfCashFlows", "http://intellipharmaceutics.com/role/ConvertibleDebenturesAndPromissoryNotesPayableDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedLiabilitiesAndOtherLiabilities": { "auth_ref": [], "calculation": { "http://intellipharmaceutics.com/role/ConsolidatedBalanceSheets": { "order": 11.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of expenses incurred but not yet paid nor invoiced, and liabilities classified as other.", "label": "Accrued liabilities (Note 6)" } } }, "localname": "AccruedLiabilitiesAndOtherLiabilities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://intellipharmaceutics.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedLiabilitiesCurrent": { "auth_ref": [ "r44" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued liabilities" } } }, "localname": "AccruedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://intellipharmaceutics.com/role/AccruedLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedLiabilitiesMember": { "auth_ref": [ "r44" ], "lang": { "en-us": { "role": { "documentation": "This item represents obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered.", "label": "Accrued Liabilities [Member]", "verboseLabel": "Accrued Liabilities" } } }, "localname": "AccruedLiabilitiesMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://intellipharmaceutics.com/role/FinancialInstrumentsDetails2" ], "xbrltype": "domainItemType" }, "us-gaap_AccruedProfessionalFeesCurrent": { "auth_ref": [ "r8", "r9", "r44" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Professional fees" } } }, "localname": "AccruedProfessionalFeesCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://intellipharmaceutics.com/role/AccruedLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": { "auth_ref": [ "r38", "r222" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.", "label": "[Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment]", "periodEndLabel": "Accumulated amortization, ending balance", "periodStartLabel": "Accumulated amortization, beginning balance" } } }, "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://intellipharmaceutics.com/role/PropertyAndEquipmentDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipmentPeriodIncreaseDecrease": { "auth_ref": [ "r220" ], "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in accumulated depreciation, depletion and amortization of property, plant and equipment.", "label": "Depreciation" } } }, "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipmentPeriodIncreaseDecrease", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://intellipharmaceutics.com/role/PropertyAndEquipmentDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": { "auth_ref": [ "r27", "r59", "r60", "r61", "r489", "r505", "r506" ], "calculation": { "http://intellipharmaceutics.com/role/ConsolidatedBalanceSheets": { "order": 19.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.", "label": "Accumulated other comprehensive income" } } }, "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://intellipharmaceutics.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeMember": { "auth_ref": [ "r58", "r61", "r65", "r66", "r67", "r116", "r117", "r118", "r372", "r501", "r502", "r548" ], "lang": { "en-us": { "role": { "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.", "label": "Accumulated Other Comprehensive Income" } } }, "localname": "AccumulatedOtherComprehensiveIncomeMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://intellipharmaceutics.com/role/ConsolidatedStatementsOfShareholdersEquityDeficiency" ], "xbrltype": "domainItemType" }, "us-gaap_AdditionalPaidInCapital": { "auth_ref": [ "r25", "r335", "r421" ], "calculation": { "http://intellipharmaceutics.com/role/ConsolidatedBalanceSheets": { "order": 18.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.", "label": "Additional paid-in capital" } } }, "localname": "AdditionalPaidInCapital", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://intellipharmaceutics.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdditionalPaidInCapitalMember": { "auth_ref": [ "r116", "r117", "r118", "r332", "r333", "r334", "r381" ], "lang": { "en-us": { "role": { "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.", "label": "Additional Paid-In Capital" } } }, "localname": "AdditionalPaidInCapitalMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://intellipharmaceutics.com/role/ConsolidatedStatementsOfShareholdersEquityDeficiency" ], "xbrltype": "domainItemType" }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature": { "auth_ref": [ "r297", "r300", "r359" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in additional paid in capital (APIC) resulting from recognition of deferred taxes for convertible debt with a beneficial conversion feature.", "label": "Deferred tax expense related to beneficial conversion feature (Note 15)" } } }, "localname": "AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://intellipharmaceutics.com/role/ConsolidatedStatementsOfShareholdersEquityDeficiency" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalOther": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of other increase (decrease) in additional paid in capital (APIC).", "label": "Additional paid in capital" } } }, "localname": "AdjustmentsToAdditionalPaidInCapitalOther", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://intellipharmaceutics.com/role/CapitalStockDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": { "auth_ref": [ "r312", "r314", "r338", "r339" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.", "label": "Stock options to employees (Note 11)" } } }, "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://intellipharmaceutics.com/role/ConsolidatedStatementsOfShareholdersEquityDeficiency" ], "xbrltype": "monetaryItemType" }, "us-gaap_AllocatedShareBasedCompensationExpense": { "auth_ref": [ "r314", "r328", "r337" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.", "label": "Stock based compensation expense components" } } }, "localname": "AllocatedShareBasedCompensationExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://intellipharmaceutics.com/role/OptionsDetails3" ], "xbrltype": "monetaryItemType" }, "us-gaap_AllowanceForDoubtfulAccountsReceivable": { "auth_ref": [ "r175", "r190", "r192", "r194" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of allowance for credit loss on accounts receivable.", "label": "Allowance for doubtful accounts" } } }, "localname": "AllowanceForDoubtfulAccountsReceivable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://intellipharmaceutics.com/role/TradeAndOtherReceivablesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent": { "auth_ref": [ "r31", "r175", "r190" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of allowance for credit loss on accounts receivable, classified as current.", "label": "[Accounts Receivable, Allowance for Credit Loss, Current]", "negatedLabel": "Less allowance for doubtful accounts" } } }, "localname": "AllowanceForDoubtfulAccountsReceivableCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://intellipharmaceutics.com/role/FinancialInstrumentsDetails1" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetImpairmentCharges": { "auth_ref": [ "r95", "r218" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill.", "label": "Impairment of asset" } } }, "localname": "AssetImpairmentCharges", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://intellipharmaceutics.com/role/PropertyAndEquipmentDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_Assets": { "auth_ref": [ "r110", "r151", "r155", "r161", "r188", "r238", "r239", "r240", "r242", "r243", "r244", "r245", "r246", "r247", "r249", "r250", "r370", "r373", "r385", "r419", "r421", "r471", "r486" ], "calculation": { "http://intellipharmaceutics.com/role/ConsolidatedBalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "[Assets]", "totalLabel": "Assets", "verboseLabel": "Assets" } } }, "localname": "Assets", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://intellipharmaceutics.com/role/ConsolidatedBalanceSheets", "http://intellipharmaceutics.com/role/SegmentedInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Assets" } } }, "localname": "AssetsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://intellipharmaceutics.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsCurrent": { "auth_ref": [ "r6", "r7", "r57", "r110", "r188", "r238", "r239", "r240", "r242", "r243", "r244", "r245", "r246", "r247", "r249", "r250", "r370", "r373", "r385", "r419", "r421" ], "calculation": { "http://intellipharmaceutics.com/role/ConsolidatedBalanceSheets": { "order": 7.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "[Assets, Current]", "totalLabel": "Current assets" } } }, "localname": "AssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://intellipharmaceutics.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableforsaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureOtherFairValueVolatilityRate": { "auth_ref": [ "r183" ], "lang": { "en-us": { "role": { "documentation": "This item represents the volatility of the security's fair value, represented as a percentage, which was considered as one of the potential factors in reaching a conclusion that the available-for-sale investments are not other-than-temporarily impaired.", "label": "Volatility" } } }, "localname": "AvailableforsaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureOtherFairValueVolatilityRate", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://intellipharmaceutics.com/role/OptionsDetails" ], "xbrltype": "percentItemType" }, "us-gaap_AwardDateAxis": { "auth_ref": [ "r315", "r330" ], "lang": { "en-us": { "role": { "documentation": "Information by date or year award under share-based payment arrangement is granted.", "label": "Award Date [Axis]" } } }, "localname": "AwardDateAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://intellipharmaceutics.com/role/FinancialInstrumentsDetails2" ], "xbrltype": "stringItemType" }, "us-gaap_AwardDateDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Date or year award under share-based payment arrangement is granted." } } }, "localname": "AwardDateDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://intellipharmaceutics.com/role/FinancialInstrumentsDetails2" ], "xbrltype": "domainItemType" }, "us-gaap_AwardTypeAxis": { "auth_ref": [ "r315", "r330" ], "lang": { "en-us": { "role": { "documentation": "Information by type of award under share-based payment arrangement.", "label": "Award Type Axis" } } }, "localname": "AwardTypeAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://intellipharmaceutics.com/role/DeferredShareUnitsDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_BalanceSheetLocationAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by location on balance sheet (statement of financial position).", "label": "Balance Sheet Location Axis" } } }, "localname": "BalanceSheetLocationAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://intellipharmaceutics.com/role/FinancialInstrumentsDetails2" ], "xbrltype": "stringItemType" }, "us-gaap_BalanceSheetLocationDomain": { "auth_ref": [ "r377", "r378" ], "lang": { "en-us": { "role": { "documentation": "Location in the balance sheet (statement of financial position)." } } }, "localname": "BalanceSheetLocationDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://intellipharmaceutics.com/role/FinancialInstrumentsDetails2" ], "xbrltype": "domainItemType" }, "us-gaap_Capital": { "auth_ref": [ "r483" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of total capital as defined by regulatory framework.", "label": "Capital stock" } } }, "localname": "Capital", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://intellipharmaceutics.com/role/CapitalStockDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_Cash": { "auth_ref": [ "r35", "r421", "r507", "r508" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "[Cash]", "periodEndLabel": "Cash, end of year", "periodStartLabel": "Cash, beginning of year" } } }, "localname": "Cash", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://intellipharmaceutics.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "auth_ref": [ "r3", "r35", "r97" ], "calculation": { "http://intellipharmaceutics.com/role/ConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "Cash" } } }, "localname": "CashAndCashEquivalentsAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://intellipharmaceutics.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsPolicyTextBlock": { "auth_ref": [ "r13", "r98" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.", "label": "Cash and cash equivalents" } } }, "localname": "CashAndCashEquivalentsPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://intellipharmaceutics.com/role/SignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect": { "auth_ref": [ "r90", "r390" ], "calculation": { "http://intellipharmaceutics.com/role/ConsolidatedStatementsOfCashFlows": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; excluding effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "[Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect]", "totalLabel": "Increase (decrease) in cash" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://intellipharmaceutics.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashEquivalentsAtCarryingValue": { "auth_ref": [ "r35" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "Cash equivalents" } } }, "localname": "CashEquivalentsAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://intellipharmaceutics.com/role/SignificantAccountingPoliciesDetailsNarratives" ], "xbrltype": "monetaryItemType" }, "us-gaap_ClassOfStockDomain": { "auth_ref": [ "r107", "r110", "r128", "r129", "r130", "r132", "r133", "r138", "r139", "r140", "r188", "r238", "r243", "r244", "r245", "r249", "r250", "r282", "r283", "r286", "r290", "r385", "r539" ], "lang": { "en-us": { "role": { "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock." } } }, "localname": "ClassOfStockDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://intellipharmaceutics.com/role/CapitalStockDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_ClassOfWarrantOrRightAxis": { "auth_ref": [ "r302", "r313" ], "lang": { "en-us": { "role": { "documentation": "Information by type of warrant or right issued.", "label": "Class of Warrant or Right [Axis]" } } }, "localname": "ClassOfWarrantOrRightAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://intellipharmaceutics.com/role/CapitalStockDetailsNarrative", "http://intellipharmaceutics.com/role/WarrantsDetails", "http://intellipharmaceutics.com/role/WarrantsDetails1", "http://intellipharmaceutics.com/role/WarrantsDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_ClassOfWarrantOrRightDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the class or type of warrant or right outstanding. Warrants and rights represent derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months." } } }, "localname": "ClassOfWarrantOrRightDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://intellipharmaceutics.com/role/CapitalStockDetailsNarrative", "http://intellipharmaceutics.com/role/WarrantsDetails", "http://intellipharmaceutics.com/role/WarrantsDetails1", "http://intellipharmaceutics.com/role/WarrantsDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": { "auth_ref": [ "r298" ], "lang": { "en-us": { "role": { "documentation": "Exercise price per share or per unit of warrants or rights outstanding.", "label": "Exercise price", "terseLabel": "Warrants to purchase common stock price per shares", "verboseLabel": "Exercise price" } } }, "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://intellipharmaceutics.com/role/CapitalStockDetailsNarrative", "http://intellipharmaceutics.com/role/WarrantsDetails", "http://intellipharmaceutics.com/role/WarrantsDetailsNarrative" ], "xbrltype": "perShareItemType" }, "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights": { "auth_ref": [ "r298" ], "lang": { "en-us": { "role": { "documentation": "Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.", "label": "Shares issuable upon exercise", "verboseLabel": "Warrants to purchase common stock shares" } } }, "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://intellipharmaceutics.com/role/WarrantsDetails", "http://intellipharmaceutics.com/role/WarrantsDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_ClassOfWarrantOrRightOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of warrants or rights outstanding.", "label": "Number outstanding", "periodEndLabel": "Outstanding, ending", "periodStartLabel": "Outstanding, Beginning" } } }, "localname": "ClassOfWarrantOrRightOutstanding", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://intellipharmaceutics.com/role/WarrantsDetails", "http://intellipharmaceutics.com/role/WarrantsDetails1" ], "xbrltype": "sharesItemType" }, "us-gaap_CommitmentsAndContingencies": { "auth_ref": [ "r47", "r236", "r476", "r493" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.", "label": "Contingencies (Note 16)" } } }, "localname": "CommitmentsAndContingencies", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://intellipharmaceutics.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Contingencies" } } }, "localname": "CommitmentsAndContingenciesDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "auth_ref": [ "r233", "r234", "r235", "r237", "r515" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for commitments and contingencies.", "label": "Commitments and Contingencies Disclosure [Text Block]", "verboseLabel": "Contingencies" } } }, "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://intellipharmaceutics.com/role/Contingencies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": { "auth_ref": [ "r48" ], "lang": { "en-us": { "role": { "documentation": "Aggregate number of common shares reserved for future issuance.", "label": "Common shares reserved maximum for issuance under the plan" } } }, "localname": "CommonStockCapitalSharesReservedForFutureIssuance", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://intellipharmaceutics.com/role/DeferredShareUnitsDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockDividendsPerShareCashPaid": { "auth_ref": [ "r300" ], "lang": { "en-us": { "role": { "documentation": "Aggregate dividends paid during the period for each share of common stock outstanding.", "label": "Common stock price" } } }, "localname": "CommonStockDividendsPerShareCashPaid", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://intellipharmaceutics.com/role/CapitalStockDetailsNarrative" ], "xbrltype": "perShareItemType" }, "us-gaap_CommonStockMember": { "auth_ref": [ "r116", "r117", "r381" ], "lang": { "en-us": { "role": { "documentation": "Stock that is subordinate to all other stock of the issuer.", "label": "Common Stock" } } }, "localname": "CommonStockMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://intellipharmaceutics.com/role/ConsolidatedStatementsOfShareholdersEquityDeficiency" ], "xbrltype": "domainItemType" }, "us-gaap_CommonStockSharesIssued": { "auth_ref": [ "r23" ], "lang": { "en-us": { "role": { "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.", "label": "Common shares, issued", "terseLabel": "Common shares issued", "verboseLabel": "Common shares, issued" } } }, "localname": "CommonStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://intellipharmaceutics.com/role/CapitalStockDetailsNarrative", "http://intellipharmaceutics.com/role/ConsolidatedBalanceSheetsParenthetical", "http://intellipharmaceutics.com/role/WarrantsDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesOutstanding": { "auth_ref": [ "r23", "r297" ], "lang": { "en-us": { "role": { "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.", "label": "Common shares, outstanding" } } }, "localname": "CommonStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://intellipharmaceutics.com/role/ConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockValue": { "auth_ref": [ "r23", "r421" ], "calculation": { "http://intellipharmaceutics.com/role/ConsolidatedBalanceSheets": { "order": 17.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Capital stock (Note 10) Authorized: Unlimited common shares without par value, Unlimited preference shares, Issued and outstanding 33,092,665 common shares (November 30, 2020 - 23,678,105)", "verboseLabel": "Common stock" } } }, "localname": "CommonStockValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://intellipharmaceutics.com/role/CapitalStockDetailsNarrative", "http://intellipharmaceutics.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_CompensationRelatedCostsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Employee costs payable" } } }, "localname": "CompensationRelatedCostsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_CompensationRelatedCostsGeneralTextBlock": { "auth_ref": [ "r306", "r307" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for compensation costs, including compensated absences accruals, compensated absences liability, deferred compensation arrangements and income statement compensation items. Deferred compensation arrangements may include a description of an arrangement with an individual employee, which is generally an employment contract between the entity and a selected officer or key employee containing a promise by the employer to pay certain amounts at designated future dates, usually including a period after retirement, upon compliance with stipulated requirements. This type of arrangement is distinguished from broader based employee benefit plans as it is usually tailored to the employee. Disclosure also typically includes the amount of related compensation expense recognized during the reporting period, the number of shares (units) issued during the period under such arrangements, and the carrying amount as of the balance sheet date of the related liability.", "label": "Compensation Related Costs, General [Text Block]", "verboseLabel": "Employee costs payable" } } }, "localname": "CompensationRelatedCostsGeneralTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://intellipharmaceutics.com/role/EmployeeCostsPayable" ], "xbrltype": "textBlockItemType" }, "us-gaap_ComprehensiveIncomePolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for comprehensive income.", "label": "Comprehensive loss" } } }, "localname": "ComprehensiveIncomePolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://intellipharmaceutics.com/role/SignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ComputerEquipmentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Long lived, depreciable assets that are used in the creation, maintenance and utilization of information systems.", "label": "Computer Equipment", "verboseLabel": "Computer Equipment" } } }, "localname": "ComputerEquipmentMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://intellipharmaceutics.com/role/PropertyAndEquipmentDetails", "http://intellipharmaceutics.com/role/SignificantAccountingPoliciesDetail" ], "xbrltype": "domainItemType" }, "us-gaap_ComputerSoftwareIntangibleAssetMember": { "auth_ref": [ "r208", "r210", "r369" ], "lang": { "en-us": { "role": { "documentation": "Collection of computer programs and related data that provide instructions to a computer, for example, but not limited to, application program, control module or operating system, that perform one or more particular functions or tasks.", "label": "Computer software" } } }, "localname": "ComputerSoftwareIntangibleAssetMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://intellipharmaceutics.com/role/SignificantAccountingPoliciesDetail" ], "xbrltype": "domainItemType" }, "us-gaap_ConversionOfStockSharesIssued1": { "auth_ref": [ "r100", "r101", "r102" ], "lang": { "en-us": { "role": { "documentation": "The number of new shares issued in the conversion of stock in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.", "label": "Convertible common shares" } } }, "localname": "ConversionOfStockSharesIssued1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://intellipharmaceutics.com/role/ConvertibleDebenturesAndPromissoryNotesPayableDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_ConvertibleDebt": { "auth_ref": [ "r18", "r473", "r488" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Including the current and noncurrent portions, carrying amount of debt identified as being convertible into another form of financial instrument (typically the entity's common stock) as of the balance sheet date, which originally required full repayment more than twelve months after issuance or greater than the normal operating cycle of the company.", "label": "Convertible debenture", "verboseLabel": "Convertible debentures, carrying amount" } } }, "localname": "ConvertibleDebt", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://intellipharmaceutics.com/role/ConvertibleDebenturesAndPromissoryNotesPayableDetailsNarrative", "http://intellipharmaceutics.com/role/FinancialInstrumentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ConvertibleDebtFairValueDisclosures": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Fair value portion of borrowing which can be exchanged for a specified number of another security at the option of the issuer or the holder, for example, but not limited to, the entity's common stock.", "label": "Convertible debt fair value", "verboseLabel": "Convertible debentures, fair value" } } }, "localname": "ConvertibleDebtFairValueDisclosures", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://intellipharmaceutics.com/role/ConvertibleDebenturesAndPromissoryNotesPayableDetailsNarrative", "http://intellipharmaceutics.com/role/FinancialInstrumentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ConvertibleNotesPayable": { "auth_ref": [ "r18", "r473", "r487", "r510" ], "calculation": { "http://intellipharmaceutics.com/role/ConsolidatedBalanceSheets": { "order": 16.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Including the current and noncurrent portions, carrying value as of the balance sheet date of a written promise to pay a note, initially due after one year or beyond the operating cycle if longer, which can be exchanged for a specified amount of one or more securities (typically common stock), at the option of the issuer or the holder.", "label": "Convertible debentures (Note 7)" } } }, "localname": "ConvertibleNotesPayable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://intellipharmaceutics.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_CostOfGoodsAndServicesSold": { "auth_ref": [ "r76", "r455" ], "calculation": { "http://intellipharmaceutics.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss": { "order": 5.0, "parentTag": "us-gaap_GrossProfit", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.", "label": "Cost of goods sold" } } }, "localname": "CostOfGoodsAndServicesSold", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://intellipharmaceutics.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_CostOfGoodsAndServicesSoldAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Cost of good sold" } } }, "localname": "CostOfGoodsAndServicesSoldAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://intellipharmaceutics.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "stringItemType" }, "us-gaap_CostOfGoodsAndServicesSoldDepreciation": { "auth_ref": [ "r74", "r220" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense for allocation of cost of tangible asset over its useful life directly used in production of good and rendering of service.", "label": "Depreciation expense within cost of goods sold" } } }, "localname": "CostOfGoodsAndServicesSoldDepreciation", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://intellipharmaceutics.com/role/PropertyAndEquipmentDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_CostsAndExpensesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Expenses" } } }, "localname": "CostsAndExpensesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://intellipharmaceutics.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentAxis": { "auth_ref": [ "r16", "r17", "r18", "r109", "r114", "r251", "r252", "r253", "r254", "r255", "r256", "r257", "r258", "r259", "r260", "r261", "r262", "r263", "r264", "r265", "r266", "r267", "r273", "r274", "r275", "r276", "r402", "r472", "r473", "r484" ], "lang": { "en-us": { "role": { "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.", "label": "Debt Instrument Axis" } } }, "localname": "DebtInstrumentAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://intellipharmaceutics.com/role/ConvertibleDebenturesAndPromissoryNotesPayableDetails1" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature": { "auth_ref": [ "r299" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of a favorable spread to a debt holder between the amount of debt being converted and the value of the securities received upon conversion. This is an embedded conversion feature of convertible debt issued that is in-the-money at the commitment date.", "label": "Beneficial conversion feature related to Debentures (Note 7)" } } }, "localname": "DebtInstrumentConvertibleBeneficialConversionFeature", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://intellipharmaceutics.com/role/ConsolidatedStatementsOfShareholdersEquityDeficiency" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent": { "auth_ref": [ "r269" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The carrying amount of the equity component of convertible debt which may be settled in cash upon conversion.", "label": "Carrying amount of convertible debt" } } }, "localname": "DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://intellipharmaceutics.com/role/ConvertibleDebenturesAndPromissoryNotesPayableDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentConvertibleConversionPrice1": { "auth_ref": [ "r253", "r270" ], "lang": { "en-us": { "role": { "documentation": "The price per share of the conversion feature embedded in the debt instrument.", "label": "Debt conversion price" } } }, "localname": "DebtInstrumentConvertibleConversionPrice1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://intellipharmaceutics.com/role/ConvertibleDebenturesAndPromissoryNotesPayableDetailsNarrative" ], "xbrltype": "perShareItemType" }, "us-gaap_DebtInstrumentInterestRateDuringPeriod": { "auth_ref": [ "r45", "r264", "r400" ], "lang": { "en-us": { "role": { "documentation": "The average effective interest rate during the reporting period.", "label": "Interest rate" } } }, "localname": "DebtInstrumentInterestRateDuringPeriod", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://intellipharmaceutics.com/role/ConvertibleDebenturesAndPromissoryNotesPayableDetailsNarrative" ], "xbrltype": "percentItemType" }, "us-gaap_DebtInstrumentInterestRateEffectivePercentage": { "auth_ref": [ "r45", "r271", "r400", "r402" ], "lang": { "en-us": { "role": { "documentation": "Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium.", "label": "Debt instrument interest rate effective" } } }, "localname": "DebtInstrumentInterestRateEffectivePercentage", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://intellipharmaceutics.com/role/ConvertibleDebenturesAndPromissoryNotesPayableDetailsNarrative" ], "xbrltype": "percentItemType" }, "us-gaap_DebtInstrumentNameDomain": { "auth_ref": [ "r46", "r109", "r114", "r251", "r252", "r253", "r254", "r255", "r256", "r257", "r258", "r259", "r260", "r261", "r262", "r263", "r264", "r265", "r266", "r267", "r273", "r274", "r275", "r276", "r402" ], "lang": { "en-us": { "role": { "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities." } } }, "localname": "DebtInstrumentNameDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://intellipharmaceutics.com/role/ConvertibleDebenturesAndPromissoryNotesPayableDetails1" ], "xbrltype": "domainItemType" }, "us-gaap_DeferredRevenue": { "auth_ref": [ "r32" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable.", "label": "Deferred revenue" } } }, "localname": "DeferredRevenue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://intellipharmaceutics.com/role/SignificantAccountingPoliciesDetailsNarratives" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsCapitalLossCarryforwards": { "auth_ref": [ "r356", "r357" ], "calculation": { "http://intellipharmaceutics.com/role/IncomeTaxesDetails": { "order": 7.0, "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible capital loss carryforwards.", "label": "Capital loss carryforwards" } } }, "localname": "DeferredTaxAssetsCapitalLossCarryforwards", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://intellipharmaceutics.com/role/IncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsGross": { "auth_ref": [ "r350" ], "calculation": { "http://intellipharmaceutics.com/role/IncomeTaxesDetails": { "order": 11.0, "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.", "label": "Deferred tax assets, gross" } } }, "localname": "DeferredTaxAssetsGross", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://intellipharmaceutics.com/role/IncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsLiabilitiesNet": { "auth_ref": [ "r352" ], "calculation": { "http://intellipharmaceutics.com/role/IncomeTaxesDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.", "label": "Net deferred tax assets", "periodEndLabel": "Balance at the end of the year", "periodStartLabel": "Balance at the beginning of the year" } } }, "localname": "DeferredTaxAssetsLiabilitiesNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://intellipharmaceutics.com/role/IncomeTaxesDetails", "http://intellipharmaceutics.com/role/IncomeTaxesDetails1" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": { "auth_ref": [ "r356", "r357" ], "calculation": { "http://intellipharmaceutics.com/role/IncomeTaxesDetails": { "order": 2.0, "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.", "label": "Non-capital loss carry-forwards" } } }, "localname": "DeferredTaxAssetsOperatingLossCarryforwards", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://intellipharmaceutics.com/role/IncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsOther": { "auth_ref": [ "r356", "r357" ], "calculation": { "http://intellipharmaceutics.com/role/IncomeTaxesDetails": { "order": 4.0, "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other.", "label": "[Deferred Tax Assets, Other]", "verboseLabel": "Other" } } }, "localname": "DeferredTaxAssetsOther", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://intellipharmaceutics.com/role/IncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsTaxCreditCarryforwards": { "auth_ref": [ "r355", "r356", "r357" ], "calculation": { "http://intellipharmaceutics.com/role/IncomeTaxesDetails": { "order": 5.0, "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, before allocation of a valuation allowances, of deferred tax assets attributable to deductible tax credit carryforwards including, but not limited to, research, foreign, general business, alternative minimum tax, and other deductible tax credit carryforwards.", "label": "Investment tax credit" } } }, "localname": "DeferredTaxAssetsTaxCreditCarryforwards", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://intellipharmaceutics.com/role/IncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost": { "auth_ref": [ "r356", "r357" ], "calculation": { "http://intellipharmaceutics.com/role/IncomeTaxesDetails": { "order": 8.0, "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.", "label": "Share issuance cost" } } }, "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://intellipharmaceutics.com/role/IncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsValuationAllowance": { "auth_ref": [ "r351" ], "calculation": { "http://intellipharmaceutics.com/role/IncomeTaxesDetails": { "order": 13.0, "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.", "label": "Valuation allowances for deferred tax assets" } } }, "localname": "DeferredTaxAssetsValuationAllowance", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://intellipharmaceutics.com/role/IncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxLiabilities": { "auth_ref": [ "r345", "r352" ], "calculation": { "http://intellipharmaceutics.com/role/IncomeTaxesDetails": { "order": 12.0, "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences without jurisdictional netting.", "label": "Deferred tax liabilities" } } }, "localname": "DeferredTaxLiabilities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://intellipharmaceutics.com/role/IncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxLiabilitiesUnrealizedCurrencyTransactionGains": { "auth_ref": [ "r356", "r357" ], "calculation": { "http://intellipharmaceutics.com/role/IncomeTaxesDetails": { "order": 9.0, "parentTag": "us-gaap_DeferredTaxLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from unrealized gains on foreign currency transactions.", "label": "[Deferred Tax Liabilities, Unrealized Currency Transaction Gains]", "verboseLabel": "Unrealized foreign exchange gain" } } }, "localname": "DeferredTaxLiabilitiesUnrealizedCurrencyTransactionGains", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://intellipharmaceutics.com/role/IncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_Depreciation": { "auth_ref": [ "r95", "r220" ], "calculation": { "http://intellipharmaceutics.com/role/ConsolidatedStatementsOfCashFlows": { "order": 21.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.", "label": "Depreciation (Note 4)" } } }, "localname": "Depreciation", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://intellipharmaceutics.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_DepreciationAndAmortization": { "auth_ref": [ "r95", "r220" ], "calculation": { "http://intellipharmaceutics.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss": { "order": 8.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.", "label": "Depreciation (Note 5)" } } }, "localname": "DepreciationAndAmortization", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://intellipharmaceutics.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_DirectOperatingCosts": { "auth_ref": [ "r77" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate direct operating costs incurred during the reporting period.", "label": "Direct costs" } } }, "localname": "DirectOperatingCosts", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://intellipharmaceutics.com/role/CapitalStockDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": { "auth_ref": [ "r341" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for share-based payment arrangement.", "label": "Share-based Payment Arrangement [Text Block]", "verboseLabel": "Options" } } }, "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://intellipharmaceutics.com/role/Options" ], "xbrltype": "textBlockItemType" }, "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Options" } } }, "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_DueToRelatedPartiesCurrent": { "auth_ref": [ "r40", "r113", "r241", "r243", "r244", "r248", "r249", "r250", "r415" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying amount as of the balance sheet date of obligations due all related parties. For classified balance sheets, represents the current portion of such liabilities (due within one year or within the normal operating cycle if longer).", "label": "Promissory note payable to two directors and officers of the Company, unsecured no annual interest rate on the outstanding loan balance" } } }, "localname": "DueToRelatedPartiesCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://intellipharmaceutics.com/role/ConvertibleDebenturesAndPromissoryNotesPayableDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EarningsPerSharePolicyTextBlock": { "auth_ref": [ "r134", "r135" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.", "label": "Loss per share" } } }, "localname": "EarningsPerSharePolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://intellipharmaceutics.com/role/SignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_EffectOnFutureCashFlowsAmount": { "auth_ref": [ "r232" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The quantified amount of the future effect on cash flows.", "label": "Undiscounted future cash flows" } } }, "localname": "EffectOnFutureCashFlowsAmount", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://intellipharmaceutics.com/role/FinancialInstrumentsDetails2" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeRelatedLiabilitiesCurrent": { "auth_ref": [ "r44" ], "calculation": { "http://intellipharmaceutics.com/role/ConsolidatedBalanceSheets": { "order": 12.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Employee costs payable (Note 8)", "verboseLabel": "Employee-related liabilities, current" } } }, "localname": "EmployeeRelatedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://intellipharmaceutics.com/role/ConsolidatedBalanceSheets", "http://intellipharmaceutics.com/role/EmployeeCostsPayableDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": { "auth_ref": [ "r329" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement.", "label": "Unrecognized compensation cost" } } }, "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://intellipharmaceutics.com/role/OptionsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_EquityComponentDomain": { "auth_ref": [ "r0", "r65", "r66", "r67", "r116", "r117", "r118", "r120", "r125", "r127", "r137", "r189", "r297", "r300", "r332", "r333", "r334", "r360", "r361", "r381", "r391", "r392", "r393", "r394", "r395", "r397", "r501", "r502", "r503", "r548" ], "lang": { "en-us": { "role": { "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc." } } }, "localname": "EquityComponentDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://intellipharmaceutics.com/role/ConsolidatedStatementsOfShareholdersEquityDeficiency" ], "xbrltype": "domainItemType" }, "us-gaap_ExtinguishmentOfDebtAxis": { "auth_ref": [ "r279" ], "lang": { "en-us": { "role": { "documentation": "Information pertaining to the debt extinguished including the amount of gain (loss), the income tax effect on the gain (loss), and the amount of gain (loss), net or the related income tax, by debt instrument.", "label": "Extinguishment of Debt [Axis]" } } }, "localname": "ExtinguishmentOfDebtAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://intellipharmaceutics.com/role/FinancialInstrumentsDetails2" ], "xbrltype": "stringItemType" }, "us-gaap_ExtinguishmentOfDebtTypeDomain": { "auth_ref": [ "r279" ], "lang": { "en-us": { "role": { "documentation": "Type of debt extinguished." } } }, "localname": "ExtinguishmentOfDebtTypeDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://intellipharmaceutics.com/role/FinancialInstrumentsDetails2" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueAdjustmentOfWarrants": { "auth_ref": [ "r95", "r280" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense (income) related to adjustment to fair value of warrant liability.", "label": "Fair value of warrants" } } }, "localname": "FairValueAdjustmentOfWarrants", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://intellipharmaceutics.com/role/WarrantsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueDisclosuresAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Financial Instruments" } } }, "localname": "FairValueDisclosuresAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_FairValueMeasurementPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.", "label": "Fair value measurement" } } }, "localname": "FairValueMeasurementPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://intellipharmaceutics.com/role/SignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueOfFinancialInstrumentsPolicy": { "auth_ref": [ "r383", "r384" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for determining the fair value of financial instruments.", "label": "Financial instruments" } } }, "localname": "FairValueOfFinancialInstrumentsPolicy", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://intellipharmaceutics.com/role/SignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_FinancialInstrumentAxis": { "auth_ref": [ "r181", "r182", "r184", "r185", "r186", "r191", "r195", "r196", "r197", "r198", "r200", "r201", "r202", "r203", "r268", "r295", "r380", "r422", "r423", "r424", "r425", "r426", "r427", "r428", "r429", "r430", "r431", "r432", "r433", "r434", "r435", "r436", "r437", "r438", "r439", "r440", "r441", "r442", "r443", "r444", "r445", "r446", "r447", "r448", "r449", "r450", "r451", "r539", "r540", "r541", "r542", "r543", "r544", "r545" ], "lang": { "en-us": { "role": { "documentation": "Information by type of financial instrument.", "label": "Financial Instrument [Axis]" } } }, "localname": "FinancialInstrumentAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://intellipharmaceutics.com/role/FinancialInstrumentsDetails2", "http://intellipharmaceutics.com/role/OptionsDetails2" ], "xbrltype": "stringItemType" }, "us-gaap_FinancialInstrumentsDisclosureTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for financial instruments. This disclosure includes, but is not limited to, fair value measurements of short and long term marketable securities, international currencies forward contracts, and auction rate securities. Financial instruments may include hedging and non-hedging currency exchange instruments, derivatives, securitizations and securities available for sale at fair value. Also included are investment results, realized and unrealized gains and losses as well as impairments and risk management disclosures.", "label": "Financial Instruments Disclosure [Text Block]", "verboseLabel": "Financial Instruments" } } }, "localname": "FinancialInstrumentsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://intellipharmaceutics.com/role/FinancialInstruments" ], "xbrltype": "textBlockItemType" }, "us-gaap_FinancialInstrumentsOwnedAtFairValueAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Financial Instruments (Tables)" } } }, "localname": "FinancialInstrumentsOwnedAtFairValueAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_FinancingReceivablesPeriodPastDueAxis": { "auth_ref": [ "r176", "r196", "r199" ], "lang": { "en-us": { "role": { "documentation": "Information by period in which financial asset is past due or not past due.", "label": "Financing Receivables Period Past Due Axis" } } }, "localname": "FinancingReceivablesPeriodPastDueAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://intellipharmaceutics.com/role/FinancialInstrumentsDetails1" ], "xbrltype": "stringItemType" }, "us-gaap_FinancingReceivablesPeriodPastDueDomain": { "auth_ref": [ "r176", "r196", "r199" ], "lang": { "en-us": { "role": { "documentation": "Period in which financial asset is past due or not past due. For past due, element name and standard label in Financial Asset, [numeric lower end] to [numeric higher end] [date measure] Past Due [Member] or Financial Asset, Greater than [low end numeric value] [date measure] Past Due [Member] or Financial Asset, Less than [high end numeric value] [date measure] Past Due [Member] formats." } } }, "localname": "FinancingReceivablesPeriodPastDueDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://intellipharmaceutics.com/role/FinancialInstrumentsDetails1" ], "xbrltype": "domainItemType" }, "us-gaap_FiniteLivedIntangibleAssetUsefulLife": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Expected life (in years)" } } }, "localname": "FiniteLivedIntangibleAssetUsefulLife", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://intellipharmaceutics.com/role/OptionsDetails" ], "xbrltype": "durationItemType" }, "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": { "auth_ref": [ "r208", "r209", "r211", "r212", "r456", "r457" ], "lang": { "en-us": { "role": { "documentation": "Information by major type or class of finite-lived intangible assets.", "label": "Finite-Lived Intangible Assets by Major Class [Axis]" } } }, "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://intellipharmaceutics.com/role/SignificantAccountingPoliciesDetail" ], "xbrltype": "stringItemType" }, "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": { "auth_ref": [ "r208", "r210" ], "lang": { "en-us": { "role": { "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company." } } }, "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://intellipharmaceutics.com/role/SignificantAccountingPoliciesDetail" ], "xbrltype": "domainItemType" }, "us-gaap_ForeignCurrencyTransactionGainLossBeforeTax": { "auth_ref": [ "r386", "r387", "r388", "r389" ], "calculation": { "http://intellipharmaceutics.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss": { "order": 17.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount before tax of foreign currency transaction realized and unrealized gain (loss) recognized in the income statement.", "label": "Net foreign exchange (loss) gain" } } }, "localname": "ForeignCurrencyTransactionGainLossBeforeTax", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://intellipharmaceutics.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_ForeignCurrencyTransactionGainLossUnrealized": { "auth_ref": [ "r96", "r388", "r389" ], "calculation": { "http://intellipharmaceutics.com/role/ConsolidatedStatementsOfCashFlows": { "order": 10.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount before tax of foreign currency transaction unrealized gain (loss) recognized in the income statement.", "label": "Unrealized foreign exchange gain" } } }, "localname": "ForeignCurrencyTransactionGainLossUnrealized", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://intellipharmaceutics.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock": { "auth_ref": [ "r398" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.", "label": "Translation of foreign currencies" } } }, "localname": "ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://intellipharmaceutics.com/role/SignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_FurnitureAndFixturesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases.", "label": "Furniture and Fixtures", "verboseLabel": "Furniture and Fixtures" } } }, "localname": "FurnitureAndFixturesMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://intellipharmaceutics.com/role/PropertyAndEquipmentDetails", "http://intellipharmaceutics.com/role/SignificantAccountingPoliciesDetail" ], "xbrltype": "domainItemType" }, "us-gaap_GainLossOnDispositionOfAssets": { "auth_ref": [ "r95", "r219", "r224" ], "calculation": { "http://intellipharmaceutics.com/role/ConsolidatedStatementsOfCashFlows": { "order": 13.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of gain (loss) on sale or disposal of property, plant and equipment assets, excluding oil and gas property and timber property.", "label": "[Gain (Loss) on Disposition of Property Plant Equipment, Excluding Oil and Gas Property and Timber Property]", "terseLabel": "Loss on disposal of equipment", "verboseLabel": "Loss on disposal of property and equipment" } } }, "localname": "GainLossOnDispositionOfAssets", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://intellipharmaceutics.com/role/ConsolidatedStatementsOfCashFlows", "http://intellipharmaceutics.com/role/PropertyAndEquipmentDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_GainLossOnSaleOfPropertyPlantEquipment": { "auth_ref": [ "r95" ], "calculation": { "http://intellipharmaceutics.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss": { "order": 12.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of gain (loss) on sale or disposal of property, plant and equipment assets, including oil and gas property and timber property.", "label": "Loss on disposal of property and equipment", "verboseLabel": "Gain loss on sale of equipment" } } }, "localname": "GainLossOnSaleOfPropertyPlantEquipment", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://intellipharmaceutics.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss", "http://intellipharmaceutics.com/role/PropertyAndEquipmentDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_GainLossRelatedToLitigationSettlement": { "auth_ref": [ "r236" ], "calculation": { "http://intellipharmaceutics.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss": { "order": 13.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of gain (loss) recognized in settlement of litigation and insurance claims. Excludes claims within an insurance entity's normal claims settlement process.", "label": "Gain on settlement (Note 17)", "verboseLabel": "Gain on settlement" } } }, "localname": "GainLossRelatedToLitigationSettlement", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://intellipharmaceutics.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss", "http://intellipharmaceutics.com/role/FinancialInstrumentsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_GainsLossesOnExtinguishmentOfDebt": { "auth_ref": [ "r95", "r277", "r278" ], "calculation": { "http://intellipharmaceutics.com/role/ConsolidatedStatementsOfCashFlows": { "order": 17.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 }, "http://intellipharmaceutics.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss": { "order": 14.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.", "label": "[Gain (Loss) on Extinguishment of Debt]", "negatedLabel": "Gain on settlement of convertible debt (Note 7)", "terseLabel": "Gain on settlement", "verboseLabel": "Gain on settlement of convertible debt (Note 7)" } } }, "localname": "GainsLossesOnExtinguishmentOfDebt", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://intellipharmaceutics.com/role/ConsolidatedStatementsOfCashFlows", "http://intellipharmaceutics.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss", "http://intellipharmaceutics.com/role/ConvertibleDebenturesAndPromissoryNotesPayableDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_GrossProfit": { "auth_ref": [ "r75", "r110", "r151", "r154", "r157", "r160", "r163", "r188", "r238", "r239", "r240", "r243", "r244", "r245", "r246", "r247", "r249", "r250", "r385" ], "calculation": { "http://intellipharmaceutics.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss": { "order": 9.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.", "label": "[Gross Profit]", "totalLabel": "Gross Margin" } } }, "localname": "GrossProfit", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://intellipharmaceutics.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill": { "auth_ref": [ "r95", "r213" ], "calculation": { "http://intellipharmaceutics.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss": { "order": 11.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of an intangible asset (excluding goodwill) to fair value.", "label": "[Impairment of Intangible Assets (Excluding Goodwill)]", "negatedLabel": "Impairment of fixed asset (Note 5)" } } }, "localname": "ImpairmentOfIntangibleAssetsExcludingGoodwill", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://intellipharmaceutics.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock": { "auth_ref": [ "r216", "r226" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.", "label": "Impairment of long-lived assets" } } }, "localname": "ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://intellipharmaceutics.com/role/SignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": { "auth_ref": [ "r70", "r151", "r154", "r157", "r160", "r163", "r470", "r477", "r481", "r496" ], "calculation": { "http://intellipharmaceutics.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss": { "order": 19.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.", "label": "[Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest]", "totalLabel": "Net loss before income taxes" } } }, "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://intellipharmaceutics.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeStatementAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Consolidated Statements of Operations and Comprehensive Loss" } } }, "localname": "IncomeStatementAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementLocationAxis": { "auth_ref": [ "r225", "r231" ], "lang": { "en-us": { "role": { "documentation": "Information by location in the income statement.", "label": "Income Statement Location Axis" } } }, "localname": "IncomeStatementLocationAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://intellipharmaceutics.com/role/OptionsDetails3" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementLocationDomain": { "auth_ref": [ "r231" ], "lang": { "en-us": { "role": { "documentation": "Location in the income statement." } } }, "localname": "IncomeStatementLocationDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://intellipharmaceutics.com/role/OptionsDetails3" ], "xbrltype": "domainItemType" }, "us-gaap_IncomeTaxDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Income Taxes" } } }, "localname": "IncomeTaxDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxDisclosureTextBlock": { "auth_ref": [ "r111", "r347", "r348", "r354", "r362", "r364", "r366", "r367", "r368" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.", "label": "Income Tax Disclosure [Text Block]", "verboseLabel": "Income Taxes" } } }, "localname": "IncomeTaxDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://intellipharmaceutics.com/role/IncomeTaxes" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncomeTaxExpenseBenefit": { "auth_ref": [ "r112", "r126", "r127", "r150", "r346", "r363", "r365", "r497" ], "calculation": { "http://intellipharmaceutics.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss": { "order": 20.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.", "label": "Provision for income taxes (Note 15)" } } }, "localname": "IncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://intellipharmaceutics.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxPolicyTextBlock": { "auth_ref": [ "r64", "r343", "r344", "r348", "r349", "r353", "r358" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.", "label": "Income taxes" } } }, "localname": "IncomeTaxPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://intellipharmaceutics.com/role/SignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncomeTaxesPaid": { "auth_ref": [ "r91", "r99" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income.", "label": "Taxes paid" } } }, "localname": "IncomeTaxesPaid", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://intellipharmaceutics.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities": { "auth_ref": [ "r94" ], "calculation": { "http://intellipharmaceutics.com/role/ConsolidatedStatementsOfCashFlows": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.", "label": "Accounts payable, accrued liabilities and employee costs payable" } } }, "localname": "IncreaseDecreaseInAccountsPayableAndAccruedLiabilities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://intellipharmaceutics.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccountsReceivable": { "auth_ref": [ "r94" ], "calculation": { "http://intellipharmaceutics.com/role/ConsolidatedStatementsOfCashFlows": { "order": 9.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.", "label": "Accounts receivable" } } }, "localname": "IncreaseDecreaseInAccountsReceivable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://intellipharmaceutics.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable": { "auth_ref": [ "r94" ], "calculation": { "http://intellipharmaceutics.com/role/ConsolidatedStatementsOfCashFlows": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the period in the amount due for taxes based on the reporting entity's earnings or attributable to the entity's income earning process (business presence) within a given jurisdiction.", "label": "Income tax payable" } } }, "localname": "IncreaseDecreaseInAccruedIncomeTaxesPayable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://intellipharmaceutics.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInDeferredRevenue": { "auth_ref": [ "r94" ], "calculation": { "http://intellipharmaceutics.com/role/ConsolidatedStatementsOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable.", "label": "Deferred revenue (Note 3)" } } }, "localname": "IncreaseDecreaseInDeferredRevenue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://intellipharmaceutics.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInIncomeTaxes": { "auth_ref": [ "r94" ], "calculation": { "http://intellipharmaceutics.com/role/ConsolidatedStatementsOfCashFlows": { "order": 8.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the amounts payable to taxing authorities for taxes that are based on the reporting entity's earnings, net of amounts receivable from taxing authorities for refunds of overpayments or recoveries of income taxes, and in deferred and other tax liabilities and assets.", "label": "[Increase (Decrease) in Income Taxes]", "verboseLabel": "Investment tax credits" } } }, "localname": "IncreaseDecreaseInIncomeTaxes", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://intellipharmaceutics.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInInventories": { "auth_ref": [ "r94" ], "calculation": { "http://intellipharmaceutics.com/role/ConsolidatedStatementsOfCashFlows": { "order": 7.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.", "label": "Inventory" } } }, "localname": "IncreaseDecreaseInInventories", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://intellipharmaceutics.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Change in non-cash operating assets & liabilities" } } }, "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://intellipharmaceutics.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_InterestExpense": { "auth_ref": [ "r68", "r149", "r399", "r401", "r480" ], "calculation": { "http://intellipharmaceutics.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss": { "order": 15.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.", "label": "[Interest Expense]", "negatedLabel": "Interest expense" } } }, "localname": "InterestExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://intellipharmaceutics.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestExpenseDebt": { "auth_ref": [ "r80", "r265", "r272", "r275", "r276" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of the cost of borrowed funds accounted for as interest expense for debt.", "label": "Coupon interest on the debenture" } } }, "localname": "InterestExpenseDebt", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://intellipharmaceutics.com/role/ConvertibleDebenturesAndPromissoryNotesPayableDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestPaid": { "auth_ref": [ "r99" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash paid for interest, including, but not limited to, capitalized interest and payment to settle zero-coupon bond attributable to accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount; classified as operating and investing activities.", "label": "Interest paid" } } }, "localname": "InterestPaid", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://intellipharmaceutics.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryFinishedGoods": { "auth_ref": [ "r51" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before valuation and LIFO reserves of completed merchandise or goods expected to be sold within one year or operating cycle, if longer.", "label": "Finished goods" } } }, "localname": "InventoryFinishedGoods", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://intellipharmaceutics.com/role/SignificantAccountingPoliciesDetailsNarratives" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryNet": { "auth_ref": [ "r4", "r54", "r421" ], "calculation": { "http://intellipharmaceutics.com/role/ConsolidatedBalanceSheets": { "order": 6.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.", "label": "Inventory (Note 3)" } } }, "localname": "InventoryNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://intellipharmaceutics.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryPolicyTextBlock": { "auth_ref": [ "r11", "r55", "r104", "r136", "r204", "r206", "r207", "r453" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost.", "label": "Inventory, Policy [Policy Text Block]", "verboseLabel": "Inventory" } } }, "localname": "InventoryPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://intellipharmaceutics.com/role/SignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_InventoryRawMaterials": { "auth_ref": [ "r53" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before valuation and LIFO reserves of raw materials expected to be sold, or consumed within one year or operating cycle, if longer.", "label": "Raw materials" } } }, "localname": "InventoryRawMaterials", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://intellipharmaceutics.com/role/SignificantAccountingPoliciesDetailsNarratives" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryWorkInProcess": { "auth_ref": [ "r52" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before valuation and LIFO reserves of merchandise or goods in the production process expected to be completed within one year or operating cycle, if longer.", "label": "Work in process" } } }, "localname": "InventoryWorkInProcess", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://intellipharmaceutics.com/role/SignificantAccountingPoliciesDetailsNarratives" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryWriteDown": { "auth_ref": [ "r205" ], "calculation": { "http://intellipharmaceutics.com/role/ConsolidatedStatementsOfCashFlows": { "order": 15.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of loss from reductions in inventory due to subsequent measurement adjustments, including, but not limited to, physical deterioration, obsolescence, or changes in price levels.", "label": "Write-down of inventory (Note 3)" } } }, "localname": "InventoryWriteDown", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://intellipharmaceutics.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_InvestmentIncomeInterest": { "auth_ref": [ "r79", "r148" ], "calculation": { "http://intellipharmaceutics.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss": { "order": 16.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.", "label": "Interest income" } } }, "localname": "InvestmentIncomeInterest", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://intellipharmaceutics.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_InvestmentOwnedAtFairValue": { "auth_ref": [ "r509", "r511", "r512" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Value of the investment at close of period. For schedules of investments that are categorized, the value would be aggregated by category. For investment in and advances to affiliates, if operations of any controlled companies are different in character from those of the company, group such affiliates within divisions and by type of activities.", "label": "Estimated fair vaue" } } }, "localname": "InvestmentOwnedAtFairValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://intellipharmaceutics.com/role/WarrantsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_LeaseCost": { "auth_ref": [ "r410", "r411" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of lease cost recognized by lessee for lease contract.", "label": "Operating lease cost" } } }, "localname": "LeaseCost", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://intellipharmaceutics.com/role/LeaseDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_LeaseholdImprovementsMember": { "auth_ref": [ "r221" ], "lang": { "en-us": { "role": { "documentation": "Additions or improvements to assets held under a lease arrangement.", "label": "Leasehold Improvements", "verboseLabel": "Leasehold Improvements" } } }, "localname": "LeaseholdImprovementsMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://intellipharmaceutics.com/role/PropertyAndEquipmentDetails", "http://intellipharmaceutics.com/role/SignificantAccountingPoliciesDetail" ], "xbrltype": "domainItemType" }, "us-gaap_LeasesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Lease" } } }, "localname": "LeasesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_LeasesOfLesseeDisclosureTextBlock": { "auth_ref": [ "r403" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for lessee entity's leasing arrangements including, but not limited to, all of the following: (a.) The basis on which contingent rental payments are determined, (b.) The existence and terms of renewal or purchase options and escalation clauses, (c.) Restrictions imposed by lease agreements, such as those concerning dividends, additional debt, and further leasing.", "label": "Leases of Lessee Disclosure [Text Block]", "verboseLabel": "Lease" } } }, "localname": "LeasesOfLesseeDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://intellipharmaceutics.com/role/Lease" ], "xbrltype": "textBlockItemType" }, "us-gaap_LesseeLeasesPolicyTextBlock": { "auth_ref": [ "r407" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee.", "label": "Lessee, Leases [Policy Text Block]", "verboseLabel": "Lease" } } }, "localname": "LesseeLeasesPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://intellipharmaceutics.com/role/SignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_LesseeOperatingLeaseDiscountRate": { "auth_ref": [ "r408" ], "lang": { "en-us": { "role": { "documentation": "Discount rate used by lessee to determine present value of operating lease payments.", "label": "Estimated incremental borrowing rate" } } }, "localname": "LesseeOperatingLeaseDiscountRate", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://intellipharmaceutics.com/role/LeaseDetails1" ], "xbrltype": "percentItemType" }, "us-gaap_Liabilities": { "auth_ref": [ "r43", "r110", "r156", "r188", "r238", "r239", "r240", "r243", "r244", "r245", "r246", "r247", "r249", "r250", "r371", "r373", "r374", "r385", "r419", "r420" ], "calculation": { "http://intellipharmaceutics.com/role/ConsolidatedBalanceSheets": { "order": 21.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.", "label": "[Liabilities]", "totalLabel": "Liabilities" } } }, "localname": "Liabilities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://intellipharmaceutics.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liabilities" } } }, "localname": "LiabilitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://intellipharmaceutics.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesAndStockholdersEquity": { "auth_ref": [ "r30", "r110", "r188", "r385", "r421", "r474", "r491" ], "calculation": { "http://intellipharmaceutics.com/role/ConsolidatedBalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.", "label": "[Liabilities and Equity]", "totalLabel": "Liabilities and shareholders' (deficiency)/equity" } } }, "localname": "LiabilitiesAndStockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://intellipharmaceutics.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LitigationSettlementExpense": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of litigation expense, including but not limited to legal, forensic, accounting, and investigative fees.", "label": "Settlement expense" } } }, "localname": "LitigationSettlementExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://intellipharmaceutics.com/role/ContingenciesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The equity interest of noncontrolling shareholders, partners or other equity holders in consolidated entity.", "label": "Noncontrolling interest, ownership percentage by noncontrolling owners" } } }, "localname": "MinorityInterestOwnershipPercentageByNoncontrollingOwners", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://intellipharmaceutics.com/role/CapitalStockDetailsNarrative" ], "xbrltype": "percentItemType" }, "us-gaap_NatureOfOperations": { "auth_ref": [ "r141", "r142" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward.", "label": "Nature of Operations [Text Block]", "verboseLabel": "Nature of Operations" } } }, "localname": "NatureOfOperations", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://intellipharmaceutics.com/role/NatureOfOperations" ], "xbrltype": "textBlockItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "auth_ref": [ "r90" ], "calculation": { "http://intellipharmaceutics.com/role/ConsolidatedStatementsOfCashFlows": { "order": 32.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.", "label": "[Net Cash Provided by (Used in) Financing Activities]", "totalLabel": "Cash flows provided from financing activities" } } }, "localname": "NetCashProvidedByUsedInFinancingActivities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://intellipharmaceutics.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Financing activities" } } }, "localname": "NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://intellipharmaceutics.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "auth_ref": [ "r90" ], "calculation": { "http://intellipharmaceutics.com/role/ConsolidatedStatementsOfCashFlows": { "order": 33.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.", "label": "[Net Cash Provided by (Used in) Investing Activities]", "totalLabel": "Cash flows provided from (used in) investing activities" } } }, "localname": "NetCashProvidedByUsedInInvestingActivities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://intellipharmaceutics.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Investing activity" } } }, "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://intellipharmaceutics.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "auth_ref": [ "r90", "r93", "r96" ], "calculation": { "http://intellipharmaceutics.com/role/ConsolidatedStatementsOfCashFlows": { "order": 31.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.", "label": "[Net Cash Provided by (Used in) Operating Activities]", "totalLabel": "Cash flows (used in) provided from operating activities" } } }, "localname": "NetCashProvidedByUsedInOperatingActivities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://intellipharmaceutics.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetIncomeLoss": { "auth_ref": [ "r1", "r62", "r63", "r67", "r71", "r96", "r110", "r119", "r121", "r122", "r123", "r124", "r126", "r127", "r131", "r151", "r154", "r157", "r160", "r163", "r188", "r238", "r239", "r240", "r243", "r244", "r245", "r246", "r247", "r249", "r250", "r382", "r385", "r478", "r494" ], "calculation": { "http://intellipharmaceutics.com/role/ConsolidatedStatementsOfCashFlows": { "order": 22.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 }, "http://intellipharmaceutics.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.", "label": "[Net Income (Loss) Attributable to Parent]", "terseLabel": "Net loss", "totalLabel": "Net loss and comprehensive loss", "verboseLabel": "Net loss" } } }, "localname": "NetIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://intellipharmaceutics.com/role/ConsolidatedStatementsOfCashFlows", "http://intellipharmaceutics.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss", "http://intellipharmaceutics.com/role/ConsolidatedStatementsOfShareholdersEquityDeficiency", "http://intellipharmaceutics.com/role/NatureOfOperationsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_NoninterestBearingDepositLiabilities": { "auth_ref": [ "r475" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate amount of all domestic and foreign noninterest-bearing deposits liabilities held by the entity.", "label": "Non-interest bearing promissory notes" } } }, "localname": "NoninterestBearingDepositLiabilities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://intellipharmaceutics.com/role/ConvertibleDebenturesAndPromissoryNotesPayableDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_NotesAndLoansPayableCurrent": { "auth_ref": [ "r41" ], "calculation": { "http://intellipharmaceutics.com/role/ConsolidatedBalanceSheets": { "order": 15.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying values as of the balance sheet date of the portions of all long-term notes and loans payable due within one year or the operating cycle if longer.", "label": "Promissory notes payable (Note 7)" } } }, "localname": "NotesAndLoansPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://intellipharmaceutics.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_NotesPayable": { "auth_ref": [ "r18", "r473", "r488" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Including the current and noncurrent portions, aggregate carrying amount of all types of notes payable, as of the balance sheet date, with initial maturities beyond one year or beyond the normal operating cycle, if longer.", "label": "Promissory notes payable", "verboseLabel": "Promissory notes payable, carrying amount" } } }, "localname": "NotesPayable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://intellipharmaceutics.com/role/ConvertibleDebenturesAndPromissoryNotesPayableDetails1", "http://intellipharmaceutics.com/role/FinancialInstrumentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_NotesPayableFairValueDisclosure": { "auth_ref": [ "r42" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Fair value portion of notes payable.", "label": "Promissory notes payable, fair value" } } }, "localname": "NotesPayableFairValueDisclosure", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://intellipharmaceutics.com/role/FinancialInstrumentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingExpenses": { "auth_ref": [], "calculation": { "http://intellipharmaceutics.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss": { "order": 10.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.", "label": "[Operating Expenses]", "totalLabel": "Expenses" } } }, "localname": "OperatingExpenses", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://intellipharmaceutics.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingIncomeLoss": { "auth_ref": [ "r151", "r154", "r157", "r160", "r163" ], "calculation": { "http://intellipharmaceutics.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss": { "order": 18.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The net result for the period of deducting operating expenses from operating revenues.", "label": "[Operating Income (Loss)]", "totalLabel": "Loss from operations" } } }, "localname": "OperatingIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://intellipharmaceutics.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiability": { "auth_ref": [ "r405" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.", "label": "Total lease liability" } } }, "localname": "OperatingLeaseLiability", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://intellipharmaceutics.com/role/LeaseDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityCurrent": { "auth_ref": [ "r405" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.", "label": "Current operating lease liability" } } }, "localname": "OperatingLeaseLiabilityCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://intellipharmaceutics.com/role/LeaseDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityNoncurrent": { "auth_ref": [ "r405" ], "calculation": { "http://intellipharmaceutics.com/role/ConsolidatedBalanceSheets": { "order": 13.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.", "label": "Operating lease liability (Note 9)" } } }, "localname": "OperatingLeaseLiabilityNoncurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://intellipharmaceutics.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeasePayments": { "auth_ref": [ "r406", "r409" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.", "label": "Lease payments" } } }, "localname": "OperatingLeasePayments", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://intellipharmaceutics.com/role/LeaseDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseRightOfUseAsset": { "auth_ref": [ "r404" ], "calculation": { "http://intellipharmaceutics.com/role/ConsolidatedBalanceSheets": { "order": 9.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's right to use underlying asset under operating lease.", "label": "Right-of-use asset (Note 9)", "verboseLabel": "Operating lease right-of-use asset" } } }, "localname": "OperatingLeaseRightOfUseAsset", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://intellipharmaceutics.com/role/ConsolidatedBalanceSheets", "http://intellipharmaceutics.com/role/LeaseDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLossCarryforwards": { "auth_ref": [ "r355" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.", "label": "Operating loss carryforwards", "verboseLabel": "Operating loss carryforwards" } } }, "localname": "OperatingLossCarryforwards", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://intellipharmaceutics.com/role/IncomeTaxesDetails3", "http://intellipharmaceutics.com/role/IncomeTaxesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_OptionMember": { "auth_ref": [ "r376" ], "lang": { "en-us": { "role": { "documentation": "Contracts conveying rights, but not obligations, to buy or sell a specific commodity, or financial or equity instrument, at a specified price during a specified period (an American option) or at a specified date (a European option) which were purchased or otherwise acquired, excluding options written (for which a premium was received).", "label": "Option [Member]" } } }, "localname": "OptionMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://intellipharmaceutics.com/role/OptionsDetails2" ], "xbrltype": "domainItemType" }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Nature of Operations" } } }, "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": { "auth_ref": [ "r2", "r375" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.", "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]", "verboseLabel": "Basis of Presentation" } } }, "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://intellipharmaceutics.com/role/BasisOfPresentation" ], "xbrltype": "textBlockItemType" }, "us-gaap_OtherAccruedLiabilitiesCurrent": { "auth_ref": [ "r8", "r9", "r10", "r44" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.", "label": "Other" } } }, "localname": "OtherAccruedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://intellipharmaceutics.com/role/AccruedLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherAdditionalCapital": { "auth_ref": [ "r50", "r81" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of additional paid-in capital (APIC) classified as other.", "label": "[Other Additional Capital]", "verboseLabel": "Additional paid-in capital" } } }, "localname": "OtherAdditionalCapital", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://intellipharmaceutics.com/role/ConvertibleDebenturesAndPromissoryNotesPayableDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossBeforeTax": { "auth_ref": [ "r65", "r66", "r72", "r187", "r391", "r396", "r397", "r479", "r495" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount before tax, after reclassification adjustments of other comprehensive income (loss).", "label": "Recognized loss" } } }, "localname": "OtherComprehensiveIncomeLossBeforeTax", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://intellipharmaceutics.com/role/ConvertibleDebenturesAndPromissoryNotesPayableDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherReceivables": { "auth_ref": [ "r56" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount due from parties in nontrade transactions, classified as other.", "label": "Other receivable", "verboseLabel": "Other receivable within trade and other receivables" } } }, "localname": "OtherReceivables", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://intellipharmaceutics.com/role/FinancialInstrumentsDetails1", "http://intellipharmaceutics.com/role/FinancialInstrumentsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_OverAllotmentOptionMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Right given to the underwriter to sell additional shares over the initial allotment.", "label": "Over-Allotment Option [Member]" } } }, "localname": "OverAllotmentOptionMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://intellipharmaceutics.com/role/CapitalStockDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_PartnersCapitalAccountUnitsSoldInPublicOffering": { "auth_ref": [ "r300", "r301" ], "lang": { "en-us": { "role": { "documentation": "The number of units sold in a public offering of each class of partners' capital account. Units represent shares of ownership of the general, limited, and preferred partners.", "label": "Underwritten public offering" } } }, "localname": "PartnersCapitalAccountUnitsSoldInPublicOffering", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://intellipharmaceutics.com/role/WarrantsDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_PayablesAndAccrualsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Accrued Liabilities" } } }, "localname": "PayablesAndAccrualsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_PaymentsForFees": { "auth_ref": [ "r92" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash outflow for fees classified as other.", "label": "Initial payment" } } }, "localname": "PaymentsForFees", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://intellipharmaceutics.com/role/FinancialInstrumentsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsForLegalSettlements": { "auth_ref": [ "r92" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount of cash paid for the settlement of litigation or for other legal issues during the period.", "label": "Purdue paid" } } }, "localname": "PaymentsForLegalSettlements", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://intellipharmaceutics.com/role/FinancialInstrumentsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsOfCapitalDistribution": { "auth_ref": [ "r86" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Cash outflow to owners or shareholders, excluding ordinary dividends. Includes special dividends.", "label": "Additional payment" } } }, "localname": "PaymentsOfCapitalDistribution", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://intellipharmaceutics.com/role/FinancialInstrumentsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsOfDebtIssuanceCosts": { "auth_ref": [ "r88" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt.", "label": "Debt issuance costs", "verboseLabel": "Issuance cost" } } }, "localname": "PaymentsOfDebtIssuanceCosts", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://intellipharmaceutics.com/role/CapitalStockDetailsNarrative", "http://intellipharmaceutics.com/role/ConvertibleDebenturesAndPromissoryNotesPayableDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsOfFinancingCosts": { "auth_ref": [ "r89" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow for loan and debt issuance costs.", "label": "[Payments of Financing Costs]", "negatedLabel": "Cost of private placement financing (Note 10)" } } }, "localname": "PaymentsOfFinancingCosts", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://intellipharmaceutics.com/role/ConsolidatedStatementsOfShareholdersEquityDeficiency" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsOfStockIssuanceCosts": { "auth_ref": [ "r89" ], "calculation": { "http://intellipharmaceutics.com/role/ConsolidatedStatementsOfCashFlows": { "order": 26.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow for cost incurred directly with the issuance of an equity security.", "label": "[Payments of Stock Issuance Costs]", "negatedLabel": "Share issuance cost (Note 10)" } } }, "localname": "PaymentsOfStockIssuanceCosts", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://intellipharmaceutics.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": { "auth_ref": [ "r83" ], "calculation": { "http://intellipharmaceutics.com/role/ConsolidatedStatementsOfCashFlows": { "order": 30.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.", "label": "[Payments to Acquire Property, Plant, and Equipment]", "negatedLabel": "Purchase of property and equipment (Note 4)" } } }, "localname": "PaymentsToAcquirePropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://intellipharmaceutics.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PlanNameAxis": { "auth_ref": [ "r315", "r330" ], "lang": { "en-us": { "role": { "documentation": "Information by plan name for share-based payment arrangement.", "label": "Plan Name [Axis]" } } }, "localname": "PlanNameAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://intellipharmaceutics.com/role/ConvertibleDebenturesAndPromissoryNotesPayableDetailsNarrative", "http://intellipharmaceutics.com/role/SignificantAccountingPoliciesDetail" ], "xbrltype": "stringItemType" }, "us-gaap_PlanNameDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Plan name for share-based payment arrangement." } } }, "localname": "PlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://intellipharmaceutics.com/role/ConvertibleDebenturesAndPromissoryNotesPayableDetailsNarrative", "http://intellipharmaceutics.com/role/SignificantAccountingPoliciesDetail" ], "xbrltype": "domainItemType" }, "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": { "auth_ref": [ "r6", "r33", "r34" ], "calculation": { "http://intellipharmaceutics.com/role/ConsolidatedBalanceSheets": { "order": 5.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.", "label": "Prepaid expenses, sundry and other assets" } } }, "localname": "PrepaidExpenseAndOtherAssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://intellipharmaceutics.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_PrivatePlacementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A private placement is a direct offering of securities to a limited number of sophisticated investors such as insurance companies, pension funds, mezzanine funds, stock funds and trusts.", "label": "Private Placement [Member]" } } }, "localname": "PrivatePlacementMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://intellipharmaceutics.com/role/ConvertibleDebenturesAndPromissoryNotesPayableDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_ProceedsFromIssuanceOfDebt": { "auth_ref": [ "r85" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow during the period from additional borrowings in aggregate debt. Includes proceeds from short-term and long-term debt.", "label": "Proceeds from debt" } } }, "localname": "ProceedsFromIssuanceOfDebt", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://intellipharmaceutics.com/role/ConvertibleDebenturesAndPromissoryNotesPayableDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromIssuanceOfOtherLongTermDebt": { "auth_ref": [ "r85" ], "calculation": { "http://intellipharmaceutics.com/role/ConsolidatedStatementsOfCashFlows": { "order": 28.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow from issuance of long-term debt classified as other.", "label": "[Proceeds from Issuance of Other Long-term Debt]", "verboseLabel": "Debenture financing, net (Note 7)" } } }, "localname": "ProceedsFromIssuanceOfOtherLongTermDebt", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://intellipharmaceutics.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromIssuanceOfPrivatePlacement": { "auth_ref": [ "r84" ], "calculation": { "http://intellipharmaceutics.com/role/ConsolidatedStatementsOfCashFlows": { "order": 25.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow associated with the amount received from entity's raising of capital via private rather than public placement.", "label": "Proceeds from private placement (Note 10)" } } }, "localname": "ProceedsFromIssuanceOfPrivatePlacement", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://intellipharmaceutics.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions": { "auth_ref": [ "r84", "r331" ], "calculation": { "http://intellipharmaceutics.com/role/ConsolidatedStatementsOfCashFlows": { "order": 27.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow from issuance of shares under share-based payment arrangement. Includes, but is not limited to, option exercised.", "label": "Proceeds from issuance of shares on exercise of warrants (Note 14)" } } }, "localname": "ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://intellipharmaceutics.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromIssuanceOfWarrants": { "auth_ref": [ "r84" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from issuance of rights to purchase common shares at predetermined price (usually issued together with corporate debt).", "label": "Cash proceeds from pre funded warrants" } } }, "localname": "ProceedsFromIssuanceOfWarrants", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://intellipharmaceutics.com/role/WarrantsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromNotesPayable": { "auth_ref": [ "r85" ], "calculation": { "http://intellipharmaceutics.com/role/ConsolidatedStatementsOfCashFlows": { "order": 24.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from a borrowing supported by a written promise to pay an obligation.", "label": "Proceeds from promissory notes payable (Note 7)" } } }, "localname": "ProceedsFromNotesPayable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://intellipharmaceutics.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment": { "auth_ref": [ "r82" ], "calculation": { "http://intellipharmaceutics.com/role/ConsolidatedStatementsOfCashFlows": { "order": 29.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from the sale of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale.", "label": "Sale of property and equipment (Note 4)", "verboseLabel": "Proceeds from sale of equipment" } } }, "localname": "ProceedsFromSaleOfPropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://intellipharmaceutics.com/role/ConsolidatedStatementsOfCashFlows", "http://intellipharmaceutics.com/role/PropertyAndEquipmentDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromStockOptionsExercised": { "auth_ref": [ "r84", "r331" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement.", "label": "Options exercised" } } }, "localname": "ProceedsFromStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://intellipharmaceutics.com/role/OptionsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Property and Equipment" } } }, "localname": "PropertyPlantAndEquipmentAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentAdditions": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of acquisition of long-lived, physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.", "label": "Additions" } } }, "localname": "PropertyPlantAndEquipmentAdditions", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://intellipharmaceutics.com/role/PropertyAndEquipmentDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentByTypeAxis": { "auth_ref": [ "r38", "r223" ], "lang": { "en-us": { "role": { "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.", "label": "Long-Lived Tangible Asset [Axis]" } } }, "localname": "PropertyPlantAndEquipmentByTypeAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://intellipharmaceutics.com/role/PropertyAndEquipmentDetails", "http://intellipharmaceutics.com/role/PropertyAndEquipmentDetailsNarrative", "http://intellipharmaceutics.com/role/SignificantAccountingPoliciesDetail" ], "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": { "auth_ref": [ "r227", "r516", "r517", "r518" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.", "label": "Property, Plant and Equipment Disclosure [Text Block]", "verboseLabel": "Property and Equipment" } } }, "localname": "PropertyPlantAndEquipmentDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://intellipharmaceutics.com/role/PropertyAndEquipment" ], "xbrltype": "textBlockItemType" }, "us-gaap_PropertyPlantAndEquipmentDisposals": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of divestiture of long-lived, physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.", "label": "[Property, Plant and Equipment, Disposals]", "negatedLabel": "Dispostion" } } }, "localname": "PropertyPlantAndEquipmentDisposals", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://intellipharmaceutics.com/role/PropertyAndEquipmentDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives": { "auth_ref": [ "r217" ], "lang": { "en-us": { "role": { "documentation": "Describes the periods of time over which an entity anticipates to receive utility from its property, plant and equipment (that is, the periods of time over which an entity allocates the initial cost of its property, plant and equipment).", "label": "Leasehold improvements" } } }, "localname": "PropertyPlantAndEquipmentEstimatedUsefulLives", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://intellipharmaceutics.com/role/SignificantAccountingPoliciesDetail" ], "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentGross": { "auth_ref": [ "r37", "r221" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "[Property, Plant and Equipment, Gross]", "periodEndLabel": "Cost, ending balance", "periodStartLabel": "Cost, beginning balance" } } }, "localname": "PropertyPlantAndEquipmentGross", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://intellipharmaceutics.com/role/PropertyAndEquipmentDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentNet": { "auth_ref": [ "r14", "r15", "r223", "r421", "r482", "r492" ], "calculation": { "http://intellipharmaceutics.com/role/ConsolidatedBalanceSheets": { "order": 8.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Property and equipment, net (Note 5)", "terseLabel": "Total property and equipment", "verboseLabel": "Net book value" } } }, "localname": "PropertyPlantAndEquipmentNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://intellipharmaceutics.com/role/ConsolidatedBalanceSheets", "http://intellipharmaceutics.com/role/PropertyAndEquipmentDetails", "http://intellipharmaceutics.com/role/SegmentedInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": { "auth_ref": [ "r36", "r223", "r516", "r517" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.", "label": "Property and equipment" } } }, "localname": "PropertyPlantAndEquipmentPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://intellipharmaceutics.com/role/SignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_PropertyPlantAndEquipmentTypeDomain": { "auth_ref": [ "r14", "r221" ], "lang": { "en-us": { "role": { "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software." } } }, "localname": "PropertyPlantAndEquipmentTypeDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://intellipharmaceutics.com/role/PropertyAndEquipmentDetails", "http://intellipharmaceutics.com/role/PropertyAndEquipmentDetailsNarrative", "http://intellipharmaceutics.com/role/SignificantAccountingPoliciesDetail" ], "xbrltype": "domainItemType" }, "us-gaap_ProvisionForDoubtfulAccounts": { "auth_ref": [ "r73", "r193" ], "calculation": { "http://intellipharmaceutics.com/role/ConsolidatedStatementsOfCashFlows": { "order": 20.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense (reversal of expense) for expected credit loss on accounts receivable.", "label": "Provision for doubtful debts (Note 4)" } } }, "localname": "ProvisionForDoubtfulAccounts", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://intellipharmaceutics.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ReceivablesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Trade and other receivables" } } }, "localname": "ReceivablesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_ReceivablesPolicyTextBlock": { "auth_ref": [ "r174", "r178", "r179", "r180" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for receivable. Includes, but is not limited to, accounts receivable and financing receivable.", "label": "Receivable [Policy Text Block]", "verboseLabel": "Accounts receivable" } } }, "localname": "ReceivablesPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://intellipharmaceutics.com/role/SignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_RegulatoryIncomeTaxesPolicy": { "auth_ref": [ "r530", "r531" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for income taxes, including investment tax credits, and the related regulatory treatment (for example, whether deferred income tax accounting - normalization - is allowed in rate making).", "label": "Regulatory Income Taxes, Policy [Policy Text Block]", "verboseLabel": "Investment tax credits" } } }, "localname": "RegulatoryIncomeTaxesPolicy", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://intellipharmaceutics.com/role/SignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_RelatedPartyDomain": { "auth_ref": [ "r309", "r414", "r415" ], "lang": { "en-us": { "role": { "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests." } } }, "localname": "RelatedPartyDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://intellipharmaceutics.com/role/OptionsDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_RelatedPartyTransactionAxis": { "auth_ref": [ "r309", "r414", "r415", "r416" ], "lang": { "en-us": { "role": { "documentation": "Information by type of related party transaction.", "label": "Related Party Transaction [Axis]" } } }, "localname": "RelatedPartyTransactionAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://intellipharmaceutics.com/role/SignificantAccountingPoliciesDetailsNarratives" ], "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionDomain": { "auth_ref": [ "r309" ], "lang": { "en-us": { "role": { "documentation": "Transaction between related party." } } }, "localname": "RelatedPartyTransactionDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://intellipharmaceutics.com/role/SignificantAccountingPoliciesDetailsNarratives" ], "xbrltype": "domainItemType" }, "us-gaap_RelatedPartyTransactionsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Convertible Debentures" } } }, "localname": "RelatedPartyTransactionsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": { "auth_ref": [ "r309", "r414", "r416", "r458", "r459", "r460", "r461", "r462", "r463", "r464", "r465", "r466", "r467", "r468", "r469" ], "lang": { "en-us": { "role": { "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.", "label": "Related Party [Axis]" } } }, "localname": "RelatedPartyTransactionsByRelatedPartyAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://intellipharmaceutics.com/role/OptionsDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": { "auth_ref": [ "r412", "r413", "r415", "r417", "r418" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.", "label": "Related Party Transactions Disclosure [Text Block]", "verboseLabel": "Convertible Debentures" } } }, "localname": "RelatedPartyTransactionsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://intellipharmaceutics.com/role/ConvertibleDebentures" ], "xbrltype": "textBlockItemType" }, "us-gaap_RepaymentsOfConvertibleDebt": { "auth_ref": [ "r87" ], "calculation": { "http://intellipharmaceutics.com/role/ConsolidatedStatementsOfCashFlows": { "order": 23.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow from the repayment of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.", "label": "[Repayments of Convertible Debt]", "negatedLabel": "Repayment of principal on convertible debentures (Note 7)" } } }, "localname": "RepaymentsOfConvertibleDebt", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://intellipharmaceutics.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_RepaymentsOfDebt": { "auth_ref": [ "r87" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow during the period from the repayment of aggregate short-term and long-term debt. Excludes payment of capital lease obligations.", "label": "Principal repayment" } } }, "localname": "RepaymentsOfDebt", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://intellipharmaceutics.com/role/ConvertibleDebenturesAndPromissoryNotesPayableDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_ResearchAndDevelopmentExpense": { "auth_ref": [ "r342", "r454", "r532" ], "calculation": { "http://intellipharmaceutics.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss": { "order": 6.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.", "label": "Research and development" } } }, "localname": "ResearchAndDevelopmentExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://intellipharmaceutics.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_ResearchAndDevelopmentExpenseMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.", "label": "Research and Development Expense" } } }, "localname": "ResearchAndDevelopmentExpenseMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://intellipharmaceutics.com/role/OptionsDetails3" ], "xbrltype": "domainItemType" }, "us-gaap_ResearchDevelopmentAndComputerSoftwarePolicyTextBlock": { "auth_ref": [ "r39", "r214", "r215", "r532" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for its research and development and computer software activities including the accounting treatment for costs incurred for (1) research and development activities, (2) development of computer software for internal use, (3) computer software to be sold, leased or otherwise marketed as a separate product or as part of a product or process and (4) in-process research and development acquired in a purchase business combination.", "label": "Research and development costs" } } }, "localname": "ResearchDevelopmentAndComputerSoftwarePolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://intellipharmaceutics.com/role/SignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "auth_ref": [ "r26", "r300", "r335", "r421", "r490", "r504", "r506" ], "calculation": { "http://intellipharmaceutics.com/role/ConsolidatedBalanceSheets": { "order": 20.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Accumulated deficit", "verboseLabel": "Accumulated deficit" } } }, "localname": "RetainedEarningsAccumulatedDeficit", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://intellipharmaceutics.com/role/ConsolidatedBalanceSheets", "http://intellipharmaceutics.com/role/NatureOfOperationsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_RetainedEarningsMember": { "auth_ref": [ "r0", "r116", "r117", "r118", "r120", "r125", "r127", "r189", "r332", "r333", "r334", "r360", "r361", "r381", "r501", "r503" ], "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Accumulated Deficit" } } }, "localname": "RetainedEarningsMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://intellipharmaceutics.com/role/ConsolidatedStatementsOfShareholdersEquityDeficiency" ], "xbrltype": "domainItemType" }, "us-gaap_RevenueRecognitionPolicyTextBlock": { "auth_ref": [ "r105", "r106" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources.", "label": "Revenue recognition" } } }, "localname": "RevenueRecognitionPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://intellipharmaceutics.com/role/SignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_Revenues": { "auth_ref": [ "r69", "r110", "r146", "r147", "r153", "r158", "r159", "r165", "r166", "r169", "r188", "r238", "r239", "r240", "r243", "r244", "r245", "r246", "r247", "r249", "r250", "r385", "r481" ], "calculation": { "http://intellipharmaceutics.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss": { "order": 4.0, "parentTag": "us-gaap_GrossProfit", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).", "label": "[Revenues]", "totalLabel": "Revenue", "verboseLabel": "Revenues" } } }, "localname": "Revenues", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://intellipharmaceutics.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss", "http://intellipharmaceutics.com/role/SegmentedInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RevenuesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Revenue" } } }, "localname": "RevenuesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://intellipharmaceutics.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "stringItemType" }, "us-gaap_SaleOfStockNameOfTransactionDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement." } } }, "localname": "SaleOfStockNameOfTransactionDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://intellipharmaceutics.com/role/CapitalStockDetailsNarrative", "http://intellipharmaceutics.com/role/ConvertibleDebenturesAndPromissoryNotesPayableDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_SegmentReportingAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Segmented Information" } } }, "localname": "SegmentReportingAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_SegmentReportingDisclosureTextBlock": { "auth_ref": [ "r143", "r144", "r145", "r151", "r152", "r157", "r161", "r162", "r163", "r164", "r165", "r168", "r169", "r170" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.", "label": "Segment Reporting Disclosure [Text Block]", "verboseLabel": "Segmented Information" } } }, "localname": "SegmentReportingDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://intellipharmaceutics.com/role/SegmentedInformation" ], "xbrltype": "textBlockItemType" }, "us-gaap_SellingGeneralAndAdministrativeExpense": { "auth_ref": [ "r78" ], "calculation": { "http://intellipharmaceutics.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss": { "order": 7.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.", "label": "Selling, general and administrative" } } }, "localname": "SellingGeneralAndAdministrativeExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://intellipharmaceutics.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_SellingGeneralAndAdministrativeExpensesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption encompassing selling, general and administrative expense.", "label": "Selling, General and Administrative Expenses" } } }, "localname": "SellingGeneralAndAdministrativeExpensesMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://intellipharmaceutics.com/role/OptionsDetails3" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensation": { "auth_ref": [ "r94" ], "calculation": { "http://intellipharmaceutics.com/role/ConsolidatedStatementsOfCashFlows": { "order": 19.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncash expense for share-based payment arrangement.", "label": "Stock-based compensation (Note 8)" } } }, "localname": "ShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://intellipharmaceutics.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": { "auth_ref": [ "r326" ], "lang": { "en-us": { "role": { "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.", "label": "Dividend yield" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://intellipharmaceutics.com/role/WarrantsDetailsNarrative" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": { "auth_ref": [ "r325" ], "lang": { "en-us": { "role": { "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.", "label": "Volatility rate" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://intellipharmaceutics.com/role/WarrantsDetailsNarrative" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": { "auth_ref": [ "r327" ], "lang": { "en-us": { "role": { "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares.", "label": "Risk free interest rate" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://intellipharmaceutics.com/role/WarrantsDetailsNarrative" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The maximum risk-free interest rate assumption that is used in valuing an option on its own shares.", "label": "Risk free interest rate, maximum" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://intellipharmaceutics.com/role/WarrantsDetailsNarrative" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The minimum risk-free interest rate assumption that is used in valuing an option on its own shares.", "label": "Risk free interest rate, minimum" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://intellipharmaceutics.com/role/WarrantsDetailsNarrative" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": { "auth_ref": [ "r330" ], "lang": { "en-us": { "role": { "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.", "label": "Share-based compensation arrangement by share-based payment award, number of shares available for grant" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://intellipharmaceutics.com/role/DeferredShareUnitsDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": { "auth_ref": [ "r320" ], "lang": { "en-us": { "role": { "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.", "label": "Options exercisable", "verboseLabel": "Options exercisable" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://intellipharmaceutics.com/role/OptionsDetails1", "http://intellipharmaceutics.com/role/OptionsDetails2" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": { "auth_ref": [ "r320" ], "lang": { "en-us": { "role": { "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.", "label": "Weighted average exercise price exercisable" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://intellipharmaceutics.com/role/OptionsDetails1" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageIntrinsicValue": { "auth_ref": [ "r323" ], "lang": { "en-us": { "role": { "documentation": "The combined weighted average of the accumulated differences between the fair values on underlying shares and exercises prices to acquire such shares as of the grant date on options that were either forfeited or lapsed.", "label": "[Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Intrinsic Value]", "verboseLabel": "Expired" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageIntrinsicValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://intellipharmaceutics.com/role/OptionsDetails1" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": { "auth_ref": [ "r322" ], "lang": { "en-us": { "role": { "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.", "label": "[Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period]", "negatedLabel": "Forfeited" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://intellipharmaceutics.com/role/OptionsDetails1" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Gross number of share options (or share units) granted during the period.", "label": "Share-based compensation arrangement by share-based payment award, options, grants in period" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://intellipharmaceutics.com/role/OptionsDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": { "auth_ref": [ "r319", "r330" ], "lang": { "en-us": { "role": { "documentation": "Number of options outstanding, including both vested and non-vested options.", "label": "[Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number]", "periodEndLabel": "Options outstanding, ending" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://intellipharmaceutics.com/role/OptionsDetails1" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": { "auth_ref": [ "r318" ], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.", "label": "[Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price]", "periodEndLabel": "Weighted average exercise price outstanding, ending" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://intellipharmaceutics.com/role/OptionsDetails1" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "auth_ref": [ "r313", "r316" ], "lang": { "en-us": { "role": { "documentation": "Award under share-based payment arrangement." } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://intellipharmaceutics.com/role/DeferredShareUnitsDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired.", "label": "[Share-based Compensation Arrangements by Share-based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price]", "verboseLabel": "Expired" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://intellipharmaceutics.com/role/OptionsDetails1" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.", "label": "[Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price]", "verboseLabel": "Forfeited" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://intellipharmaceutics.com/role/OptionsDetails1" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": { "auth_ref": [ "r315", "r317" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.", "label": "Stock-based compensation" } } }, "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://intellipharmaceutics.com/role/SignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodRiskFreeInterestRate": { "auth_ref": [ "r327" ], "lang": { "en-us": { "role": { "documentation": "The risk-free interest rate assumption that is used in valuing a nonvested share or option award issued to other than an employee.", "label": "Risk-free interest rate" } } }, "localname": "ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodRiskFreeInterestRate", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://intellipharmaceutics.com/role/OptionsDetails" ], "xbrltype": "percentItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": { "auth_ref": [ "r324", "r336" ], "lang": { "en-us": { "role": { "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Expected life" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://intellipharmaceutics.com/role/WarrantsDetailsNarrative" ], "xbrltype": "durationItemType" }, "us-gaap_SharesHeldInEmployeeStockOptionPlanAllocated": { "auth_ref": [ "r340" ], "lang": { "en-us": { "role": { "documentation": "Number of allocated shares held by the Employee Stock Option Plan at balance sheet date. Allocated shares are shares that have been assigned to individual participant accounts based on a known formula.", "label": "Stock options vested" } } }, "localname": "SharesHeldInEmployeeStockOptionPlanAllocated", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://intellipharmaceutics.com/role/OptionsDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_SharesIssued": { "auth_ref": [ "r297" ], "lang": { "en-us": { "role": { "documentation": "Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.", "label": "[Shares, Issued]", "periodEndLabel": "Balance, shares", "periodStartLabel": "Balance, shares" } } }, "localname": "SharesIssued", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://intellipharmaceutics.com/role/ConsolidatedStatementsOfShareholdersEquityDeficiency" ], "xbrltype": "sharesItemType" }, "us-gaap_SharesIssuedPricePerShare": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Per share or per unit amount of equity securities issued.", "label": "Exercise price per share" } } }, "localname": "SharesIssuedPricePerShare", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://intellipharmaceutics.com/role/WarrantsDetailsNarrative" ], "xbrltype": "perShareItemType" }, "us-gaap_SharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.", "label": "Outstanding shares" } } }, "localname": "SharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://intellipharmaceutics.com/role/DeferredShareUnitsDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_SignificantAccountingPoliciesTextBlock": { "auth_ref": [ "r103", "r115" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.", "label": "Significant Accounting Policies [Text Block]", "verboseLabel": "Significant Accounting Policies" } } }, "localname": "SignificantAccountingPoliciesTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://intellipharmaceutics.com/role/SignificantAccountingPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_StatementClassOfStockAxis": { "auth_ref": [ "r21", "r22", "r23", "r107", "r110", "r128", "r129", "r130", "r132", "r133", "r138", "r139", "r140", "r188", "r238", "r243", "r244", "r245", "r249", "r250", "r282", "r283", "r286", "r290", "r297", "r385", "r539" ], "lang": { "en-us": { "role": { "documentation": "Information by the different classes of stock of the entity.", "label": "Class of Stock [Axis]" } } }, "localname": "StatementClassOfStockAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://intellipharmaceutics.com/role/CapitalStockDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_StatementEquityComponentsAxis": { "auth_ref": [ "r0", "r49", "r65", "r66", "r67", "r116", "r117", "r118", "r120", "r125", "r127", "r137", "r189", "r297", "r300", "r332", "r333", "r334", "r360", "r361", "r381", "r391", "r392", "r393", "r394", "r395", "r397", "r501", "r502", "r503", "r548" ], "lang": { "en-us": { "role": { "documentation": "Information by component of equity.", "label": "Statement Equity Components [Axis]" } } }, "localname": "StatementEquityComponentsAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://intellipharmaceutics.com/role/ConsolidatedStatementsOfShareholdersEquityDeficiency" ], "xbrltype": "stringItemType" }, "us-gaap_StatementLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Statement [Line Items]" } } }, "localname": "StatementLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://intellipharmaceutics.com/role/CapitalStockDetailsNarrative", "http://intellipharmaceutics.com/role/ConsolidatedStatementsOfShareholdersEquityDeficiency", "http://intellipharmaceutics.com/role/ConvertibleDebenturesAndPromissoryNotesPayableDetails1", "http://intellipharmaceutics.com/role/ConvertibleDebenturesAndPromissoryNotesPayableDetailsNarrative", "http://intellipharmaceutics.com/role/DeferredShareUnitsDetailsNarrative", "http://intellipharmaceutics.com/role/FinancialInstrumentsDetails1", "http://intellipharmaceutics.com/role/FinancialInstrumentsDetails2", "http://intellipharmaceutics.com/role/IncomeTaxesDetails3", "http://intellipharmaceutics.com/role/OptionsDetails", "http://intellipharmaceutics.com/role/OptionsDetails2", "http://intellipharmaceutics.com/role/OptionsDetails3", "http://intellipharmaceutics.com/role/OptionsDetailsNarrative", "http://intellipharmaceutics.com/role/PropertyAndEquipmentDetails", "http://intellipharmaceutics.com/role/PropertyAndEquipmentDetailsNarrative", "http://intellipharmaceutics.com/role/SegmentedInformationDetails", "http://intellipharmaceutics.com/role/SignificantAccountingPoliciesDetail", "http://intellipharmaceutics.com/role/SignificantAccountingPoliciesDetailsNarratives", "http://intellipharmaceutics.com/role/WarrantsDetails", "http://intellipharmaceutics.com/role/WarrantsDetails1", "http://intellipharmaceutics.com/role/WarrantsDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_StatementOfCashFlowsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Consolidated Statements of Cash Flows" } } }, "localname": "StatementOfCashFlowsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfFinancialPositionAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Consolidated Balance Sheets" } } }, "localname": "StatementOfFinancialPositionAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Consolidated Statements of Shareholders' Equity (Deficiency)" } } }, "localname": "StatementOfStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementTable": { "auth_ref": [ "r116", "r117", "r118", "r137", "r455" ], "lang": { "en-us": { "role": { "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.", "label": "Statement [Table]" } } }, "localname": "StatementTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://intellipharmaceutics.com/role/CapitalStockDetailsNarrative", "http://intellipharmaceutics.com/role/ConsolidatedStatementsOfShareholdersEquityDeficiency", "http://intellipharmaceutics.com/role/ConvertibleDebenturesAndPromissoryNotesPayableDetails1", "http://intellipharmaceutics.com/role/ConvertibleDebenturesAndPromissoryNotesPayableDetailsNarrative", "http://intellipharmaceutics.com/role/DeferredShareUnitsDetailsNarrative", "http://intellipharmaceutics.com/role/FinancialInstrumentsDetails1", "http://intellipharmaceutics.com/role/FinancialInstrumentsDetails2", "http://intellipharmaceutics.com/role/IncomeTaxesDetails3", "http://intellipharmaceutics.com/role/OptionsDetails", "http://intellipharmaceutics.com/role/OptionsDetails2", "http://intellipharmaceutics.com/role/OptionsDetails3", "http://intellipharmaceutics.com/role/OptionsDetailsNarrative", "http://intellipharmaceutics.com/role/PropertyAndEquipmentDetails", "http://intellipharmaceutics.com/role/PropertyAndEquipmentDetailsNarrative", "http://intellipharmaceutics.com/role/SegmentedInformationDetails", "http://intellipharmaceutics.com/role/SignificantAccountingPoliciesDetail", "http://intellipharmaceutics.com/role/SignificantAccountingPoliciesDetailsNarratives", "http://intellipharmaceutics.com/role/WarrantsDetails", "http://intellipharmaceutics.com/role/WarrantsDetails1", "http://intellipharmaceutics.com/role/WarrantsDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_StockIssuedDuringPeriodSharesNewIssues": { "auth_ref": [ "r22", "r23", "r297", "r300" ], "lang": { "en-us": { "role": { "documentation": "Number of new stock issued during the period.", "label": "Common stock" } } }, "localname": "StockIssuedDuringPeriodSharesNewIssues", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://intellipharmaceutics.com/role/CapitalStockDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesOther": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of shares of stock issued attributable to transactions classified as other.", "label": "Common shares issued during period" } } }, "localname": "StockIssuedDuringPeriodSharesOther", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://intellipharmaceutics.com/role/WarrantsDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": { "auth_ref": [ "r22", "r23", "r297", "r300", "r321" ], "lang": { "en-us": { "role": { "documentation": "Number of share options (or share units) exercised during the current period.", "label": "Shares exercised" } } }, "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://intellipharmaceutics.com/role/DeferredShareUnitsDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_StockRepurchasedDuringPeriodShares": { "auth_ref": [ "r22", "r23", "r297", "r300" ], "lang": { "en-us": { "role": { "documentation": "Number of shares that have been repurchased during the period and have not been retired and are not held in treasury. Some state laws may govern the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock.", "label": "Warrants to purchase" } } }, "localname": "StockRepurchasedDuringPeriodShares", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://intellipharmaceutics.com/role/CapitalStockDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_StockholdersEquity": { "auth_ref": [ "r23", "r28", "r29", "r110", "r177", "r188", "r385", "r421" ], "calculation": { "http://intellipharmaceutics.com/role/ConsolidatedBalanceSheets": { "order": 22.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.", "label": "[Stockholders' Equity Attributable to Parent]", "periodEndLabel": "Balance, amount", "periodStartLabel": "Balance, amount", "totalLabel": "Shareholders' (deficiency)/equity" } } }, "localname": "StockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://intellipharmaceutics.com/role/ConsolidatedBalanceSheets", "http://intellipharmaceutics.com/role/ConsolidatedStatementsOfShareholdersEquityDeficiency" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Shareholders' deficiency" } } }, "localname": "StockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://intellipharmaceutics.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_StockholdersEquityNoteAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Capital Stock" } } }, "localname": "StockholdersEquityNoteAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_StockholdersEquityNoteDisclosureTextBlock": { "auth_ref": [ "r108", "r283", "r285", "r286", "r287", "r288", "r289", "r290", "r291", "r292", "r293", "r294", "r296", "r300", "r303" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.", "label": "Stockholders' Equity Note Disclosure [Text Block]", "verboseLabel": "Capital Stock" } } }, "localname": "StockholdersEquityNoteDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://intellipharmaceutics.com/role/CapitalStock" ], "xbrltype": "textBlockItemType" }, "us-gaap_StockholdersEquityNoteRedeemablePreferredStockIssuePolicy": { "auth_ref": [ "r19", "r20", "r281" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for redeemable preferred stock issued. This disclosure may include the accounting treatment for the difference, if there is any, between the carrying value and redemption amount. For example, describe whether the issuer accretes changes in the redemption value.", "label": "Share issue costs" } } }, "localname": "StockholdersEquityNoteRedeemablePreferredStockIssuePolicy", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://intellipharmaceutics.com/role/SignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_SubsidiarySaleOfStockAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by type of sale of the entity's stock.", "label": "Sale of Stock [Axis]" } } }, "localname": "SubsidiarySaleOfStockAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://intellipharmaceutics.com/role/CapitalStockDetailsNarrative", "http://intellipharmaceutics.com/role/ConvertibleDebenturesAndPromissoryNotesPayableDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_SupplementalCashFlowElementsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Supplemental cash flow information" } } }, "localname": "SupplementalCashFlowElementsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://intellipharmaceutics.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_TaxCreditCarryforwardAmount": { "auth_ref": [ "r355" ], "calculation": { "http://intellipharmaceutics.com/role/ConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.", "label": "Investment tax credits" } } }, "localname": "TaxCreditCarryforwardAmount", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://intellipharmaceutics.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_TaxPeriodAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information about the period subject to enacted tax laws.", "label": "Tax Period [Axis]" } } }, "localname": "TaxPeriodAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://intellipharmaceutics.com/role/IncomeTaxesDetails3" ], "xbrltype": "stringItemType" }, "us-gaap_TaxPeriodDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Identified tax period." } } }, "localname": "TaxPeriodDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://intellipharmaceutics.com/role/IncomeTaxesDetails3" ], "xbrltype": "domainItemType" }, "us-gaap_TaxesPayableCurrent": { "auth_ref": [ "r41" ], "calculation": { "http://intellipharmaceutics.com/role/ConsolidatedBalanceSheets": { "order": 14.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable for statutory income, sales, use, payroll, excise, real, property and other taxes. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Income tax payable (Note 15)" } } }, "localname": "TaxesPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://intellipharmaceutics.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_TradingActivityByTypeAxis": { "auth_ref": [ "r379" ], "lang": { "en-us": { "role": { "documentation": "Information by type of trading activity.", "label": "Trading Activity [Axis]" } } }, "localname": "TradingActivityByTypeAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://intellipharmaceutics.com/role/CapitalStockDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_TradingActivityByTypeDomain": { "auth_ref": [ "r379" ], "lang": { "en-us": { "role": { "documentation": "Gains and losses on trading activities (including both derivative and nonderivative instruments) recognized in the statement of financial performance, separately by major types of items (such as fixed income/interest rates, foreign exchange, equity, commodity, and credit)." } } }, "localname": "TradingActivityByTypeDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://intellipharmaceutics.com/role/CapitalStockDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": { "auth_ref": [ "r181", "r182", "r184", "r185", "r186", "r268", "r295", "r380", "r422", "r423", "r424", "r425", "r426", "r427", "r428", "r429", "r430", "r431", "r432", "r433", "r434", "r435", "r436", "r437", "r438", "r439", "r440", "r441", "r442", "r443", "r444", "r445", "r446", "r447", "r448", "r449", "r450", "r451", "r539", "r540", "r541", "r542", "r543", "r544", "r545" ], "lang": { "en-us": { "role": { "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms." } } }, "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://intellipharmaceutics.com/role/FinancialInstrumentsDetails2", "http://intellipharmaceutics.com/role/OptionsDetails2" ], "xbrltype": "domainItemType" }, "us-gaap_UnsecuredDebt": { "auth_ref": [ "r18", "r473", "r488" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Including the current and noncurrent portions, carrying value as of the balance sheet date of uncollateralized debt obligations (with maturities initially due after one year or beyond the operating cycle if longer).", "label": "Unsecured convertible debt, principal amount" } } }, "localname": "UnsecuredDebt", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://intellipharmaceutics.com/role/SignificantAccountingPoliciesDetailsNarratives" ], "xbrltype": "monetaryItemType" }, "us-gaap_WarrantsAndRightsNoteDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Warrants (Tables)" } } }, "localname": "WarrantsAndRightsNoteDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" } }, "unitCount": 5 } }, "std_ref": { "r0": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "105", "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695" }, "r1": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760" }, "r10": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e7018-107765" }, "r100": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4304-108586" }, "r101": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4313-108586" }, "r102": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4332-108586" }, "r103": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18726-107790" }, "r104": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18823-107790" }, "r105": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18823-107790" }, "r106": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18823-107790" }, "r107": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(d))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r108": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(e)(1))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r109": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(f))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r11": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766" }, "r110": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r111": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h)(2))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r112": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r113": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(k)(1))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r114": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.12-04(a))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690" }, "r115": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "235", "URI": "http://asc.fasb.org/topic&trid=2122369" }, "r116": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793" }, "r117": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793" }, "r118": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793" }, "r119": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794" }, "r12": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(19)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r120": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(3)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794" }, "r121": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794" }, "r122": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794" }, "r123": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794" }, "r124": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794" }, "r125": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794" }, "r126": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794" }, "r127": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794" }, "r128": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1252-109256" }, "r129": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1278-109256" }, "r13": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r130": { "Name": "Accounting Standards Codification", "Paragraph": "55", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e2626-109256" }, "r131": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256" }, "r132": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256" }, "r133": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257" }, "r134": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257" }, "r135": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257" }, "r136": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "270", "URI": "http://asc.fasb.org/extlink&oid=124437754&loc=d3e543-108305" }, "r137": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "http://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054" }, "r138": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "http://asc.fasb.org/extlink&oid=125520817&loc=d3e70229-108054" }, "r139": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "272", "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055" }, "r14": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(13))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r140": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "272", "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70478-108055" }, "r141": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r142": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "275", "URI": "http://asc.fasb.org/topic&trid=2134479" }, "r143": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8657-108599" }, "r144": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8721-108599" }, "r145": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8721-108599" }, "r146": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r147": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r148": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r149": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r15": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(14))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r150": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r151": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r152": { "Name": "Accounting Standards Codification", "Paragraph": "26", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8844-108599" }, "r153": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599" }, "r154": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599" }, "r155": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599" }, "r156": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599" }, "r157": { "Name": "Accounting Standards Codification", "Paragraph": "31", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8924-108599" }, "r158": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r159": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r16": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(19))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r160": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r161": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r162": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r163": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r164": { "Name": "Accounting Standards Codification", "Paragraph": "34", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8981-108599" }, "r165": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9031-108599" }, "r166": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599" }, "r167": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599" }, "r168": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599" }, "r169": { "Name": "Accounting Standards Codification", "Paragraph": "42", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9054-108599" }, "r17": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(20))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r170": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "280", "URI": "http://asc.fasb.org/topic&trid=2134510" }, "r171": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=124259787&loc=d3e4647-111522" }, "r172": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=124259787&loc=d3e4428-111522" }, "r173": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=124259787&loc=d3e4531-111522" }, "r174": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=123577603&loc=d3e5033-111524" }, "r175": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=123577603&loc=d3e5074-111524" }, "r176": { "Name": "Accounting Standards Codification", "Paragraph": "7A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=123577603&loc=SL6953401-111524" }, "r177": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 4.E)", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707" }, "r178": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=84159169&loc=d3e10133-111534" }, "r179": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=84159169&loc=d3e10149-111534" }, "r18": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(22))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r180": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=84159169&loc=d3e10178-111534" }, "r181": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27232-111563" }, "r182": { "Name": "Accounting Standards Codification", "Paragraph": "5A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=SL120269820-111563" }, "r183": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27290-111563" }, "r184": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "321", "URI": "http://asc.fasb.org/extlink&oid=123583765&loc=SL75117539-209714" }, "r185": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "321", "URI": "http://asc.fasb.org/extlink&oid=123583765&loc=SL75117539-209714" }, "r186": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "321", "URI": "http://asc.fasb.org/extlink&oid=123583765&loc=SL75117539-209714" }, "r187": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "323", "URI": "http://asc.fasb.org/extlink&oid=109237563&loc=d3e33775-111570" }, "r188": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "323", "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571" }, "r189": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437" }, "r19": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(27)(b))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r190": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124255206&loc=SL82895884-210446" }, "r191": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919244-210447" }, "r192": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447" }, "r193": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447" }, "r194": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(f)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447" }, "r195": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447" }, "r196": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919253-210447" }, "r197": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919258-210447" }, "r198": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919230-210447" }, "r199": { "Name": "Accounting Standards Codification", "Paragraph": "80", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124267575&loc=SL82922355-210448" }, "r2": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "205", "URI": "http://asc.fasb.org/topic&trid=2122149" }, "r20": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(27)(c))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r200": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL82922888-210455" }, "r201": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL82922895-210455" }, "r202": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL82922900-210455" }, "r203": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "30", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121590138&loc=SL82922954-210456" }, "r204": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "330", "URI": "http://asc.fasb.org/extlink&oid=116847112&loc=d3e4492-108314" }, "r205": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "330", "URI": "http://asc.fasb.org/extlink&oid=116847112&loc=d3e4542-108314" }, "r206": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "330", "URI": "http://asc.fasb.org/extlink&oid=116847112&loc=d3e4556-108314" }, "r207": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "330", "URI": "http://asc.fasb.org/topic&trid=2126998" }, "r208": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275" }, "r209": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275" }, "r21": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(27))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r210": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r211": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(1)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r212": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r213": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16373-109275" }, "r214": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "30", "SubTopic": "40", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=118172244&loc=d3e17916-109280" }, "r215": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "25", "SubTopic": "50", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=16397303&loc=d3e19347-109286" }, "r216": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "05", "SubTopic": "10", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=109226317&loc=d3e202-110218" }, "r217": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=123364984&loc=d3e1205-110223" }, "r218": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=123351718&loc=d3e2420-110228" }, "r219": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=123351718&loc=d3e2443-110228" }, "r22": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(28))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r220": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r221": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r222": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r223": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r224": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230" }, "r225": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230" }, "r226": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.CC)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=27011434&loc=d3e125687-122742" }, "r227": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "360", "URI": "http://asc.fasb.org/topic&trid=2155823" }, "r228": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "410", "URI": "http://asc.fasb.org/extlink&oid=6392676&loc=d3e7480-110848" }, "r229": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=6394232&loc=d3e17558-110866" }, "r23": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(29))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r230": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869" }, "r231": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869" }, "r232": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 5.P.4)", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747" }, "r233": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "440", "URI": "http://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308" }, "r234": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "440", "URI": "http://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308" }, "r235": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "440", "URI": "http://asc.fasb.org/topic&trid=2144648" }, "r236": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349" }, "r237": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "450", "URI": "http://asc.fasb.org/topic&trid=2127136" }, "r238": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r239": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(ii))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r24": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(3))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r240": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r241": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(B))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r242": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r243": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r244": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(5))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r245": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(i))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r246": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r247": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r248": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(C))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r249": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r25": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r250": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(5))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r251": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r252": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r253": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r254": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r255": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(e)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r256": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(f)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r257": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r258": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611" }, "r259": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611" }, "r26": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r260": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611" }, "r261": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611" }, "r262": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611" }, "r263": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611" }, "r264": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611" }, "r265": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611" }, "r266": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611" }, "r267": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611" }, "r268": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611" }, "r269": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466204&loc=SL6031897-161870" }, "r27": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(4))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r270": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466204&loc=SL6031898-161870" }, "r271": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466204&loc=SL6036836-161870" }, "r272": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466204&loc=SL6036836-161870" }, "r273": { "Name": "Accounting Standards Codification", "Paragraph": "69B", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612" }, "r274": { "Name": "Accounting Standards Codification", "Paragraph": "69C", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612" }, "r275": { "Name": "Accounting Standards Codification", "Paragraph": "69E", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495743-112612" }, "r276": { "Name": "Accounting Standards Codification", "Paragraph": "69F", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495745-112612" }, "r277": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "40", "SubTopic": "50", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123467658&loc=d3e12317-112629" }, "r278": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "40", "SubTopic": "50", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123467658&loc=d3e12355-112629" }, "r279": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=7516071&loc=d3e13374-112631" }, "r28": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r280": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "25", "SubTopic": "10", "Topic": "480", "URI": "http://asc.fasb.org/extlink&oid=109262497&loc=d3e20148-110875" }, "r281": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "05", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467743&loc=d3e20905-112640" }, "r282": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r283": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r284": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r285": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r286": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r287": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(i)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r288": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r289": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644" }, "r29": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(31))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r290": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644" }, "r291": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644" }, "r292": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496180-112644" }, "r293": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644" }, "r294": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644" }, "r295": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644" }, "r296": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644" }, "r297": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21463-112644" }, "r298": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21475-112644" }, "r299": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21538-112644" }, "r3": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r30": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(32))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r300": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770" }, "r301": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 4.F)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187171-122770" }, "r302": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "50", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=6784392&loc=d3e188667-122775" }, "r303": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "505", "URI": "http://asc.fasb.org/topic&trid=2208762" }, "r304": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130545-203045" }, "r305": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046" }, "r306": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "710", "URI": "http://asc.fasb.org/extlink&oid=6409950&loc=d3e20396-108366" }, "r307": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "710", "URI": "http://asc.fasb.org/topic&trid=2127225" }, "r308": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(i)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r309": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(n)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r31": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(4)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r310": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(d)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947" }, "r311": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "80", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948" }, "r312": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=123468992&loc=d3e4534-113899" }, "r313": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901" }, "r314": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901" }, "r315": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901" }, "r316": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a),(g)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r317": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b),(f)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r318": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r319": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(i)-(ii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r32": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(5))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r320": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r321": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r322": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(3)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r323": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r324": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r325": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(ii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r326": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r327": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iv)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r328": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(1)(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r329": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r33": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(7))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r330": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r331": { "Name": "Accounting Standards Codification", "Paragraph": "2A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=SL79508275-113901" }, "r332": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r333": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r334": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r335": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(g)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r336": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 14.D.2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809" }, "r337": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 14.F)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809" }, "r338": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=122142933&loc=d3e11149-113907" }, "r339": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=122142933&loc=d3e11178-113907" }, "r34": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(8))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r340": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(d)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=109244661&loc=d3e17540-113929" }, "r341": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "718", "URI": "http://asc.fasb.org/topic&trid=2228938" }, "r342": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "730", "URI": "http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373" }, "r343": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e32247-109318" }, "r344": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e32280-109318" }, "r345": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e31931-109318" }, "r346": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32672-109319" }, "r347": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319" }, "r348": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319" }, "r349": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32840-109319" }, "r35": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.1)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r350": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319" }, "r351": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319" }, "r352": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319" }, "r353": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32847-109319" }, "r354": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319" }, "r355": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32559-109319" }, "r356": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32621-109319" }, "r357": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32632-109319" }, "r358": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319" }, "r359": { "Name": "Accounting Standards Codification", "Paragraph": "51", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=124434304&loc=d3e34017-109320" }, "r36": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.13(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r360": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277" }, "r361": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(3)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277" }, "r362": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 6.I.5.Q1)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817" }, "r363": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 6.I.7)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817" }, "r364": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.C)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817" }, "r365": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324" }, "r366": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "270", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338" }, "r367": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331" }, "r368": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "740", "URI": "http://asc.fasb.org/topic&trid=2144680" }, "r369": { "Name": "Accounting Standards Codification", "Paragraph": "38", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=123410050&loc=d3e5504-128473" }, "r37": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.13)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r370": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988" }, "r371": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988" }, "r372": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c),(3)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r373": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bb)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685" }, "r374": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685" }, "r375": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "810", "URI": "http://asc.fasb.org/topic&trid=2197479" }, "r376": { "Name": "Accounting Standards Codification", "Paragraph": "83", "Publisher": "FASB", "Section": "15", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=125514181&loc=d3e34841-113949" }, "r377": { "Name": "Accounting Standards Codification", "Paragraph": "4A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959" }, "r378": { "Name": "Accounting Standards Codification", "Paragraph": "4B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959" }, "r379": { "Name": "Accounting Standards Codification", "Paragraph": "4F", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624186-113959" }, "r38": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.14)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r380": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(f)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123477628&loc=d3e90205-114008" }, "r381": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(3)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r382": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r383": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "60", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=7493716&loc=d3e21868-110260" }, "r384": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13279-108611" }, "r385": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612" }, "r386": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=120253306&loc=d3e28228-110885" }, "r387": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "35", "SubTopic": "20", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=123602790&loc=d3e30226-110892" }, "r388": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=125521441&loc=d3e30690-110894" }, "r389": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=124440516&loc=d3e30840-110895" }, "r39": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.15)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r390": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "230", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906" }, "r391": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900" }, "r392": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r393": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r394": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r395": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r396": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r397": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901" }, "r398": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "830", "URI": "http://asc.fasb.org/topic&trid=2175825" }, "r399": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391" }, "r4": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r40": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r400": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=124435984&loc=d3e28551-108399" }, "r401": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=124435984&loc=d3e28555-108399" }, "r402": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=124429444&loc=SL124452920-239629" }, "r403": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "840", "URI": "http://asc.fasb.org/topic&trid=2208923" }, "r404": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977" }, "r405": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977" }, "r406": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918643-209977" }, "r407": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918666-209980" }, "r408": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(3)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918673-209980" }, "r409": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(1)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980" }, "r41": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19,20)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r410": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980" }, "r411": { "Name": "Accounting Standards Codification", "Paragraph": "53", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123414884&loc=SL77918982-209971" }, "r412": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r413": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r414": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r415": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r416": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864" }, "r417": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39691-107864" }, "r418": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "850", "URI": "http://asc.fasb.org/topic&trid=2122745" }, "r419": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "852", "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765" }, "r42": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19,20,22)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r420": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "852", "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765" }, "r421": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "852", "URI": "http://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766" }, "r422": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)(i)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r423": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)(ii)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r424": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r425": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r426": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r427": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r428": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r429": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r43": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19-26)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r430": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r431": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r432": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r433": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r434": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r435": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=66007379&loc=d3e113888-111728" }, "r436": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=109249958&loc=SL34722452-111729" }, "r437": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122625-111746" }, "r438": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122625-111746" }, "r439": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122625-111746" }, "r44": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.20)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r440": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(4)(i)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122625-111746" }, "r441": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746" }, "r442": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746" }, "r443": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746" }, "r444": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(4)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746" }, "r445": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(5)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746" }, "r446": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(6)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746" }, "r447": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(7)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746" }, "r448": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(b)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746" }, "r449": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(e)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746" }, "r45": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22(a)(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r450": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(e)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746" }, "r451": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(e)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746" }, "r452": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "910", "URI": "http://asc.fasb.org/extlink&oid=123353855&loc=SL119991595-234733" }, "r453": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "330", "Topic": "912", "URI": "http://asc.fasb.org/extlink&oid=6471895&loc=d3e55923-109411" }, "r454": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "25", "SubTopic": "730", "Topic": "912", "URI": "http://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433" }, "r455": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.L)", "Topic": "924", "URI": "http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856" }, "r456": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "926", "URI": "http://asc.fasb.org/extlink&oid=120154696&loc=d3e54445-107959" }, "r457": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "340", "Topic": "928", "URI": "http://asc.fasb.org/extlink&oid=6473545&loc=d3e61844-108004" }, "r458": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e61929-109447" }, "r459": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e61929-109447" }, "r46": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r460": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62059-109447" }, "r461": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62059-109447" }, "r462": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62395-109447" }, "r463": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62395-109447" }, "r464": { "Name": "Accounting Standards Codification", "Paragraph": "33", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62479-109447" }, "r465": { "Name": "Accounting Standards Codification", "Paragraph": "33", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62479-109447" }, "r466": { "Name": "Accounting Standards Codification", "Paragraph": "35A", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=SL6807758-109447" }, "r467": { "Name": "Accounting Standards Codification", "Paragraph": "35A", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=SL6807758-109447" }, "r468": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(c)(1)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e61872-109447" }, "r469": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(c)(2)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e61872-109447" }, "r47": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.25)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r470": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "25", "SubTopic": "20", "Topic": "940", "URI": "http://asc.fasb.org/extlink&oid=123384075&loc=d3e41242-110953" }, "r471": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(11))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r472": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(13))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r473": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(16))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r474": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(23))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r475": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.12)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r476": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.17)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r477": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(15))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r478": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(22))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r479": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(23))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r48": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r480": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04.9)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r481": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "235", "Subparagraph": "(SX 210.9-05(b)(2))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884" }, "r482": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630" }, "r483": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "505", "Subparagraph": "(c)(1)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=117337116&loc=SL5958568-112826" }, "r484": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(16))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r485": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(5))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r486": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(12))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r487": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(16)(a))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r488": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(16))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r489": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r49": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29-31)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r490": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r491": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(25))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r492": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(8))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r493": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.(a),19)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r494": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(18))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r495": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(19))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r496": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(8))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r497": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(9))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r498": { "Name": "Accounting Standards Codification", "Paragraph": "7A", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(d)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439" }, "r499": { "Name": "Accounting Standards Codification", "Paragraph": "13H", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Subparagraph": "(b)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117783719-158441" }, "r5": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r50": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.30(a)(2))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r500": { "Name": "Accounting Standards Codification", "Paragraph": "29F", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117819544-158441" }, "r501": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r502": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(1)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r503": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(2)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r504": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(i)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r505": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(ii)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r506": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(h)(2)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r507": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "210", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=118262064&loc=SL116631418-115840" }, "r508": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "45", "SubTopic": "210", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=118262064&loc=SL116631419-115840" }, "r509": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "210", "Subparagraph": "(b)", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=99383244&loc=d3e12121-115841" }, "r51": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.6(a)(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r510": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(13))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=120401414&loc=d3e603758-122996" }, "r511": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column C))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010" }, "r512": { "Name": "Accounting Standards Codification", "Paragraph": "5D", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-13D(Column C))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=SL120429264-123010" }, "r513": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "310", "Subparagraph": "(SX 210.12-29(Footnote 4))", "Topic": "948", "URI": "http://asc.fasb.org/extlink&oid=120402547&loc=d3e617274-123014" }, "r514": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "310", "Topic": "954", "URI": "http://asc.fasb.org/extlink&oid=123366838&loc=d3e3073-115593" }, "r515": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "440", "Subparagraph": "(a)", "Topic": "954", "URI": "http://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629" }, "r516": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Subparagraph": "(d)", "Topic": "958", "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=d3e99779-112916" }, "r517": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "958", "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=d3e99893-112916" }, "r518": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "958", "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=SL120174063-112916" }, "r519": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column B))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r52": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.6(a)(3))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r520": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column C))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r521": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column D))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r522": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column E))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r523": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column F))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r524": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column G))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r525": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column H))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r526": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column I))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r527": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Footnote 2))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r528": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Subparagraph": "(c)", "Topic": "976", "URI": "http://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663" }, "r529": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Subparagraph": "(b)", "Topic": "978", "URI": "http://asc.fasb.org/extlink&oid=123360121&loc=d3e27327-108691" }, "r53": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.6(a)(4))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r530": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "25", "SubTopic": "740", "Topic": "980", "URI": "http://asc.fasb.org/extlink&oid=6501382&loc=d3e54053-110423" }, "r531": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "25", "SubTopic": "740", "Topic": "980", "URI": "http://asc.fasb.org/extlink&oid=6501382&loc=d3e54136-110423" }, "r532": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "985", "URI": "http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756" }, "r533": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12" }, "r534": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r535": { "Name": "Form 10-K", "Number": "249", "Publisher": "SEC", "Section": "310" }, "r536": { "Name": "Form 20-F", "Number": "249", "Publisher": "SEC", "Section": "220", "Subsection": "f" }, "r537": { "Name": "Form 40-F", "Number": "249", "Publisher": "SEC", "Section": "240", "Subsection": "f" }, "r538": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1" }, "r539": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(a)", "Publisher": "SEC", "Section": "1402" }, "r54": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.6(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r540": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(b)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(1)" }, "r541": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(b)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(2)" }, "r542": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(b)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(3)" }, "r543": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(c)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(2)(i)" }, "r544": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(c)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(2)(ii)" }, "r545": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(c)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(2)(iii)" }, "r546": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405" }, "r547": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "405" }, "r548": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)(3)(iii)(03)", "Topic": "848" }, "r55": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.6(b))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r56": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.8)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r57": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.9)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r58": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580" }, "r59": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e637-108580" }, "r6": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r60": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e681-108580" }, "r61": { "Name": "Accounting Standards Codification", "Paragraph": "14A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669686-108580" }, "r62": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580" }, "r63": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580" }, "r64": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL116659661-227067" }, "r65": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067" }, "r66": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067" }, "r67": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067" }, "r68": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(210.5-03(11))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r69": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(1))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r7": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6801-107765" }, "r70": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(10))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r71": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(20))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r72": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(21))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r73": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(5))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r74": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(b)(2))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r75": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.1,2)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r76": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.2(a),(d))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r77": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.2)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r78": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.4)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r79": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.7(b))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r8": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6911-107765" }, "r80": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.8)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r81": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.T)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868742-224227" }, "r82": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3179-108585" }, "r83": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3213-108585" }, "r84": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3255-108585" }, "r85": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3255-108585" }, "r86": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3291-108585" }, "r87": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3291-108585" }, "r88": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3291-108585" }, "r89": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3291-108585" }, "r9": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6935-107765" }, "r90": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3521-108585" }, "r91": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585" }, "r92": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585" }, "r93": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585" }, "r94": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585" }, "r95": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585" }, "r96": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585" }, "r97": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3044-108585" }, "r98": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4273-108586" }, "r99": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4297-108586" } }, "version": "2.1" }